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CHAPTER! 
General introduction 
The human body is always in close contact with billions of bacteria located at all mucosal 
sites and prominently in the gut. This bacterial population, commonly referred to as the 
microflora, is established early following birth, remains constant in a given individual over 
his or her life span and is of great importance to the host. The bacteria degrade and ferment 
many of the food components that are not absorbed in the small intestine. Furthermore, the 
intestinal flora acts as a barrier against food-borne pathogenic bacteria. The mucosal flora 
also represents a large amount of potent immunostimulatory structures like lipopolysaccha-
rides (LPS) in gram-negative bacteria and peptidoglycan (PG) in both gram-negative and 
gram-positive bacteria. These structures are important in the resistance to infections but it is 
cOlrunonly believed that these structures are the major cause of bacterially induced sepsis. 
It has also been suggested that PG is involved in the persistence of chronic inflammation. 
In this thesis the role of PG in the pathogenesis of the chronic inflammatory diseases rheu-
matoid arthritis (RA) and multiple sclerosis (MS) is studied. In this chapter an introduction 
will be given about PG and its biological activities, and about the pathogenesis ofRA and MS. 
PEPTIDOGLYCAN 
Structure 
Peptidoglycan is present in the cell walls of most bacteria and is the major constituent 
(30-70 % v/v) of gram-positive cell walls (figure I). In gram-negative bacteria PG consti-
tutes only 10% of the cell wall. This bag-shaped molecule surrounds the cell and gives it 
strength to withstand the turgor pressure exe11ed by the cytoplasm. The structure ofPG was 
studied extensively by Schleifer (I). Shortly, PG is composed of alternating pl-4-linked 
residues ofN-acetyl glycosamine (GlcNAc) and muramic acid (MurNAc). The latter is usu-
ally N-acetylated, but in mycobacteria and some nocardial species the N-acetyl group is 
oxidized to give the N-glycosylated form. Muramic acid acts as the linking moiety between 
peptides and sugars through an amide bound at the carboxyl group of the D-Iactic ether at 
C-3. Usually L-alanine is bound to muramic acid, followed by D-glutatic acid, which is 
linked by its y-carboxyl group to an L-diamino acid (mostly mesodiaminopimelic acid), and 
finally D-alanine is attached forming the stem peptide (figure I). These stem peptides are 
crosslinked by interpeptide bridges usually between the third amino acid of one stem pep-
tide and the fourth of the other peptide. Although conservative in its general architecture, 
several hundreds different peptidoglycans have been described. These are distinguished by 
a large number of variations within the peptide moiety or by minor modifications within 
the disaccharide unit. The greatest variation of amino acids in the stem peptide occurs in 
position 3. Variation also occurs in the mode of crosslinking and in the interpeptide bridge. 
According to the mode of crosslinking PG is divided into group A (cross-linkage between 
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General introduction 
positions 3 and 4 ofthe stem peptide) and the less common group B (cross-linkage between 
positions 2 and 4 of the stem peptide). The chemical structure of PG monomers theoreti-
cally allows the formation of sugar chains of indefinite length. The actual chain length, 
however, is quite short and differs between bacterial species. In different organisms the 
average chain length varies between 10 and 65 disaccharide units. 
c 
Figure 2. Mab 2E9 detects S. epidermidis peptidoglycan (a) Immuno-EM microscopy of S. epider-
midis (arrow) intracellularly surviving in macrophages (b) Sections labeJed with Mab 2E9 directed 
against PG-PS show high density labeling of coccoid structures. (c) In the sections exposed to the 
isotype control Mab NS7 labeling was very rare or absent similar to primary antibody omission COll-
trollabeling (data not shown). 
In the gram-negative cell wall, the PG covalently linked to lipoprotein molecules forms 
a unimolecular rigid layer between the outer membrane and the cytoplasmatic membrane 
of the cell envelope (figure I). The N-acetylmuramic acid residues are linked to stem tet-
rapeptides composed of L-alanyl-D-isoglutamyl-(L)-mesodiaminopimelyl (L)-D-alanine. 
Approximately two thirds of these stem peptides are crosslinked through D-alanyl (D)-
mesodiaminopimelate linkages. 
On the outer part of gram-positive bacteria, the PG is covered by a polysaccharide layer 
covalently coupled to it, protecting the bacterial cell wall against enzymatic breakdown by 
Figure 1. Composition and structure of gram-positive peptidoglycan. Peptidoglycan is a major com-
ponent of the cell wall of gram-positive bacteria. Alternating N-acetyl glucosamine (G + GlcNAc) and 
N-acetyl muramic acid (M + MurNAc) are connected by peptide bonds resulting in a crosslinked net-
work. These stem peptides and the interpeptide bridges [I] are variable between strains. Peptidogly-
can can be degraded by N-acetylmuramyl-L-alanine amidase (NAMLAA) and Lysozym. NAMLAA 
hydrolyses the lactate bond between N-acetyl muramic acid (MurNAc) and the first amino acid of the 
peptidoglycan chain L-alanine and lysozyme hydrolyses the bond between MurNAc and GlucNAc. 
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lysozyme (figure I). PG contains several structures that make it an unique molecule in biol-
ogy, e.g. the occurrence of muramic acid, which is a glycosamine connected via an ether 
bridge with a lactate, the alternating sequence of L- and D-amino acids, and the linkage of 
a diamino acid to the y-carboxyl group of glutamic acid. Because the presence of muramic 
acid can be analyzed with different techniques, it is a valuable clue for the measurement of 
PG (2,3). Furthennore PG can be detected with a monoclonal antibody (Mab 2E9) directed 
against PG-PS as shown in figure 2. 
Degradatioll oj PG 
Degradation of PG in human tissues occurs by three different hydrolytic enzymes: lyso-
zyme, N-acetylglucosaminidase and N-acetylmuramyl-L-alanine amidase (NAMLAA) (4). 
Lysozyme is able to cleave peptidoglycan sugar chains, producing monomeric muramyl 
peptides (5). N-acetylglucosaminidase is capable of hydrolyzing free N-acetylglucosamine 
groups from the non-reducing ends of the PG backbone (6). NAMLAA was shown to 
hydrolyze the lactamide bound which links MurNAc of the polysaccharide chains to L-ala-
nine of the peptide side chain (7) (figure I). 
Lipopolysaccharide 
Another molecule possessing biological properties similar to PG (table I), which is present 
in the membrane of gram-negative bacteria, is lipopolysaccharide (LPS), a component of 
the outer lipid bilayer of gram-negative bacteria. LPS is composed of polysaccharide side 
chains attached to a basal core oligosaccharide, which in tum is covalently bound to a lipid 
moiety known as lipid A (8). 
Table 1. Similarities and differences between LPS and PO 
LPS 
Gram-negative bacteria + 
Gram-positive bacteria 
CD 14 receptor + 
LPS binding protein + 
Toll like receptors + 
Cytokine induction + 
T cell activation + 
B cell activation + 
CD14 receptor 
PO 
+ 
+++ 
+ 
+ 
+ 
+ 
+ 
Bacterial PG and LPS can interact with cells of the human body. It has been shown that 
both PG and LPS can bind to the CD 14 receptor expressed by monocytes and granulocytes 
(9,10). 
CDI4 is a receptor which exists in two forms, the membrane bound form (mCDI4), a 
glycosylphosphatidylinositol (GPI)-anchored glycoprotein present on myeloid cells, and a 
soluble form (sCDI4) present in the circulation (11,12). sCDI4 can act as a coligand for 
the activation of cells devoid of mCD 14, such as endothelial and epithelial cells, astrocytes, 
12 
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or vascular smooth musele cells (13-16). Recently it has been shown that CD 14 is involved 
in the regulation of apoptosis and apoptotic cell recognition (17) but its major function is 
the interaction with bacterial membrane molecules. PG is able to bind to CDl4 (18,19) and 
activate cells through CD 14 (20). In contrast to LPS, no binding protein is needed (21,22). 
PG induces CDI4 dependent differential activation ofthe MAP kinases, ERK, p38 and JNK 
and ofCREBiATF and AP-I and NK-kB transcription factors (9,20,23). Since CD14 is a 
GPI-anchored molecule that does not traverse the cell membrane, the mechanisms by which 
it confers PG responsiveness to cells has remained a long-standing question in the field. 
This question is not restricted to CD14 since it remains unknown how other GPI-anchored 
receptors mediate intracellular signaling (24). Most recently some members of the family of 
human Toll-like receptors (TLR), specifically TLR2 and TLR4, have been linked to CDI4 
activation (25-30). TLR represent a family of homologous proteins that are characterized 
by an extracellular leucine-rich domain and a cytoplasmic domain that is responsible for 
signal transduction. TLR playa crucial role in Drosophila and mammalian host defense 
(26,31,32). Recently it has been shown that the expression of human TLR2, but not TLR4, 
imparts PG responsiveness to otherwise PG-unresponsive cells. The expression of mCD 14 
greatly enhanced the responsiveness of the cells to LPS and PG, and CDI4 was shown to 
interact with TLR2 to fonn the PG receptor (33,34). Therefore, it is hypothesized that bind-
ing of PG to a complex of CD 14 with TLR2 results in activation of macrophages leading to 
an immune response (35,36). 
Effects of PG all the immulle system 
PG possesses potent adjuvant properties (37,38) and is able to induce sleep (39). The effects 
involving the immune system depend strongly on the structure of PG. As described above, 
the structure of PG differs between bacterial species, explaining why not all effects are 
shared by all bacterial species. The minimal structure which is required for immunogenic 
stimulation is thought to be muramyl dipeptide (40). However, it has recently been shown 
that crosslinked stem peptides obtained after degradation of PG by NAMLAA can also 
induce TNF-o: production in monocytes (41). 
PG can activate complement (42), granulocytes (43) and upregulate adhesion molecules 
on endothelial cells (44). PG is able to induce polyclonal antibody fonnation in peripheral 
blood monuelear cells (PBMC) of healthy donors dependent on the presence ofT lympho-
cytes and monocytes (45,46). In addition, it has been shown that PG is able to induce rheu-
matoid factor (RF) (47,48). IgM, IgA and IgG antibodies specific for PG have been found 
in sera of all humans (49,50). 
A few studies on T cell activation by PG showed that T cells respond to PG only in the 
presence of monocytes, suggesting that uptake of PG by APC is necessary to elicit T cell 
responses (45,51). Furthennore, it has been shown that T cell lines specific for PG can 
induce a delayed type hypersensitivity (DTH) response in Lewis rats (52,53). 
The best studied and major effect of PG is on monocytesimacrophages, which are antigen 
presenting cells of the immune system. PG is a potent inducer of the production of the pro-
inflammatory cytokines TNF-o:, IL-I and IL-6 by human monocytes (54-56). The induction 
of these cytokines can be inhibited by blocking the CD 14 receptor (18,56), confirming that 
binding ofPG to CDI4 is required for its biological activity. Furthennore it has been shown 
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that PG can induce production of IL-12p40 by murine macrophages (57). 
These functions are all important for the induction of septic shock. It is therefore believed 
that PG is the inductor of sepsis by gram-positive bacteria, similarly as LPS has been shown 
to be for gram-negative bacterial sepsis (58,59). It is hypothesized that during a severe bac-
terial infection massive amounts ofPG are released into the bloodstream resulting in patho-
physiological reactions due to overstimulation of the immune system. These pathophysi-
ological reactions include fever or hypothermia, hypotension, tachypnoe, multi-organ fail-
ure and irreversible shock (60). 
Peptidoglycan associated with ilifiammatOlY diseases 
Besides models in which PG causes septic shock (61) there are also models in which PG 
causes chronic inflammation. The in vivo studies on chronic inflammation have mostly 
been perfomled using peptidoglycan-polysaccharides (PG-PS) in which also polysaccha-
rides chains like rhamnose are present. These animal models show that PG-PS can induce 
multisystemic disease involving injury in liver, spleen, intestines, skin, eyes, heart and bone 
marrow (62-64), but arthritis is the most extensively studied PG-induced disease. 
PG from different sources can induce chronic inflammatory arthritis in susceptible rat and 
mouse strains (65,66). PG-PS isolated from group A streptococci induces chronic erosive 
polyarthritis characterized by spontaneous remissions and exacerbations in inbred Lewis 
rats (67). The chronic features persist for at least 10 months, during which time two to five 
spontaneous reactivations of inflammation occur. The phenomenon of spontaneous reacti-
vation is important because it is an unique feature ofPG-PS-induced inflammation as com-
pared with other agents which cause acute inflammation only. It was also shown that PG is 
able to reactivate arthritis induced by other agents like superantigen, intraarticular injection 
ofPDGF, IL-I, TNF-a or the creation of small-bowel bacterial overgrowth (68-72). It has 
been hypothesized that PG-PS accumulates in the liver and that it is released from the liver 
and redistributed to other tissues including the joint, thus accounting for the reactivation of 
arthritis (73). Because PG-PS found in the joints was smaller compared to that found in the 
liver, it is postulated that the liver is able to degrade PG-PS (74). Total degradation ofPG by 
enzymes as lysozyme (75) and NAMLAA (76) inhibits arthritis induction which supports 
the ill vitro data that the structure ofPG is important. 
The induction of arthritis in animal models is probably dependent on the persistence of PG 
in tissues. After intraperitoneal injection in rats, PG-PS is localized in liver, spleen, lymph 
nodes andjoints (74,77,78). In humans, PG has been detected in liver and spleen (74,79,80), 
synovial tissues of arthritis patients (81), urine (82), synovial fluid of septic arthritis patients 
(83,84) and circulating peripheral blood leukocytes (85,86) using different techniques. The 
latter suggests that circulation of PG also occurs in healthy humans. 
Muramic acid has also been detected in brain tissue of conventional rats and it has been 
shown that PG and different muramyl peptides are able to induce leukocytosis, blood brain 
barrier penneability and brain edema (87-89). 
In this thesis the role of PG in RA and MS is studied. Therefore the pathogenesis of these 
two chronic inflammatory diseases is discussed below. 
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RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a chronic and systemic inflammatory joint disease which affects 
1-2% of the population world-wide. The primary manifestations are pain, swelling, and 
limited mobility of joints. Some patients may experience a mild illness, but in the majority 
of the patients the disease leads to joint destruction, defonnity, and disability. The signs 
and symptoms are not restricted to the joints; a variety of extra-articular manifestations 
may occur: subcutaneous nodules, vasculitis, pericarditis, pulmonary nodules or intestinal 
fibrosis, mononeuritis multiplex and scleritis. 
The aetiology of RA is still unknown but it is generally accepted that immune-mediated 
mechanisms are of crucial importance. In RA, the synovial membrane is characterized by a 
thickened lining layer which consists mainly of type A macrophage-like synoviocytes and 
type B fibroblast-like synoviocytes, and the infiltration of macrophages, T cells, plasma 
cells, and to a lesser extent B cells, fibroblasts and dendritic cells into the synovial sub lin-
ing, foruling a pannus. The role of these different cell types present in RA is discussed 
below. 
normal 
bone ---1'--1-
cartilage 
synovial fluid 
synovial 
membrane 
rheumatoid arthritis 
bone 
Figure 3. Diagranunatic representation of rheumatoid arthritis in the joint. Pannus forming is medi-
ated by infiltration ofT cells, macrophages, dendritic cells and plasma cells. The release ofinflamma-
tory mediators like cytokines, matrix metalloproteillasesJ reactive oxygen species and antibodies lead 
to destruction of cartilage and bone. 
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Cells illvolved ill the pathogellesis o/rhellmatoid arthritis 
Resident cells 
The macrophage-like synoviocytes, which are particularly found in the more superficial 
parts ofthe lining layer (90), are probably bone marrow derived monocytes migrating to the 
lining layer in response to chemotactic factors (91). The fibroblast-like synoviocytes, which 
are peculiar to synovium, appear to be of fibroblast origin. Both macrophage-like synovio-
cytes and fibroblast-like synoviocytes appear highly activated, based on their morphology, 
expression of HLA-DR and capability to secrete proinflammatory cytokines. These cells 
may be involved in scavenging of debris released from articular structures and elimination 
of microorganisms entering the joints via the bloodstream or directly after traumatic events. 
In arthritis these functions may be involved in the inflammatory process either by a direct 
contribution through inflammatory mediators or by carrying microorganisms or other anti-
genic material into the joints (92). 
T cells 
T cells, in particular CD4+ T cells, are believed to play an important role in the pathogenesis 
of RA. The association of susceptibility to RA and disease outcome with HLA-DR4IDRI 
antigens (93,94) has been regarded as the strongest argument for the T cell-dependent 
nature of the disease, since the only known function of the major histocompatibility com-
plex (MHC) molecules is to present antigenic peptides to T cells via ligation of their T cell 
receptor (TCR). Another argument for the role ofT cells in RA is the phenotypic evidence 
of activation displayed by synovial tissue-infiltrating T cells. These T cells predominantly 
consist of the primed CD45RO subset, expressing early and late activation antigens (95-97) 
and molecules involved in the interaction between T cells and APC, like CD28, CD40L 
and CTLA4 (98-100). The oligoclonality ofT cells found in the joints ofRA patients sug-
gests that T cells react against a specific antigen in RA (101-103). However, several findings 
argue against the T cell as the initiator of RA. First the hypo responsive state of the T cell 
population at the site of inflammation (104, I 05), second the fact that T cell-derived cyto-
kines like IL-2, IL-4 and IFN-ycan hardly be detected in RAjoints (106,107), and third that 
T cell-directed therapies using depleting anti-CD4 Mabs, and IL-2-receptor immunotoxins 
have been disappointing so far (i 08-110). 
B cells 
Although B cells and plasma cells are not the most prominent cell types present in the 
synovial infiltrate, evidence has been presented for the involvement of humoral immune 
mechanisms in the pathophysiology ofRA (III). B cells in all stages of differentiation from 
mature B cells to plasma cells have been detected in the joints of RA patients (111-114) 
and there is some molecular evidence that B cells are specifically activated and clonally 
expanded in the synovium (115-117). Within the synovium organized structures can occur 
resembling genninal centers, which contain follicular dendritic cells and CD4+ T cells and 
reveal clonal expansion ofB cells exhibiting isotype switching and somatic hyperrnutation 
(i 14,116,118,119). Other evidence for the involvement of B cells in RA is the presence 
of RF in serum (i 20) and joint fluid in the major part of the RA patients (112). RF repre-
16 
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sents an IgM, IgA or IgG antibody reacting with antigenic epitopes in the CH2 and CH3 
domains of IgG (121). IgM RF reaction with autologous IgG has been demonstrated to 
activate the complement system and to stimulate B cell activation (121,122), but may also 
serve to focus or aggregate antigens or APC and in that way function as an immune response 
stimulator (123,124). Furthennore, it was shown recently that a T cell receptor transgenic 
mouse model that spontaneously develops a disease with most of the clinical, hlstological, 
and immunological features ofRA, critically depends on the presence ofB cells and autoan-
tibody production. The specificity of these autoantibodies, however, is stillunkown (125). 
Antigen presenting cells 
Infiltrating APC are also believed to be of cmcial importance in the pathogenesis of RA. 
Peripheral blood monocytes infiltrate into the synovial membrane and mature into macro-
phages or dendritic cells which are both enriched in the rheumatoid synovium and are also 
found within the destmctive pannus tissue (126,127). In addition, macrophages produce 
large amounts ofcytokines such as IL-I, IL-6 and TNF-a (128) as measured in synovial 
tissue and fluid, while peripheral blood monocytes show increased phagocytic activity (129) 
in RA patients. APC are highly activated in RA patients as shown by the expression of 
costimulatory activation markers, such as B7-1 (CD80), B7-2 (CD86) and CD40 in the 
synovium (100,130,131). Furthennore, therapies blocking TNF-a, a cytokine produced in 
large amounts by macrophages in RA have beneficial effects (132,133). The development 
of spontaneous arthritis in human TNF-a overexpressing mice is a strong indication for the 
important role of TNF-a in the pathogenesis of RA (134). 
Activation of APC contributing to the autoimmune events in RA occur probably by phago-
cytosis of antigens, although the cmcial antigen(s) are not defined yet. Such activation of the 
phagocytezed antigens results in the production of inflammatory mediators and presentation 
to T cells leading to T cell proliferation. Antigens can be picked up in the synovium but it 
is also possible that they are phagocytized by APC elsewhere in the body, for instance in 
the lymph nodes or at the mucosa and that such macrophages then migrate to the synovium 
leading to local pathology (135,136). A relation between the gut and synovial tissues has 
been shown by mucosal macrophages, which preferably migrate to joints by binding to high 
endothelial venules with P-selectin (137). 
Mediators ofitiflammatioll alld tisslle destructioll 
Although the cell types initiating the inflammatory reaction are not defined yet, our under-
standing of the mechanisms involved in the pathogenesis of RA has recently substantially 
increased. The severity and progression of synovitis depend on the local accumulation and 
activation of cells that release cytokines, which may regulate growth, differentiation and 
activity of other cells participating in inflammatory and immunological reactions of the 
rheumatic joint (138,139). 
Pl'oilljlammatory cytokilles 
Cytokines can be divided into three groups, the proinflammatory, immunoregulatory and 
chemotactic cytokines. As reviewed by Feldmann (128) and shown in table 2, cytokines 
of all three subtypes can be found in the synovium of RA patients. The proinflammatory 
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cytokines are mainly produced by macrophages and monocytes and can function as growth 
factors for T, Band NK cells, activate other macrophages, neutrophils and fibroblasts and 
stimulate the production of other cytokines and proteinases (140-144). These cytokines 
such as IL-I, IL-6 and TNF-a also have direct effects on cartilage and bone leading to 
destruction of the joints (145-147). Cartilage destruction can be induced by cytokines by 
inhibition of new matrix synthesis (148,149) and proteoglycan synthesis (150), activation of 
chondrocytes (148,151) and activation of plasminogen activator (152) leading to conversion 
of plasminogen into plasmin (153,154). In addition, bone destruction was induced by induc-
tion of prostaglandin production, inhibition of collagen synthesis and induction of alkaline 
phosphatase activity (143,153,155-159). These ill vitro studies are supported by studies in 
animal models where IL-I, IL-6 and TNF-a have been shown to cause destruction of bone 
and cartilage (134,160-163). 
Table 2. Cytokine expression in synovial tissue and synovial fluid ofRA patients 
Proinfiammatory cytokines Immunoregulatory cytokines Chemotactic cytokines 
IL-lo1~ ++H-* IL-IO +++ IL-8 +++ 
IL-2 +1- IL-ll ++ GRO-a + 
IL-6 +++ IL-13 + MIP-lo11~ + 
lL-12 ++ TGF-~ +++ MCP-l + 
IL-15 ++ lL-16 + ENA-78 + 
IL-17 + RANTES + 
IL-18 + 
IFN-01~ly +1-
LIF + 
LT + 
GM-CSF + 
M-CSF + 
TNF-a ++H-
·relative amounts 
Data obtained from: ref 128,166,171,328-332 
ImmulloregulatolJl cytokines 
Immunoregulatory cytokines such as IL-I 0 have mainly inhibitory effects on the inflamma-
tory process. It has been shown that IL-I 0, produced by T/B cells and macrophages, inhibits 
T cell proliferation and TNF-a and IL-I production (164). Treatment with IL-IO has shown 
beneficial effects on the pathogenesis of RA (165). Recently it was shown that IL-ll is 
also able to inhibit inflammation by dowmegulating TNF-a and matrix metalloproteinase 
(MMP) I and 3 (166). Besides inhibitory effects these cytokines also have proinflammatory 
activity such as stimulation of B cells (167), which may account for the production of RF. 
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Chemokines 
Next to their role in the destruction of bone and cartilage, IL-I and TNF-o: can induce the 
production of IL-8 (168), one of the most important chemokines in RA able to attract T 
cells and mediate angiogenesis, an important early feature of pannus formation (169,170). 
Other chemokines present in RA are ORO-a, ENA-78, MIPs and RANTES. The cellular 
source of these chemokines appeared to be mononuclear and polymorphonuclear cells infil-
trating the synovial lining as well as synovial fibroblasts and mononuclear cells found in 
synovial fluid. These chemokines account for the attraction of monocytes and T cells into 
the joint (171-173). Neutralization of chemokine activity leads to reduction of joint swell-
ing in animal models (174,175). 
T cell derived cytokines 
In rheumatoid synovium there are only low levels of the T cell derived cytokines IFN-y, 
IL-2 (proinflammatory) and IL-4 and IL-5 (innnunoregulatory). Only IL-15 (proinflamma-
tory) is relatively abundant. Cloning studies have showed that the majority of the T cells 
were Thl like producing IL-2 and IFN-y (176,177). 
O.\ygen species and matrix melal/oproteillases 
Other mediators involved in the pathogenesis of RA are reactive oxygen species (ROS) 
and MMP, which can be both induced by TNF-o: (178). ROS, among which NO, has been 
shown to be increased in RA (179). It is involved in RA by degrading the proteoglycans in 
the cartilage (180-182), by cytotoxic mechanisms of activated macrophages, chemotaxis of 
polymorphonuclear leukocytes and inhibition of iron-sulfur-centered enzymes (179). 
MMP are produced by leukocytes, chondroblasts and fibroblasts (183,184). They play an 
important role in connective tissue destmction by degrading components of the extracellu-
lar matrix (168,185). [n RA, large amounts of MMP have been detected in several different 
types of rheumatoid synovial cells, especially in perivascular infiltrates (168,183,185-188). 
Cal/didate al/tigel/s il/volved iI/ the pathogel/esis o/rheumatoid arthritis 
Collagen 
Although a trigger causing the activation of T and B cells or macrophages has not been 
defined yet, different candidate (auto)antigens have been suggested. Several intra-articular 
components such as type II collagen and proteoglycan are considered as potential RA 
specific autoantigens (189,190). Considering the involvement of peripheral joints in RA, 
immune reactivity to type II collagen (CII) has been extensively investigated since this pro-
tein constitutes a major part of joint cartilage and mainly occurs in this tissue. Evidence 
for the involvement for collagen in RA is found in the detection of antibodies to CII in 
th~ semm and synovial fluid of RA patients (191-193). Furthermore, collagen I and col-
lagen II could be recognized by T cell clones isolated from synovial fluid of RA patients 
(189,194,195). Relevant in this context is also the observation that in rat and mouse strains 
arthritis can be induced by Cll (196). In such models T cells have been shown to play 
an important role (197,198). Although oral tolerance has been proven to be effective in 
collagen-induced experimental animal models of autoimmune diseases (199), attempts to 
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orally tolerize RA patients for collagen have not shown convincing evidence for a benefi-
cial effect so far (200,20 I). 
68kd alltigell, P205 alld HC-gp39 
Recently, three different autoantigens have been described as candidate antigens in RA. 
First, the ubiquitously expressed 68k autoantigen (thought to be a glycoprotein) (202) has 
been shown to be a major target for self-reactive antibodies in RA, Autoreactive T cells 
specific for this antigen could be identified in 19 of 27 RA patients (202). Second, a P20S 
antigen has been suggested to be a important molecule in RA. P20S, which is identical to 
an immunoglobulin sequence located within a domain that is reactive with RF, appears to 
be a major target of autoreactive T cells in RA. P20S-primed T cells were more abundant 
in the synovial fluid than in the peripheral blood (203). The third antigen is human carti-
lage glycoprotein 39 (HC-gp39). HC-gp39 is not expressed in nonnal cartilage tissues but 
is detected in cartilage of RA patients. Peptides from HC-gp39 binding to the HLA-DR4 
(DRBI*0401) molecule were found to be T cell targets in RA patients, as well as to be 
arthritogenic in certain BALB/c mouse substrains (204,20S). 
Heal shock protein 
Other antigens possibly involved in RA are the heat shock proteins (HSP). HSP are a family 
of proteins of which the expression is increased by a number of stress stimuli. They show 
a high level of sequence homology throughout phylogeny (206,207) and are immunodomi-
nant in the humoral response to a number of infectious organisms (208). The 6SkD HSP 
of Mycobacterium tuberculosis is of particular interest, since it has been implicated in the 
pathogenesis of an arthritis model in rats (209) and the disease can be transferred by a T cell 
clone specific for HSP 6S (210). This has raised the possibility of molecular mimicry as a 
mechanism for tolerance breakdown (210-212), in which immune responses against an HSP 
of an infective organism could elicit a cross-reactive autoimmune response to self-protein 
that shares the same antigenic epitope. Although increased expression of endogenous HSP 
60 in RA synovia (213) and T cell reactivity to bacterial and human HSP supported a patho-
genic role of HSP 60 in RA, the finding that proliferative responses against HSP correlated 
with better disease prognosis (214,2IS) supports a protective role ofHSP specific T cells in 
RA (216). 
Infectious agents 
A role of infectious agents have also been hypothezised in the etiology of RA. One of the 
suspects for such an agent is a virus, because viral infections such as rubella, human parvo-
virus B19, cytomegalovirus, human T cell leukemia virus I, Epstein-Barr virus and HIV-I 
have all been shown to be associated with an acute onset of polyarthritis (217-223). 
In addition to viruses an important role for bacteria has been implicated in RA. In other 
forms of RA like septic arthritis and reactive arthritis the role of bacterial antigens has 
been confirmed. In reactive arthritis, the triggering antigens are thought to be microbes that 
cause infections of the gut or urogenital tract, such as Yersillia and Salmollella species or 
Chlamydia trachoma tis (224). Antigens derived from these bacteria have been detected in 
synovial cells (22S,226), and T cells specific for these antigens have been found in the 
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synovium (227-231). Indications for a microbial cause in RA are the presence of bacterial 
antigens in synovial tissues (232-234) and the observation that diseases related to intesti-
nal bacteria and intestinal diseases (Crohn's disease, ulcerative colitis, jejunal bypass syn-
drome) are often accompanied by attacks of joint inflammation (235). Furthermore, an 
immunological link has been shown between the mucosa and the joint by the fact that 
mucosal leukocytes preferably home to the joints (137,236-238). 
Several authors hypothesized therefore that bacterial fragments, derived from the intestinal 
flora, may pass the bowel wall, are distributed over the body and cause a local and/or sys-
temic reaction leading to arthritis (239-242). Evidence for this hypothesis has come mainly 
from animal studies. For instance, cell wall fragments from several human anaerobic intes-
tinal gram-positive bacteria induced severe chronic arthritis when injected intraperitone-
ally in rats (243-246). In addition, PG-PS isolated from ileostomy effluent induced a severe 
chronic arthritis in rats (247) and a T cell line specific for PG-PS was also able to induce 
arthritis (248). Systemic absorption of bacterial cell wall polymers has been demonstrated 
after feeding and after intracecal injection of streptoccocal PG-PS (249,250). In the serum 
ofrats with ajejunal bypass, an increased titer ofanti-PG-PS antibodies was found, indicat-
ing that a higher intraluminal bacterial load resulted in an increased uptake ofPG-PS by an 
intact intestine (251). In RA patients differences in the anaerobic flora have been found and 
a vegan diet has proved to be benefical in RA patients indicating a role ofthe intestinal flora 
(252,253). The intestinal permeability is higher in RA patients compared to healthy controls 
and recently it has been shown that RA patients have ultrastructural bowel lesions (254), 
but this might also be due to the effects of non-steroidal anti-inflammatory dmgs (NSAID) 
intake (255,256). The beneficial effect of antibiotic agents like minocycline in RA patients 
(257-259) is also supportive for a microbial cause ofRA, although it is suggested that these 
effects are due to the inhibition ofMMP production (260,261). 
MULTIPLE SCLEROSIS 
Multiple sclerosis is a chronic inflammatory disease like rheumatoid arthritis but affects the 
central nervous system (CNS) instead of the joints. The incidence in North-America and 
Europe ranges from 0.1 %-0.2%. Different forms ofMS occur, the relapsing-remitting fonn 
being the most prominent one. This form of MS mostly develops between the ages of 18 
and 50 and affects about twofold more females than males. Relapsing-remitting MS begins 
as a relapsing illness with episodes of neurological dysfunction lasting several weeks, fol-
lowed by substantial or complete improvement. With the exception of uveitis, pathological 
findings are confined to the CNS, with prominent involvement of the optic nerves, periven-
tricular white matter, brain stem and spinal cord. The lesion of MS is primarily inflamma-
tory and demyelinating although axonal loss and scarring may be important in the develop-
ment of irreversible disability. Early in the development of MS lesions, lymphocytes and 
macrophages can be demonstrated in the perivascular inflammatory cuff, i.e. cells located 
between the endothelial cells and the basal lamina of blood vessels. When the blood-brain-
barrier becomes defective, monocytes derived from the blood circulation and T cells invade 
the brain parenchyma forming an inflammatory plaque (262). 
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In MS four kinds of plaques can be distinguished depending on the presence of only 
inflanunatory cells (inflammatory) or myelin degradation products (demyelinating) or both 
(inflammatory and demyelinating) or without both signs (inactive) (263). These four types 
can also be distinguished in acute and chronic plaques. Acute plaques are not clearly demar-
cated and they contain T cells, B cells and macrophages and myelin fragments which is 
indicative for demyelination activity. Remyelination and oligodendrocyte proliferation are 
observed in the majority of acute plaques. Chronic plaques contain hypertrophic astrocytes, 
microglia and plasma cells, producing antibodies of unknown specificity. Although the 
cause of MS is still unknown, it seems likely that the disease is the result of an interplay 
between certain susceptibility genes and environmental factors. Evidence for the genetic 
influence in MS are the fact that 26% of monozygotic twins were both affected with MS 
in contrast to only 2.3% of dizygotic twins (264,265). The association of inflammatory 
cells with new MS lesions implicates an association of the immune system in active tissue 
destruction. The possible role of mononuclear cell types in these lesions are discussed 
below. 
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Figure 4. Lesion fonnation in the central nervous system in multiple sclerosis. Astrocytes, oligoden-
drocytes and infiltrating T cells, macrophages and plasma cells are involved in the fomtation of lesions 
(arrows) in the central nervous system. The release ofcytokines, matrix metalloproteinases, oxygen 
species and antibodies by these ceBs promote demyelination of nervous tissue. 
Cells ill valved ill the pathogellesis o/Illultiple sclerosis 
T cells 
T cells are thought to play an important role in the pathogenesis of MS. The major hypoth-
esis is that activated autoreactive Th 1 cells directed against CNS antigens attack nonnal 
brain tissue. Especially CD4+ T cells are present in high numbers at the initial peri vas-
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cular sites involved in plaque fonnation (266,267). Most studies provide evidence for an 
enhanced state of activation of these Th cells (268-270). Like in other inflammatory dis-
eases, costimulatory molecules like CD40L, CD28 and CTLA4 are present on the T cells 
in MS (268). The concept that MS is a T cell mediated disease is strongly based on studies 
using animal models. Experimental autoimmune encephalomyelits (EAE) can be induced in 
susceptible rodents and monkeys by an emulsion that consists of whole spinal cord, purified 
myelin or specific myelin proteins like myelin basic protein (MBP) or proteolipid protein 
(PLP) emulsified in an adjuvant like Freund complete adjuvant with killed Mycobacterium 
tuberculosis. The disease can be transferred using CD4+ T cells from animals sensitized 
against CNS antigens indicating that EAE is a Th cell mediated disease (271). It has to 
be noted that in many respects acute EAE differs significantly from MS. First, in rodent 
EAE demyelination hardly occurs in contrast to MS and secondly, most EAE models are in 
general monophasic diseases while MS follows a relapsing-remitting pattern with cumula-
tive neuro1ogic damage over time. 
B cells 
There is circumstantial evidence that B cells are also involved in the pathogenesis of MS. 
Persistent oligoclonal jgG synthesis in the cerebrospinal fluid (CSF) and a high antibody 
specificity index, which is the CSF/serum quotient of specific antibodies and total [gG level 
(272), are indicative for sustained B-cell activation within the CNS ofMS patients. In both 
CSF and sera ofMS patients antibodies have been detected directed against components of 
brain tissue (273) and a variety of putative CNS antigens like cerebellar soluble lectin (274), 
MBP, PLP (275), and myelin associated glycoprotein (276). 
Antigen presenting cells 
APC are thought to be responsible for most of the damage occurring during relapses of 
MS (277). Next to cytotoxicity of T cells and antibodies, macrophages are responsible for 
removal of myelin through phagocytosis. These macrophages can be microglia, the resident 
macrophages of the CNS or monocytes derived from the blood (278). Demyelination in MS 
may well be caused by destruction of oligodendrocytes. The involvement of macrophages 
in EAE has been shown by depleting or inhibiting the recruitment of blood-borne macro-
phages, which resulted in a strong decrease of clinical signs (279-282). 
Mediators oj iI!fIammotioll alld tisslle destmctioll 
Although the focus in MS research has been on the T cell and its interaction with CNS 
structures, recently the importance of non-specific inflammatory mechanisms, in particular 
cytokines and chemokines and induced mediators including proteinases, has come to the 
forefront (277,283). Multiple mechanisms have been proposed for oligodendrocyte destruc-
tion including MOG antibodies (284), activation of death signals (285,286) and cytokines 
or cytotoxicity (287-289). In vitro studies have implicated the free radical NO in oligoden-
drocyte death (289,290). 
Although cytokines are important in the initiation, propagation and regulation of immune 
and inflammatory responses, overexpression of these proteins can also result in tissue 
damage. Different cytokines like IL-l, IL-4, IL-6, IL-8, IL-IO, IL-12, IFN-y, GM-CSF and 
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TNF-a are abundantly expressed in MS (291,292). TNF-a and TNF-f} can damage oligo-
dendrocytes (293) by inducing apoptosis of these cells (294). The importance ofproinfiam-
matory cytokine production in MS pathology has been shown by the beneficial effects on 
disease activity by IFN-a therapy which leads to decreased production ofIFN-yand TNF-a 
(295). MMP are also expressed in MS tissue and CSF (296,297). MMP are able to degrade 
the basement membrane and the extracellular matrix and promote extravasation of leuko-
cytes (298), but they also have the capacity within the CNS to cleave MBP into fragments 
retaining encephalitogenicity (299-301). This implies that MMP can contribute to altera-
tions in the permeability of the blood-brain barrier, enzymatic demyelination, induction of 
neuronal loss and generation of modified peptides contributing to autoimmunity (299,300). 
Cal/didate al/tigells iI/valved iI/ the pathogel/esis a/multiple scierosis 
Autoantigells 
A candidate target for the autoreactivity in MS is MBP, the major component of the 
myelin sheath (302), but other antigens including PLP (303), myelin-associated glyco-
protein (MAG) (276), myelin oligodendrocyte glycoprotein (MOG) (304), the HSP a-B-
crystallin (305), and the oligodendroglia I enzyme transaldolase (TAL) (B 10) have also been 
proposed. MBP is the most studied of all these antigens. MBP-specific T cells have been 
detected in the sera and CSF of MS patients (306). It was shown that the MBP epitope 
sequence 154-172 was recognized by T cell clones derived from MS patients. In addition 
the overlapping epitope sequence 149-171 is able to induce CNS demyelination in rhesus 
monkeys. a-B-crystallin, generally considered as a HSP has been shown to be an important 
immunodominant T cell antigen in MS-affected myelin. Immunohistochemical examination 
of white matter sections containing active MS lesions revealed intense expression of a-B-
crystallin in both oligodendrocytes and astrocytes within and adjacent to the lesion (307). 
The exact role of these T cells specific for autoantigens in MS remains elusive because 
autoreactive T cells against myelin components are also found in healthy donors (308). 
Infectious agents 
Autoreactive cells can be activated by cross-reactive epitopes of pathogenic agents like bac-
teria and viruses. This phenomenon, sharing of antigenic determinants, is called molecular 
mimicry. Because ofthe relationship between relapses and viral infections, researchers have 
considered that viruses may cause MS (309,310). Viruses isolated from MS brain are mul-
tiple sclerosis-associated retrovirus (311), and human hel]les virus 6 (HHV-6). The latter 
could be detected in neuroglial cells in active lesions (312-315). Increased HHV-6 IgM 
titers in and HHV-6 DNA identified in the serum ofMS patients indicate recent active viral 
infection. Finally, it has been postulated that MS might be caused by an initial infection 
with a common MS-retrovirus followed by an infection with the Epstein-Barr virus in early 
adulthood or later in life (316). The molecular similarity between virus and myelin antigens 
may enable immunological cross-reactivity between HHV-6 and myelin antigens. In this 
model, T cells become activated by exposure to virus, cross the blood-brain barrier and, 
in genetically predisposed persons, recognize normal myelin antigens as virus resulting in 
tissue injury (305,317-319). However, the role of viruses in the pathogenesis ofMS remains 
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elusive because recently HHV-6 has also been detected in control brain tissue (318-320). 
The role of bacteria in the pathogenesis of MS has not been studied extensively. Recently 
Chlamydia trachoma tis and antibodies against Chlamydia trachomatis have been detected 
in CSF ofMS patients (321), suggesting a role in the pathogenesis of MS. Although the 
brain parenchyma is more resistant to acute inflammation compared to other human tis-
sues, injection of LPS has been shown to result in upregulation of adhesion molecules and 
leukocyte recruitment in the mouse brain (322). Stronger reactions have been observed after 
inoculation with BCG (Bacillus Calmette-Guerin), an attenuated strain of Mycobacterium 
bovis, which after peripheral sensitization resulted in a rapid acute inflammatory response 
mediated by neutrophils and monocytes followed by an inflammatory lesion consisting ofT 
cells and macrophages at the site of inoculation (323-326). Furthennore, it has been show 
that LPS is able to enhance the disease severity in virus induced MS models, for example 
Theiller's murine encephalomyelitis virus induced demyelinating disease (327). 
SUMMARY 
In summary, RA and MS are both chronic inflammatory diseases with unknown etiology. 
Bacterial PG has been shown to possess all the biological properties needed to induce 
inflammation. In this thesis the role ofPG in MS but especially in RA has been investigated 
in detail. 
INTRODUCTION INTO THE EXPERIMENTAL WORK 
The purpose of the studies described in this thesis was to analyze whether PG is involved in 
the pathogenesis of the chronic inflammatory diseases RA and MS. 
PG has many inflammatory properties such as inducing cytokine production and activation 
of B cells and T cells. This was studied using PG isolated from bacterial cultures. The pres-
ence of PG in different tissues including diseased but also nonnal tissues has been shown 
using different methods. One of these methods included the isolation of PG from normal 
human spleen (80). 
In chapter 2 we investigated whether PG present in human tissues, which may be exposed 
to several PG-degrading enzymes, still has the same biological activities as PG isolated 
from bacterial cultures. The method used to isolate PG (80) from human spleen tissue was 
improved to obtain a pure PG fraction suitable for in vitro experiments (chapter 2.1). 
To analyze whether PG present in human tissues is biologically active, its capability to 
induce cytokine production was determined (chapter 2.1). Previously, it has been shown that 
PG induces activation ofT cells dependent on monocytes (51), but the relevant mechanisms 
ofT cell activation have not been identified yet. In chapter 2.2 we investigated whether PG 
isolated from human spleen is able to induce T cell proliferation and in addition whether 
CD 14, the receptor for PG, and antigen processing or presentation are involved. 
The presence of PG in synovial tissues and the ability of PG to induce arthritis in rats indi-
cate that PG may be involved in the pathogenesis ofRA. Whether inunune reactivity to PG 
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is disturbed in RA patients was investigated in chapter 3. To establish whether antibodies 
against PG-PS might be involved in protection against RA or conversely in pathological 
events related to RA, local and systemic levels of antibodies against PG-PS were analyzed 
in semm and synovial fluid samples (chapter 3.1). Chapter 3.2 presents a study performed 
to determine disturbances in T cell proliferation against PG and the ability ofPG to induce 
cytokines which are thought to be of cmcial importance in RA-related joint pathology. 
The biological activity of PG was extensively studied using ill vitro experiments. However, 
lymphoid cell functions and interactions analyzed ill vitro do not always reflect the ill vivo 
situation. The immunohistochemical ill situ approach allows the study of ill vivo events at a 
given moment in time. Whether PG is present in synovial tissues and whether these cens are 
active antigen presenting cells and are able to induce cytokines can therefore be determined 
using immunohistochemistry as presented in chapter 4. To study costimulatOlY molecules 
and cytokines ill situ, cryosections have to be used. These sections maintain antigenicity but 
morphology is often poor. In 4.1 an alternative fixation method for cryosections is described 
which improves the morphology without affecting the antigenicity of the tissues. A Mab, 
called 2E9, was used to detect PG in such treated tissue sections. 2E9 is a murine Mab 
(IgG3) raised against a pure fraction of PG-PS isolated from normal human feces. With this 
Mab 2E9 we were able to study the presence of PG in RA tissues and its involvement in the 
inflammatory processes (chapter 4.2). 
Because PO is also expressed in tissues other than RA synovial tissues, e.g. human spleen, it 
can be hypothesized that PG can also playa role in other chronic inflallllllations besides RA. 
Therfore we examined whether PG is present in healthy brain and MS brain tissues. We also 
investigated whether PG might be able to contribute to the pathological lesions observed 
in MS brain (chapter 4.3). The implications of these findings are discussed in chapter 5 
together with suggestions for further research. 
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Bacterial peptidoglycan-polysaccharides present in sterile human 
spleen induce proinfiammatory cytokine production 
by human blood cells 
Ingrid A. Schrijver', Marie-Jose Melier , Frits Eulderink', Maarten P. Hazenberg' and 
Jon D. Laman' 
J Department of Immunology, Erasmus University Rotterdam alld 
University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands 
} Diagnostic Center SSDZ, Delfl, The Netherlands 
ABSTRACT 
Peptidoglycan (PG) is the major component of the cell wall of gram-positive bacteria. In 
vitro, PO isolated from conventional bacterial cultures can induce secretion of proinflam-
matory cytokines by human monocytes, indicating that PG may be involved in immune 
responses against infections by gram-positive bacteria. To investigate the biological activity 
of PG present in human tissues, an improved method was developed to isolate significant 
amounts of PG from sterile human spleen tissue. Biochemical analysis demonstrated that 
PG isolated from human spleen is largely intact. Human whole blood cell cultures were 
able to produce the proinflammatory cytokines TNF-o:, IL-I and IL-6 after stimulation with 
PG isolated from human spleen. Cytokine induction was not sensitive to inhibition by poly-
myxin B in contrast to lipopolysaccharide. Collectively, the data show that intact PG pres-
ent in sterile human tissue is biologically active and may induce local proinflammatory 
cytokine production. 
INTRODUCTION 
Peptidoglycan (PG) is the major component of the cell wall of gram-positive bacteria. PG 
is composed of alternating N-acetyl glycosamine (GlcNAc) and N-acetyl muramic acid 
(MurNAc) long sugar chains, that are interlinked by peptide bridges resulting in a large 
complex macromolecular structure (I). During bacterial infection, PG and several other cell 
wall components are thought to be involved in the inflammatory reaction (2). In gram-neg-
ative infections, lipopolysaccharide (LPS) is a well-known activator of the innate immune 
system (3,4). During gram-positive infections, when no endotoxin is present, PG is able 
to activate complement (5,6) and granulocytes (7,8), and also to upregulate expression of 
adhesion molecules on endothelial cells (8). Of importance, PG can also induce produc-
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tion of proinflammatory cytokines such as IL-I, IL-6 and TNF-a by monocytes ill vitro 
(9,10). Similar to LPS-induced cytokine production, inhibition can be achieved by prevent-
ing uptake of PG andior activation of macrophages and monocytes by blocking the CD 14 
receptor (II ,12). 
In addition to the role of PG in gram-positive infections it has been hypothesized that PG 
is involved in the pathogenesis of chronic inflammation such as rheumatoid atthritis (RA) 
(13-15). We are interested in the relationship between PG derived from the nonnal intestinal 
flora and the pathogenesis of arthritis (16,17). The presence of PG in relevant tissues is a 
prerequisite for this relationship. Most studies investigating the presence of PG in human 
tissues focus on the detection of muramic acid, the characteristic aminosugar in the glycan 
backbone of PG which can be detected after release of the N-acetyl group of MurNac by 
acid hydrolysis. Furthermore, radiolabeled PG has been used to study the localization ofPG 
ill vivo. With these different techniques PG was detected in liver and spleen (18,19), syno-
vial tissues (18,19), urine (20), synovial fluid (21) and peripheral blood leukocytes (22). We 
detected PG in dendritic cells and macrophages of normal human spleen and synovial tis-
sues of RA patients (23) by use of a monoclonal antibody (Mab) directed against bacterial 
flora-derived PG isolated from human feces (24). We also isolated PG from nonnal human 
spleen using biochemical methods (25). 
The presence of PG in human tissues other than the gastro-intestinal tract suggests that 
our body is constantly exposed to bacterial products, even in the absence of clinically appar-
ent infection. PG present in human tissues is probably derived from the normal gut flora. 
Experiments in rats have shown that PG can be absorbed from the bowel wall (26). 
All studies performed to determine the biological activity of PG have focused on PG iso-
lated from bacterial cultures. Thus far the biological properties ofPG present in human tis-
sues have never been studied. Therefore, the aim of the study was to detemline whether 
PG present in sterile human tissues has the capacity to induce production of proinflamma-
tory cytokines by human peripheral blood mononuclear cells. To this end, we developed an 
improved method to isolate high amounts of structurally intact PG with minimal traces of 
contaminating protein from sterile human spleen tissue. This PG was subsequently demon-
strated to induce release of the proinflammatory cytokines TNF-a, IL-I and IL-6 by human 
whole blood cell cultures. Biological activity of this PG fraction was determined by analysis 
of its ability to induce production of proinflammatory cytokines by human blood cells. 
MATERIALS AND METHODS 
Spleell IIsed Jar isolatioll oj PG 
Seven unfixed human spleens were obtained from the pathology department immediately 
after surgery (SSDZ, Delft, The Netherlands) and kept frozen (-20'C) until use. Spleens 
were removed for surgical reasons from three patients with a gastric carcinoma and from 
four patients because of splenomegaly due to hematological diseases. Spleen samples 
were aerobically and anaerobically cultured on blood agar base (Oxoid Ltd. London, UK) 
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during 48 h at 37'C. The anaerobic plates were cultured in a jar with gaspack generator 
envelopes with palladium catalyst (Becton Dickinson, San Jose, CAl. Bacterial growth was 
not observed, confinuing that no bacteremia ill vivo nor contamination of the tissue after 
surgery had occurred. 
IlIIlIIullohistoc!lelllisfly for detectioll of PG ill spleell 
To determine whether the spleens obtained to isolate PG from indeed contained PG in anti-
gen presenting cells, immunohistochemical staining of frozen sections was done according 
to the method of Kool et al. for the staining of rat spleen (24). We used the same Mab (2E9 
;mouse IgG3) recognizing human intestinal flora-derived PG. 
PG isolatioll [rom hUlllall feces 
PG from feces of a healthy subject was prepared as described previously (27). In brief, feces 
were diluted in distilled water (40 g in 100 ml) and homogenized in a laboratory Blender 
(model 400, Stomacher, Colworth, UK). After cambric gauze filtration the suspension was 
centrifuged for 45 min at 5,000 g. Four volumes of96% ethanol were added to I volume of 
supernatant, and after 2 hours at 4°C, the precipitate was centrifuged for 15 minutes at 5,000 
g. The pellet was dissolved in and dialyzed against Milli-Q water (Millipore, Bedford, MA) 
for 48 hours. Next, the suspension was centrifuged for I h at 100,000 g and the clear super-
natant was collected. Size exclusion chromatography was done using dilutions of 15-60 mg! 
30 ml (depending on the viscosity of the solution), with a TSKHW75 column (gel bed 700 
x eluent). Afler passage of 100 ml of void volume, fractions (8 milS minutes) were collected 
and assayed for their protein and carbohydrate contents. High-molecular-weight fractions 
containing carbohydrates but no proteins were pooled, dialyzed, and lyophilized. From 100 
g of feces about 50 mg PG could be retrieved by this procedure. 
Isolatioll of PG ji'Olllizumall spleell 
Some 50-100 g of minced spleen tissue in 500-1,000 ml Milli-Q water was homogenized 
in a homogenizer (Virtis company, New York, NY) at 10,000 rpm for 30 s. The homog-
enate was sonicated five times for I min at maximum amplitude (MSE soniprep 150, UK). 
Acetic acid (96%) was added to a final concentration of 0.2 M. The extract was incubated at 
room temperature for 2 hr under rotation and was subsequently heated gradually in a water 
bath by 100°C over 30 min. The extract was centrifuged at 10,000 g for 60 min (4'C). The 
volume of the supernatant was reduced by lyophilization to 25-50 ml and the extract was 
then centrifuged at 100,000 g for 60 min (4'C). The supernatants were separated by gel 
filtration on a 275 ml gel bed of Sephadex G-25 (Phannacia, Uppsala, Sweden). Muramic 
acid and protein content was detennined in all fractions according to the methods ofHadzija 
(28) with some modifications (29) and Bradford (30), respectively. The high-molecular-
weight fraction containing muramic acid was collected and size exclusion was done by 
loading I-ml fractions on a Superdex 200 column (Phanuacia) connected to an FPLC (Fast 
Perfonuance Liquid Chromatography) (Phanuacia). Protein was determined in all frac-
tions according to Bradford, and PG was measured by ELISA. Fractions were pooled (see 
below), dialyzed against Milli-Q water and lyophilized. 
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Allalysis of PG isolaled frolll IlIIlIIall spleen 
PG detectioll by ELISA 
To measure PG in the fractions after Superdex 200 (Pharmacia) gelfiltration an ELISA 
was performed. We coated 50 III of the fractions overnight at 50'C in 96-well polystyrene 
microtiter plates. The plates were washed 3 times with PBS-0.02% Tween 20 (Fluka Chemie 
AG, Buchs, Switzerland). 100 III ofMab 2E9 (10 lIg1ml in PBS-0.2%Tween) was added to 
the wells. After I hour at 37'C, unbound antibody was removed by 3 wash steps. As detect-
ing antibody, we used peroxidase conjugated rabbit anti-mouse immunoglobulin (P260, 
Dako, Glostmp, Denmark) diluted I: 1000 in PBS-Tween 0.2%. After 3 washes the colo-
rimetric assay was developed at 37'C for 30-45 min after the addition of 100 III of ortho--
phenylenediamine/H,O,. The reaction was stopped by the addition of 50 III 4M H,S04 and 
the optical density was measured at a wavelength of 492 nm (Titertek Multiskan; Flow 
Laboratories, Irvine, Scotland). Results were expressed as optical density (OD) units. 
Protein analysis according 10 LowI), 
The amount of protein in the pooled fractions was determined according to LOWlY (31) with 
modifications (32). We added I ml of 2% Na,CO, in 0.1 M NaOH to 200 III of the pooled 
fractions and incubated for 45 min at 70'C. After the samples were cooled, 20 III of 0.5% 
CuSO,.5H,O was added and the mixture was incubated for 10 min at room temperature. 
Finally, 200 III of Folin-Ciocalteen reagent was added during 45 min at 37'C. Absorbance 
was measured at 620 nm. 
Muramic acid analysis with a colorimetric muramic acid assay 
In the pooled fractions, the amount of muramic acid was determined in accordance with 
the Hadzija method (28) with some modifications (29). In short, 100 III of the samples was 
hydrolyzed by heating for 2 h at 90'C with an equal volume of 5 M H,S04' then neutralized 
with 100 III 10 M NaOH. Hydrolyzed and unhydrolyzed samples (100 III) were incubated 
with 50 III I M NaOH at 37'C for 30 min. After the addition of I ml 18.8 M H,S04, samples 
were heated for 3.5 min at 100'C, rapidly cooled on ice and then mixed with 10 1110.16 
M CuSO,.5H,O in H20 and 20 III 0.09 M p-hydroxydiphenyl in ethanol. After incubation 
for 30 min at 30'C, absorbance at 570 nm was determined by Titertek Multiskan. Solu-
tions containing 0-100 IIg muramic acid (Sigma, St. Louis, MO) per ml H,O were used 
as standards. The data are given as the difference in concentration between the hydrolyzed 
and non-hydrolyzed samples. In this way, only muramic acid linked to peptides in peptido-
glycan was detennined and contaminating sugars like rhamnose and lactic acid, which are 
deternlined in the non-hydrolyzed sample, were excluded. 
Muramic acid assay by high pel/ormance liquid chromatography (HPLC) 
The presence of muramic acid in the isolated fraction was also determined with an amino-
sugar determination using high performance liquid chromatography (HPLC) reversed phase 
techniques as described by Glauner (33). In short, 300 III of the isolated PG was hydrolyzed 
with 9 M HCI for 3 h at 90'C. The sample was frozen, lyophilized and redissolved in 100 
III H20. This sample was added to 100111200 mM borate buffer pH 8.8 and 1001'120 mM 
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dansyl chloride (5-dimethylamino-naphthalene-l-sulfonyl chloride, Fluka Chemie AG) in 
acetone for 2 h at 37'C. The reaction was stopped with 35 J.ll 200 mM phosphoric acid. 
Separation of dansylated aminoacids and aminosugars was accomplished by reversed phase 
HPLC. Samples were analyzed using a single pump solvent delivery system (LAB 2248; 
Pharmacia) and a UV-VIS monitor (VWM 214[; Phanoacia) both connected to a computer 
working with HPLC Manager software to control the pump, gradient mixer and UV-VIS 
detector operating at 330 nm. Integration and analysis of chromatograms was performed 
using the same software (Phanoacia). Dansylated samples were separated using a Phanoa-
cia SuperPac Sephacil Cl8, 5 J.lm, 4x250 mn column. The flow rate used was [ ml/min 
and the buffers were as follows: buffer A, 20 mM sodium phosphate pH 5.25 and buffer 
B: 60% acetonitril and 40% 50 mM sodium phosphate pH 4.0. At 0, 10, 16 and 22 min 
the concentration of buffer B was 30, 50, [00 and 30 %, respectively. Eluted products were 
detected at 330 mn, the wavelength that is maximally absorbed by the dansyl groups. 
Iuduction oj cytokine release ill whole blood after stimulatiou with PG 
Human peripheral blood was obtained from healthy donors and collected in sodium-heparin 
tubes (Vacutainer, Becton Dickinson). We added 12.5 J.ll of RPM I 1640 (Gibco, Breda, The 
Netherlands) containing isolated PG or LPS (Sigma) with or without the LPS antagonist 
polymyxin B (Sigma) to a polypropylene tube (Falcon) containing 112.5 J.ll blood. Inhibition 
assays were performed by incubation of human blood cells with 10 and 5 J.lglml anti-CDl4 
antibody (My-4, azide-free, Coulter Clone, Hialeah, FL) or isotype control IgG2b antibody 
(MOPC-195, Coulter clone) for 30 minutes at 37"C or by incubation of the isolated PG 
fractions and LPS with proteases (1-0.001%) (elastase, trypsin, a-chymotrypsin, (Sigma)) 
during I hour at 37"C. The mixtures were incubated for 5 hours at 37"C in a 5% CO, atmo-
sphere. Then 375 J.ll RPMI was added to each tube and the mixtures were centrifuged for 
10 minutes at 400 g. The supernatants were tested in bioassays for TNF-a, IL-l, and IL-6 
activity. 
TNF-a bioactivity was measured using the murine fibroblast cell line WEHI 164.13 by a 
cytotoxicity assay (34). The cells were plated in flatbottom tissue plates with 96 wells plates 
(Costar, Cambridge, MA) at a concentration of 10' cells/well. The cells were allowed to 
adhere by incubation overnight at 37"C in a 5% CO, atmosphere. At day 2, 50 J.ll ofactino-
mycine-D (Sigma) (4 J.lglml) and 50 J.ll diluted sample were added to the cells. Samples 
were tested in triplicate. After an overnight incubation (37"C, 5% CO,) the MTT (3-(4,5 -
dimethylthiazide-2-yl)-2,5 diphenyltetrazolium bromide, Sigma) cytotoxicity test (35) was 
used to measure WEHI cell viability. 
IL-l bioactivity was measured by use of an IL-l dependent subline of the murine T cell line 
DIO.G4.1, designated DIO(N4)M, using the method designed by Hopkins and Humphreys 
(36) with some modifications (37). One hundred microliters of sample was added to 10' 
cells/well and the cells were cultured for 3 days. Proliferation of the cells was measured 
after 4 h of ['H)-thymidine incorporation (0.2 J.lCi/well). 
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IL-6 activity was detected by using the murine hybridoma cell line B9 according to Am'den 
et al. (38). In the presence of 100 III of sample the 5 x 10' cellslwell were cultured for 
three days. Proliferation of IL-6 dependent B9 cells was measured after 4 hours of ['Hl-
thymidine incorporation (0.2 llCilwell). 
Recombinant human IL-Ip (UBI, Lake Placid, NY), IL-6 (a kind gift from Prof. Dr. L.A. 
Am'den, CLB, Amsterdam, The Netherlands) and TNF-o: (Amersham) served as positive 
controls for the D 10, B9 and WEHI-assays. Cytokine activities of the samples were cor-
rected for background activity of cells cultured in the absence ofPG, and were expressed as 
Ulml with I U corresponding to a half-maximum response obtained with a titration series 
of the recombinant cytokine. 
TNF-o: ELISA 
TNF-o: production in anti-CDl4 and protease treatment experiments was measured by 
an capture ELISA. ELISA was done according to the manufacturers' guidelines (Bio-
source, Fleurus, Belgium). In brief, polystyrene microtiter wells (Immuno maxisorp, Nunc, 
Roskilde, Denmark) were coated ovemight at room temperature with monoclonal human 
anti-TNF-o: followed by washing (0.9% NaCI) and 2 h of blocking (PBS/BSA 0.5%). 
Freshly thawed samples and an human TNF-o: standard (calibrated against WHO Intema-
tional Standard, TNF-o: 87/650, National Institute for Biological Standards and Controls, 
Potters Bar, UK) were incubated for 2 h in the presence of a biotinylated second TNF-Cl. 
antibody, followed by washing steps, poly-streptavidine-HRP (CLB, Amsterdam, the Neth-
erlands) and enzyme substrate (TMB peroxidase (KPL, Gaithersburg, MD)). Optical den-
sity was measured at 450 nm. 
RESULTS 
immunohistochemical staining of human spleen 
To confinn that antigen presenting cells containing PG were present in human spleens to 
be used for purification ofPG an immunohistochemical staining was perfonned. With Mab 
2E9 directed against PG derived from the normal intestinal flora, some macrophages and 
dendritic cells in all 7 spleens stained positive (figure I). With a negative control antibody of 
the same isotype (mouse IgG3) and with irrelevant specificity (anti-sheep red blood cells), 
no staining was found. 
Isolatiolt of PG ji'Om itumalt spleelt 
The purification ofPG from 7 individual human spleens was perfonned as described. After 
homogenization and sonication the relatively low-molecular-weight fraction was discarded 
by Sephadex G25 gel filtration. Figure 2 shows the elution pattem after Sephadex G25 gel 
filtration of I human spleen. 
52 
PG present ill human spleen 
' . 
. : i,' 
, . 
Figure 1. Detection of cells containing peptidoglycan (PO) in human spleen. Immunohistochemical 
staining was perfonned using Mab 2E9. Morphology and anatomicallocalizatioll of the cells contain-
ing intracytoplasmatic PO is consistent with that of antigen presenting cells. (magnification x63). 
Protein was first found after an elution volume of 120 ml H20. Muramic acid was detected 
after an elution volume of 124 ml until 156 ml H20. After an elution volume of 156 ml 
H20 the signal for muramic acid increased sharply due to the presence of lactate, which 
interferes with the muramic acid assay. The fractions between 124 and 156 ml, which rep-
resented a relatively high-molecular-weight fraction containing PO were pooled and the 
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Figure 2. Separation of relatively high and low-molecular-weight fractions from human spleen extract. 
Twenty-five milliliters of human spleen extract was added to Sephadex 025 column. In all fractions 
the amount of protein according to Bradford and the amount of PO (muramic acid) was measured. The 
fractions between 120 and 150 ml of elution volume which represented a relatively high-molecular-
weight fraction containing muramic acid, were pooled (~). 
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relatively low-molecular-weight fraction was discarded. The pooled fraction was loaded in 
I ml aliquots onto a Superdex 200 column to remove contaminating protein. The presence 
of PO in the eluted fractions was determined by ELISA. During the column passage the 
aliquots were diluted 25 times and therefore the colorimetric muramic acid assay was not 
sensitive enough to detect muramic acid. The protein content of all fractions was measured 
using the Bradford method. Figure 3 shows the amount of protein and PO in all fractions 
after Superdex 200 column gel filtration of I ml of the extract. 
The fractions to be used for ill vitro studies should contain minimal amounts of contaminat-
ing proteins. For this reason fractions with comparable amounts of protein were pooled. 
This resulted in pooling the fractions 2-5 (PI), fractions 6-8 (P2), fractions 9-16 (P3), frac-
tion 17 (P4), fractions 18-22 (P5) and fractions 23-25 (P6). Fraction 23-25 (P6) was used as 
a control since this fraction did not contain PO or protein. After all runs of the 7 spleens the 
corresponding fractions were pooled, dialyzed against Milli-Q water, lyophilized and stored 
at -20'C. 
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Figure 3. Separation of PO using Superdex 200 gelfiltration. One milliliter of spleen extract after 
Sephadex gelfiltratioll was added to the Superdex 200 connected to the fitst performance liquid chro-
matograph. The amount of protein and PO Was measured in all fractions with Bradford and ELISA, 
respectively. Pooled fmctions: F2-S (PI), F6·8 (P2), F9-16 (P3), FI7 (P4), F18-22 (PS), F23-24 (P6) (<-». 
PG aflalysis 
Protein analysis 
After Sephadex and Superdex 200 gel filtration the level of protein in the fractions was 
measured according to Bradford. With PO preparations of EubacteriulIl aero/aciens and 
BrevibacteriulIl divel'catiulIl we showed that the method according to Lowry et al (31) was 
more sensitive to detect protein (data not shown). Because the dilutions of the pooled frac-
tions used in some of the cytokine induction experiments were based on protein concentra-
tions, we used the method according to Lowry et al.(table I). The results show that fraction 
P I and P4 contain the lowest levels of protein. 
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Muramic acid analysis by a colorimetric muramic acid assay 
To determine the amount of PO in the pooled fractions, a colorimetric muramic acid assay 
was performed. Results are shown in table I. 
Muramic acid could only be detected after acid hydrolysis to remove peptides from PO, 
indicating that PO present in human spleen is structurally mostly intact. In contrast, hydro-
lysis of PO isolated from human feces had no effect on the level of muramic acid measured 
by the colorimetric muramic acid assay. This indicates that PO in human feces contains 
no or minimal levels of peptide chains bridging the MurNac backbone. The colorimetric 
muramic acid assay could not be used to measure the amount of PO in P3 because the level 
of protein in the fraction was too high. 
Table 1. Protein and muramic acid content in pooled fractions isolated from human spleen 
Muramic acid O.tglmJ) Protein (~g!ml) 
Before After Bradford Lowry 
Fraction hydrolysis hydrolysis method method 
PI 0 70 0 63 
P2 0 62 44 170 
P3 ND ND 975 1300 
P4 0 42 293 290 
P5 0 56 34 75 
P6 0 0 0 0 
Protein was measured according to Bradford (30) and Lowry et al (31). Muramic acid was measured by colorimet-
ric muramic acid assay. ND, not done 
Muramic acid by HPLC analysis 
To confirm the presence of PO in the fractions isolated from human spleen, P I and P4 were 
analyzed for the presence of muramic acid using HPLC. These two fractions were used 
because protein levels were low. First, the fractions were applied to the column (figure 4A) 
and spiked by adding dansylated muramic acid to the fraction. The peak with a retention 
time of 12.8 minutes was covered by muramic acid added to the fraction (figure 4B). This is 
also the retention time of muramic acid when it is loaded onto the column on its own. 
There are many peaks in the chromatogram and therefore the peak with retention time 12.8 
minutes was collected and reanalyzed to assess whether it had the same retention time as 
the standard dansyl muramic acid. The only peak in the chromatogram indeed had the same 
retention time as dansyl muramic acid (figure 4C). 
This peak was spiked by adding muramic acid to the sample. The smaller peak with reten-
tion time 5.4 minutes belonged to the muramic acid added to the sample (figure 4D). In the 
PO fraction we could not detect this peak because free dansyl groups were detected after 
this retention time. These results confirm the presence of muramic acid in both fractions. 
Because muramic acid is an unique component of PO, the HPLC analysis also confirmed 
the presence of PO in the fractions. 
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Figure 4. Identification of muramic acid in P5 isolated from human spleen. Reversed-phase HPLC on 
a CI8 column (5 11m, 4 x 250 mm) in a discontinuous gradient 0-15% methanol over 27 minutes at 
1.0 mllmin of (A) hydrolysed and dansylated preparation of P5 of spleen from patient I. B was like 
A but spiked with dansylated muramic acid .. C, collected peak with retention time 12.8 minutes from 
chromatogram A. D was like C but spiked with dansylated muramic acid. Absorbance was measured 
at 330 nm. Arrows indicate peak with retention time 12.8 minutes identified as muramic acid .. PI(not 
shown) shows the same pattern. 
Jnduclion of pl'oi!!IlammatOlY cytokines by PO 
To investigate whether PG present in human spleen tissue is biologically active, production 
ofTNF-O:, IL-l and IL-6 was measured in vitro after incubation of human blood cells with 
PG isolated from human spleen. Because P I contained the lowest amount of contaminating 
protein, this fraction was used. TNF-O:, IL-l as well as IL-6 were produced after stimulation 
with PG (figure 5A-C). This production was dose-dependent, correlating with the concen-
tration of P I added to the blood cell cultures. 
Polymyxin B is an efficient antagonist of LPS-activity, thereby inhibiting LPS-induced 
cytokine production. To exclude the possibility that activity of PG isolated from human 
spleen is due to contaminating LPS, we analyzed whether cytokine induction by PG was 
blocked by polymyxin B. 
Production ofTNF-o:, fL-l and IL-6 induced by PI was not inhibited by polymyxin B. LPS 
served as a positive control in all experiments and I nglml was able to induce the same level 
of cytokines induced by PI (75 nglml muramic acid). As expected, LPS-driven induction 
of cytokines was inhibited by polymyxin B. PG isolated from human feces induced TNF-o:, 
but the concentration (based on the amount of muramic acid) needed to induce the same 
level ofcytokine production as PI was 150 times higher. 
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To exclude the possibility that contaminating proteins present in the fractions P2-6 induced 
proinfiammatory cytokine production, P 1-6 were analyzed on the basis of equal protein 
concentrations. The amount of protein was based on a I :800 dilution of fraction PI (75 
ng/ml muramic acid). This fraction contained 78 ng/ml protein (according to the Lowry 
assay). All fractions were diluted so the concentration of protein added to the blood cells 
was 78 ng/ml. As expected, P6, which contained no PG or protein, could not induce cytokine 
production by whole blood cells; however, PI, P2, P4 and P5 all induced TNF-a, IL-I, and 
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Figure 5. Production of pro-inflammatory cytokines by human blood cells after stimulation with 
peptidoglycan (PG) isolated from human spleen. Human blood cells were incubated during 5 h in 
presence ofPt with or without polymyxin B. In supernatants TNF-ct production measured by \VEHI 
164.13 in cytotoxicity assay (A). B, IL-l production measured using the IL-l dependent subline of 
the T cell line DIO.G4.1. C, IL-6 production measured by the IL-6 dependent murine hybridoma cell 
line B9 
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IL-6 (table 2). P3 did not induce cytokine production. Since P3 contains very high amounts 
of proteins a dilution to 78 ng of protein results in minimal traces of PO in the fraction. 
This clearly suggests that contaminating protein does not induce cytokine production. The 
levels ofTNF-cx, IL-l, and IL-6 induced by the distinct fractions differed strongly between 
the fractions. This indicates that protein, present at equal concentrations in all fractions 
does not induce cytokine production. Consistent with this, the cytokine production directly 
correlated with the amount of PO in the fractions (correlation coefficients were 0.9, 0.8 and 
0.9 for respectively TNF-cx, IL-l, and IL-6 production compared to the amount of PO in 
the fractions). This indicates that PO, but not protein present in the fractions induces the 
production ofTNF-cx, IL-l, and IL-6 by human blood cells. 
Table 2. Production ofTNFM(X and ILM} and IL-6 by human blood cells after stimulation by the dif-
ferent fractions pooled after Superdex 200 gel filtration. 
Fraction Muramic acid Protein TNF-a IL-I IL-6 
PI 75 78 290 ± 25 35 ± 4 853 ± 80 
P5 64 78 140 ± 20 55 ± to 476 ± 55 
P2 28 78 64 ± 7 15 ± 2 123 ± 12 
P4 II 78 38 ± 4 14 ± I 89 ± 9 
P3 ND 78 0 0 0 
P6 0 0 0 0 0 
Medium 0 0 0 0 0 
Note. Human blood cells were incubated for 5 h with all pooled fractions (PI-P6) diluted to protein concentration 
of78 ng/m!. TNF-o:, IL-J, and IL-6 measured in supernatants by bioassays, are shown in U/ml; muramic acid and 
protein are in mglml. ND, not done 
To confirm that PO and not contaminating proteins causes the cytokine production, human 
blood cells were incubated with anti-CDl4 antibody for 30 minutes by 37°C. All fractions 
were diluted 80 fold resulting in the following muramic acid concentrations:(PI) 88, (P2) 
78, (P3) not done (P4) 53, (P5) 70, and (P6) 0 ngiml. 
Anti-CD14 antibody blocked cytokine production by the different fractions in a dose-
dependent manner, TNF-cx production was completely blocked in all fractions and LPS 
using a concentration of 10 Ilgiml (figure 6). An isotype matched control Ig02b antibody 
(MOPC-195) did not affect cytokine production. 
DISCUSSION 
In the current study we show that structurally intact PO isolated from sterile human spleen 
can induce production of the proinflammatory cytokines TNF-cx, IL-l and IL-6 by human 
blood cells. Other studies have demonstrated the capacity of cytokine induction by PO 
derived from bacterial cultures (9,10), but the ability of PO present in human tissues to 
induce cytokine production has not been reported. 
PO is thought to play an important role in the immunological response against gram-positive 
58 
PG preseJlt ill human spleen 
900,-----------------------------------------, 
800 
700 
=- 600 
.§ S 500 
~ 400 
lL 
Z 
I- 300 
200 
100 
medium Pl 
..,. 
P2 P3 P4 
fraction 
o aCD14 0 Ilglml 
o aCD14 10 1l9fml 
t:] aCD14 5 ~Lglml 
Figure 6. Inhibition ofTNF-ct production by human blood cells after incubation with anti-CDl4 
antibody. Human blood cells were incubated with anti-CDl4 antibody (5 and 10 jlglml) during 30 
minutes after then stimulated with PI-P6 and LPS during 5 h. TNF-ct production was measured using 
a capture ELISA. 
infections but it has also been hypothesized that PO is involved in the pathogenesis of 
chronic inflammations like RA. Our group investigated the role of PO derived from the 
nonnal intestinal flora in the pathogenesis of RA. The presence of PO in several human 
tissues (18-23) suggests that our body is constantly exposed to PO outside the gut. It is 
possible that PO in human tissues other than the gut is derived from the nonnal intestinal 
flora. The fact that we are able to isolate 50 mg PO per 100 gram feces shows that high 
amounts of PO are continuously present in the intestine. 
We hypothesize that PO is able to traverse the intestinal wall by unknown mechanisms and 
gain access to other sites of the body through the bloodstream and/or lymph circulation. PO 
is located in antigen presenting cells in tissues like human spleen and lymph nodes but also 
in synovial tissues. This was shown by immunohistochemical staining with a Mab against 
PO isolated from human feces (23). To investigate the relevance of PO in human tissues we 
studied the biological activity of PO isolated from human spleen. To obtain a high amount 
of PO it was necessary to modify the method described earlier (25). Because the passage 
of the spleen extract after Sephadex 025 gel filtration through a DEAE and Dowex column 
causes a considerable loss of PO, we developed another method to extract the protein. This 
was performed by size exclusion using Sephadex 025 gel filtration followed by Superdex 
200 gel filtration. Because the PO containing fraction is diluted 25-fold by the Superdex 200 
column passage the colorimetric muramic acid assay is not sensitive enough to detect PO in 
each fraction. Therefore we perfonned an ELISA using a monoclonal antibody against PO 
which is a more sensitive method to detect PO. 
We used two methods to detect PO in pools P I to P6. The HPLC analysis was used to 
confirm the presence of muramic acid in the fractions leading to the conclusion that PO was 
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present. The colorimetric muramic acid assay was used to measure the amount of PO in the 
fractions. This method was also used to determine whether PO is intact or not in tenns of 
the presence of peptide interlinks. This is important because from earlier studies it is known 
that the structure of PO is very crucial for its biological activity. For example, muramyl 
dipeptide (MDP) is the minimal structure of PO which is biologically active, but a much 
higher amount is needed compared with large molecules of PO which has a repetitive nature 
(12). Furthermore, PO isolated from the ileum which is mostly intact is able to induce 
arthritis in rats. PO isolated from feces, which is not intact is not able to induce arthritis in 
rats (39). This suggests the structural integrity of PO is crucial to its biological activities. PO 
isolated from human spleen was largely intact because no muramic acid could be detected 
before hydrolysis. Analysis of PO isolated from human feces revealed that the PO is not 
intact. With the improved purification of PO we were able to isolate 1.9 11M muramic acid 
per 100 gram spleen tissue. The amount of muramic acid isolated is similar as the earlier 
described method (25) (2.3 11M /100 g spleen tissue), but the amount of protein in the 
fraction is 20-fold lower which means that the fraction is more suitable for ill vitro studies. 
The cytokine induction assays show that PO isolated from human spleen can induce 
induction of TNF-a, lL-1 and IL-6. Kinetics of cytokine induction by PO was the same 
as LPS but the amount of PO needed was 100 times higher than LPS. The fact that low 
amounts of PO isolated from human spleen were required in comparison with PO from 
human feces indicates that intact PO is more active than a more degraded fonn. 
To exclude contamination of the isolated fraction the sample was analyzed using blood 
agar plates after every purification step. The whole procedure was also performed with 
PBS. With this procedure we were not able to induce cytokine production (data not shown). 
Contamination by LPS was excluded by incubating the fractions with polymyxin B before 
the various PO preparations to the blood cells. No inllibition of the cytokine production was 
found in contrast with cytokine induction by LPS. The results show also that the levels of 
cytokine produced correlated with PO concentrations and not with protein concentrations 
confirming that PO is responsible for the cytokine induction. This was confirmed with 
fraction P3 that contained very high concentrations of protein and unknown levels of PO. 
After the sample was diluted to a concentration of 78 ng/ml protein no cytokine production 
could be measured. 
There are three other indications that the cytokines produced by the different fractions are 
elicited by peptidoglycan and not by contaminating proteins. First, the incubation of the 
spleen extract in acetic acid at 10WC for 2 h will cause a loss of the tertiary and secondary 
structure of the proteins. This will lead to a reduction if not a complete loss of function ofthe 
proteins. Second, the fact that TNF-a measured by ELISA could be completely blocked in 
all fractions by incubating the human blood cells with anti-CD 14 indicates that the proteins 
in the fraction are not responsible for the cytokine production. CD 14, which is known 
as the LPS receptor is also known to bind PO and activate cytokine production (11,12). 
Binding of proteins to CD 14 mediating cytokine production has not been described. The 
third indication that PO is responsible for the cytokine production is the fact that treatment 
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of fraction P I-P6 with proteases (elastase, trypsin and a-chymoptrysin) does not affect 
cytokine production. Using different concentrations of prot eases (0.1-0.00 I % v/v) cytokine 
induction was equal with and without treatment (data not shown). The use of higher protease 
concentrations was not possible because the proteases then induced cytokine production 
directly. The inactivation of protein could not be monitored by measuring the loss of proteins 
because the protein content of the proteases added to fractions was much higher than of the 
original low level of contaminating proteins. 
Various studies, including the present study, have shown that PO is not restricted to the gut, 
even in the absence of infection. In all 15 spleens we have obtained thus far, PO-containing 
cells could be detected by use of immunohistochemistry. All spleens used were removed 
during surgery, because this is the only way to obtain sterile human spleens. These spleens 
were removed for various reasons (including when the spleen itself was not in any way 
diseased) indicating that healthy people contain PG in their spleens. It has been hypothesized 
that these bacterial products are derived from the intestinal flora. Because the present study 
showed that PG in human spleen is mostly intact it is likely that PO will pass the bowel wall 
before it is degraded by enzymes (39). 
A prime question is whether the presence of PG in sterile human spleen tissues has any 
biological significance. To answer this question it is important to know if PG in human 
tissues has biological activity. This study shows that, in vitro, PG has the capability to 
induce cytokine production by human blood cells. If this activity is the same in the 
ill vivo situation, antigen presenting cells containing PO might be activated by PG to 
produce proinflammatory cytokines. The function of tllis cytokine production is possibly 
the triggering of a continuous immune response for controlling normal homeostasis. It was 
recently argued that continuous exposure to bacterial antigens is important in regulation of 
T helper I (Thl) versus T helper 2 (Th2) CD4 positive T-cells (40). Disturbances of this 
Th I/Th2 balance may lead to autoimmune diseases. A possible way by which this balance 
can be disturbed may the presence of too much PG in tissues because of intestinal injury. 
The presence of PO in tissues where the clearance of antigens is very difficult, for example 
synovial tissue, could induce local inflammatory processes. 
In conclusion, PO isolated from human spleen is largely intact and is able to induce cytokine 
production by human blood cells at very low concentrations. To further investigate whether 
PG-containing cells in vivo are also able to induce pro inflammatory cytokine production 
in situ, these cells will be analyzed by innnunohistochemistry. In addition, immunization 
of mice with PG will allow kinetic analysis of local cytokine induction by spleruc antigen 
presenting cells containing PO. 
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Bacterial peptidoglycan from human spleen elicits proliferation of 
CD4+ and CD8+ o:~ TCR+ T cells after proteolytic processing 
Ingrid A. Schrijver, Marie-Jose Melief, Maarten P. Hazenberg and Jon D. Laman 
Department of Immunology, Erasmus University Rotterdam alld 
Ulliversity Hospital Rotterdom-Dijkzigt, The Netherlallds 
ABSTRACT 
Peptidoglycan (PO), the major component of the cell wall of gram-positive bacteria, has 
potent proinfiammatory activity and elicits specific antibody formation including IgO. PO 
isolated from sterile human spleen is able to induce production of the proinfiammatory 
cytokines TNF-o:, IL-J and IL-6 by human monocytes ill vitro. In the present study we 
investigated whether PO isolated from human spleen can also induce T cell proliferation. 
PO stimulated tritium thymidine incorporation of peripheral blood cells. Flow cytometry 
showed that Ki-67+ proliferating cells were mainly CD4+ o:~ TCR+ T cells but a small 
fraction of CD8+ o:~ TCR+ T cells was also stimulated by PO. yo TCR+ T cells did not 
proliferate upon PO exposure. Anti-CD I 4 inhibited PO-induced T cell proliferation indicat-
ing that CD 14 is necessary for PO binding by monocytes. Furthermore, the inhibitors of 
proteolytic processing, chloroquine, Jeupeptin and brefeldin A efficiently inhibited T cell 
proliferation in a dose dependent fashion. The presentation of PO was inhibited by anti-
HLA class II antibodies and anti-HLA-class I antibodies, suggesting that PO-derived epit-
opes can be presented by both molecules to CD4+ and CD8+ T cells. These results demon-
strate that PO present in human spleen is able to elicit a proliferative response of CD4+ 
and CD8+ o:~ TCR+ T cells after binding to CDI4 on monocytes, followed by intracellular 
processing and presentation mediated by HLA-class II and I. This implies that bacterial PO 
transported by antigen presenting cells from mucosal surfaces including the gut to second-
ary lymphoid organs in a continuous fashion can elicit T cell responses, cytokine production 
and antibody formation in the absence oflocal bacterial replication. 
INTRODUCTION 
Peptidoglycan (PO) is the major component of the cell wall of gram positive bacteria. PO 
is composed of alternating N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid 
(MurNAc) residues, forming long sugar chains, which are interlinked by peptide bridges 
resulting in a large complex macromolecular structure (I). During bacterial infection, PO 
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and several other cell wall components are thought to be involved in the inflammatory reac-
tion (2). In gram-negative infections, lipopolysaccharide (LPS) is a well-known activator 
of the innate immune system (3,4). During gram-positive infections, when no endotoxin 
is present, PG is able to activate complement (5,6), to stimulate granulocytes (7,8), and to 
upregulate expression of adhesion molecules on endothelial cells (8). Importantly, PG is 
also able to induce production of pro inflammatory cytokines like IL-I, IL-6 and TNF-a by 
monocytes ill vitro (9,10). Similar to LPS-induced cytokine production, PG activities can be 
inhibited by preventing uptake of PG andlor activation of macrophages and monocytes by 
blocking the CD 14 receptor (11,12) in contrary to LPS, PG does not require LBP or semm 
(13). 
It has been hypothesized that PG is involved in the pathogenesis of chronic inflammation 
like rheumatoid arthritis (RA) (14-16). PG has been detected in liver and spleen (17,18), 
synovial tissues (17,18), urine (14), synovial fluid (19) and circulating peripheral blood 
leukocytes (20). The latter finding implies that macrophages may ingest PG at mucosal 
surfaces or after bacterial translocation, and subsequently transport it to distal non-muco-
sal sites such as the spleen. PG present in antigen presenting cells could be detected in 
normal human spleen and in synovial tissues ofRA patients (21) using a monoclonal anti-
body directed against bacterial flora-derived PG isolated from human feces (22). We were 
also able to isolate bio-active PG from sterile human spleen using biochemical methods 
(23,24). 
The proinflammatory effects of PG on antigen presenting cells have been thoroughly stud-
ied (9,10,24) but Tcell reactivity against PG has not been fully explored yet. 
Healthy donors all have systemic antibody responses against PG, including T cell depen-
dent IgG, strongly suggesting that PG is able to stimulate CD4+ T helper cell proliferation 
(25). 
Previous studies performed on this subject have focused on the mitogenic capacities for 
PG on B lymphocytes. Mouse studies have shown that PG is not mitogenic for murine T 
lymphocytes (26), while mitogenic B cell activation by PG is independent of T cells and 
macrophages (26,27). In humans, B cell activation by PG was dependent on T cells (28-30). 
Limited studies on T cell activation by PG showed that T cells respond to PG only in the 
presence of monocytes, suggesting that uptake of PG by antigen presenting cells is neces-
sary to elicit T cell responses (29,31). Furthennore, it was shown that T cell lines specific 
for PG induced a delayed type hypersensitivity (DTH) response in Lewis rats (32) (33). 
These lymphocyte-activating properties, mainly examined on PG isolated from Staphylo-
COCCIiS alirellS, are not shared by all bacterial PGs. For example, PG from E. coli (34) is 
not able to stimulate immunoglobulin synthesis and Micrococcus Iysodeikticlis (35) has no 
mitogenic capacities. 
In the present study, PG isolated from human spleen was used to further define the immuno-
stimulatory capacities of PG present in human tissues. The origin of spleen PG is unknown 
but it is most probably derived from the mucosal surfaces, especially the gut, where the 
body is continuously exposed to gram-positive bacteria. PG isolated from human spleen 
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might be derived from many various bacterial species and peptide bridges are mainly intact 
(24). This is crucial in the study ofT lymphocyte activation because previous studies have 
shown that T cell proliferation by stimulation with PG derived from bacterial cultures is 
abolished after lysozyme degradation (29). Furthermore, PG present in human tissues was 
approximately 10-100 fold more biologically active than PG isolated from human feces 
which has been exposed to degrading enzymes in the gut (24). 
The aim of this study was to assess whether PG isolated from sterile human spleen is able 
to elicit T cell responses. Our data show that spleen PG induces a~ CD4+ and CD8+ T cell 
proliferation after CD 14 binding and proteolytic processing. 
MATERIAL AND METHODS 
Isolation of PG ji'OlIl hlllllan spleen 
PG used was isolated from human spleen as described before (24). Briefly, minced spleen 
tissue was homogenized and sonicated. The extract was treated with acetic acid (96%) 
for 2 h at room temperature and 30 min at 100"C. After centrifugation the volume of the 
supernatant was reduced by lyophilization. The extract was separated by gel filtration on a 
275 ml gel bed of Sephadex G-25 (Pharnlacia, Uppsala, Sweden) followed by a Superdex 
200 column (Phannacia) connected to a FPLC {Fast Performance Liquid Chromatography 
(Phanuacia». Protein content was determined in all fractions according to Bradford, and 
PG was measured using an ELISA. Fractions were pooled (see below), dialyzed against 
milli-Q water and lyophilized. In this study we used a fraction which contained 70 Ilglml 
muramic acid, a unique component of PG and 0 Ilg/ml protein according to Bradford and 
63 ~lglml protein according to Lowry. Cytokine induction correlated with muramic acid 
content and not with protein concentration (36). 
PG isolation ji'OlIl hlllllan feces 
PG from feces ofa healthy subject was prepared as described previously (37). Briefly, feces 
was diluted in distilled water and homogenized. After cambric gauze filtration the suspen-
sion was treated with 96% ethanol for 2 h at 4'C. The precipitate was centrifuged and the 
pellet was dissolved in and dialyzed against MilliQ water. Next, the suspension was centri-
fuged for I h at 100,000 g and the clear supernatant was collected. Size exclusion chroma-
tography was perfonued with a TSK HW75 column (gel bed 700 x eluent). Fractions (8 
milS min) were collected and assayed for their protein and carbohydrate contents. High 
molecular weight fractions containing carbohydrates but no proteins were pooled, dialyzed, 
and lyophilized. From 100 g of feces about 50 mg PG could be retrieved by this procedure. 
T cell proliferation 
To detenuine whether T cell proliferation occurred upon PG stimulation, peripheral blood 
mononuclear cells (PBMC) of healthy donors were isolated from heparin blood using Ficoll 
(Phanuacia). 100 III containing 2x 10' cells were plated in 96 well round bottom plates. 50 
III of appro pi at ely diluted blocking reagents chloroquine, leupeptin, brefeldinA (all Sigma), 
anti-CD 14 (My-4 Coulter clone, azide-free, Hialeah, FL) anti-HLA-I {3FIO Ancell, azide-
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ftee, Bayport, NM} or anti-HLA-II (TDR31.1, azide-free, Ancell) or isotype-matched con-
trol antibodies were added to the wells. Unless indicated otherwise, cells were cultured 
with 50 J.ll of PG isolated from human spleen (0.35 J.lglml muramic acid), PG isolated 
from human feces (4 J.lglml muramic acid) or the recall protein antigen tetanus toxoid 
(TT) (3Lf/ml}(RIVM, Bilthoven, the Netherlands). Both cells and antigens were diluted 
in RPMI (Biowittaker, Verviers, Belgium) supplemented with 10% human serum and 
penicilinistreptavidin. All concentrations mentioned are final concentrations. The cells were 
cultured during 7 days (unless stated otherwise), the last S hours in the presence of triti-
ated thymidine (Amersham Phannacia Biotech, Little Chalfont, Buckinghamshire, UK). 
The cells were then harvested, and tritiated thymidine incorporation was counted in a liquid 
scintillation counter. The proliferative response was expressed as counts per minute (cpm) 
or stimulation index (SI), the ratio of mean cpm in the presence and absence of antigen. 
Each experiment was perfonned at least four times with PBMC of five to thirteen high 
responding donors. In the figures representative experiments of one individual donor are 
shown. 
Binding of PG 
For determination of binding ofPG, PG isolated from human feces was labeled with biotin 
as described before (3S). To assess to which cell type PG binds, double stainings were 
perfonned with PG-biotin and the FITC-Iabeled Mab Leu-4 (anti-CD3), B4 (anti-CDI9), 
Leu-Ml (anti-CDl5) (all from Becton Dickinson, San Jose, CAl or My-4 (anti-CDI4) 
(Coulter Clone) on whole blood cell samples. Kinetics of PG binding were detennined by 
incubating PG-biotin in RPMI + 10% human serum at 37'C in different concentrations 
for different incubation periods with percoll gradient-enriched monocytes. The number of 
CD I 4 positive cells was evaluated in samples incubated without PG-biotin. Binding ofPG-
biotin was analyzed by flow cytometry. 
Flo\V cylomellY 
For immunofluorescence staining of proliferating PBMC, anti-Ki-67 (Becton Dickinson) 
was used. Double staining was perfonned with antibodies against CD4, CDS, TCRap and 
TCRro <all Becton Dickinson}. After the PBMC were washed in PBS/O.5%BSA, they were 
incubated with 50 J.l1 of optimally titrated PE- or Cy labeled Mab Leu-3 (anti-CD4); Leu-2 
(anti-CDS), WT31 (anti-TCRaP), IlF2 (anti-TCRro) for 30 min at 4'C. Mouse isotype-
matched antibodies with irrelevant specificity were used as a control for non-specific bind-
ing. After two washings, cells were penneabilized using Lysing solution® (Becton Dickin-
son). After washing twice, the cells were incubated with FITC-Iabeled anti-Ki-67 for 30 min 
at 4'C. After another two washings, the cells were resuspended for analysis of the fluores-
ence intensity by means ofa FACScan® (Becton Dickinson). For assessment ofPG binding 
to monocytes or whole blood cell samples, the same procedure was followed. Double stain-
ings were performed with PG-biotin and FITC labeled anti-CD3/CDI9/CDI5 or CDI4. 
PG-biotin was detected with streptavidin-PE. 
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RESULTS 
PGfrom hllman spleen induces proliferation of PEMC 
To detennine whether PG is able to stimulate proliferation ofPBMC, cells from four healthy 
donors were incubated during 9 days with different concentrations of PG isolated from 
human spleen or human feces. Proliferation was analyzed after 2-9 days by measuring tri-
tium thymidine incorporation. Proliferation could be observed after stimulation with PG 
from spleen containing a muramic acid concentration higher than 90 nglml. 100-fold higher 
concentrations PG from feces were needed based on muramic acid content, to obtain the 
same levels of proliferation compared to PG isolated from spleen (data not shown). After 
4-5 days of culture with PG, proliferation could be measured and peak proliferation was 
observed after 7-8 days of culture. Results of a healthy donor are shown in figure I. These 
kinetics are consistent with proliferation of antigen specific T cells as measured using TT. 
In all further experiments a concentration of 360 nglml muramic acid and a culture period 
of 7 days was used. 
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Figure 1. PO isolated from human spleen induces proliferation of PBMC. PBMC isolated from a 
healthy human dOllor were incubated during 9 days with different concentrations of PO isolated from 
human spleen. After a culture period of 4-5 days) proliferation could first be observed with concentra-
tions higher than 90 nglmt muramic acid (MurNAc) measured by tritium thymidine incorporation. 
Peak proliferation was observed after 7-8 days of culture. Proliferation is expressed as mean cpm ± 
SD of triplicate cultures. 
CD14 is the receptorfor PG 
To examine the binding of PG, PG isolated from human feces was labeled with biotin and 
binding of PG was analyzed by flow cytometry. Binding of PG to cells was analyzed by 
double staining of whole blood cells of 4 healthy donors with PG-biotin and different cell 
subset markers (CD3, CDI4, CDl5, CDI9). No double staining could be observed with 
CD3 or CDI9. Double staining with PG was shown with both anti-CDl4 and anti-CDl5. 
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CDl4 is expressed by both monocytes and granulocytes, while CDl5 is only expressed on 
granulocytes. After gating ofmonocytes and granulocytes results showed that all monocytes 
(7% of blood cells) (figure 2A) and 25% of the 40% gated granulocytes bound PG (figure 
2B). This was consistent with the percentage of granulocytes expressing CD 14. Anti-CD 14 
treatment prevented PG-binding to monocytes (data not shown). The results suggest that PG 
from feces binds to CD 14 which is present on both monocytes and granulocytes. Kinetic 
studies on PG binding by monocytes showed that PG binding on CD 14 positive cells at 
37"C was first detected after 10 min, reaching 100% binding after 20 min of culture. After 
30 min PG binding gradually declined, reaching background levels after 4 hrs, probably 
reflecting intemalization (figure 2C). 
To examine whether binding of PG by CD 14 is a prerequisite for induction of T cell pro-
liferation, anti-CDl4 (My-4) known to block PG induced cytokine production (24), was 
added to PBMC of five healthy donors at different concentrations during cell culture. Prolif-
eration was measured using tritium thymidine incorporation after 7 days of culture. Results 
showed that anti-CD 14 blocked T cell proliferation in a concentration dependent manner. 2 
J.lg/ml of anti-CD 14 was able to inhibit proliferation completely. As expected, IT-induced 
proliferation could not be inhibited by anti-CD 14 as this protein antigen does not utilize 
CD 14 for intemalization (figure 2D). 
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FigUl'C 2. CD14 is involved in the binding of PO and stimulation of T cells by PO. Biotinylated 
PO isolated from human feces binds to the CD14 receptor on monocytes and granulocytes. Whole 
blood cells were cultured in the presence of PG-biotin for 30 min. PG-biotin was detected with 
streptavidin-PE using flow cytometry. On the FSCfSSC scatter monocytes (2A) and granulocytes (2B) 
were gated. Histograms of the gated cells with (thick line) and without (thin line) streptavidille-PE 
showed that PO bound to all monocytes and 65% ofgranutocytes. Experiments on the kinetics oflhe 
binding of PO to mOllocytes showed that binding was detectable after 5-10 minutes and reached bind-
ing to 100% of CD14 positive cells within 20 min at 37°C (2C). Data are expressed as percentage 
ofCD14 + cells PO-biotin was bound to. Proliferation ofPBMC was dependent on binding of PO to 
CD 14 since 2 ~gfml of anti-CD 14 (My-4) was able to completely inhibit proliferation (2D). Prolifera-
tion is expressed as mean cpm ± SD of triplicate cultures. 
CD4+ and CD8+ a~ TCR+ T cells proliferate after stilllulatiollll'ilh PG 
To assess which cellular subsets proliferate after PG stimulation, flow cytometry was per-
fonned for five PG responders after 7 days of culture. 
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Figure 3. PG stimulates proliferation of CD4+ and CDS+ ap TCR+ T cells. Flow cytometry with 
Ki-67 and CD4/CDSrrCRaprrCRyo was perfonned to identify proliferating cells afier stimulation 
with PO from human spleen. Without stimulation no proliferating cells could be observed (AJC,E,O), 
Results show that both CD4+ (B) and CD8+ T cells (D) proliferated afier PG stimulation. 95% of all 
proliferating cells were ap TCR + T celis (F) in contrast to only 5% of yo TCR+ T cells in a single 
donor (H). 
71 
Chapter 2.2 
To identifY proliferating cells, anti-Ki-67 (39) was used in combination with anti-CD4, 
anti-CDS, anti-CDl9 and anti-CDl4. Neither B cells (CDI9+) nor monocytes (CDI4+) 
proliferated after stimulation with PG (data not shown). Without stimulation, only 0-1 % 
of total PBMC were positive for Ki-67 (figure 3ADEG), but after stimulation with PG 
S%-15% ofPBMC were found to express Ki-67 in five different healthy donors dependent 
on the SJ. Double staining with anti-CD4 and anti-CDS showed that in one healthy donor 
75% of all proliferating cells were CD4+ cells and 25% were CDS+ cells (figure 3BD). The 
mean proliferation in all five healthy donors analyzed was for 70% (50-100%) due to CD4+ 
cells and for 30% (0-50%) due to CDS+ cells. 
Double staining was also performed with anti-TCR a~ and anti-TCR yo antibodies. In five 
donors analyzed, 100% ofKi-67 positive cells were a~ positive. In only one person prolif-
eration in the yo T cell subset (5% of all proliferating T cells), could be observed after PG 
stimulation (figure 3 G+H). 
Proteolytic processing oj PG is required to elicit T cell proliferation 
To determine whether processing ofPG is necessary to stimulate T cells, PBMC of7 healthy 
donors were cultured in the presence of chloroquine, brefeldin A or leupeptin, which are 
classic inhibitors of intracellular proteolytic antigen processing. Results show that all three 
processing inhibitors were independently able to inhibit T cell proliferation induced by PG 
in a dose dependent manner (figure 4). To completely block T cell proliferation, O.S 11M 
brefeldin A, 30 11M chloroquine or 25 11M leupeptin was needed. 
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Figure 4. Processing ofPG is required to stimulate T cells. To examine whether proteolytic processing 
ofPG from human spleen is required to induce proliferation, the processing inhibitors Icupeptin (3A), 
brefeldin A (3B), or chloroquine (3C) were added to PBMC cultures. Al three inhibitors were able to 
block T cell proliferation after stimulation with PO or TT stimulation. Proliferation was expressed 
as mean cpm +/- SD oftripiicate cultures. Levels of proliferation differ as several donors were evalu-
ated. 
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As expected, 'IT-induced T cell proliferation could also be blocked by all three processing 
inhibitors independently in the same concentrations. 
Cell viability was measured after 7 days of culture using trypan blue staining, confinning 
that inhibitor treatment did not negatively affect T cell proliferation. 
Preselltatioll oJPG-epitopes is mediated by both HLA-IJ alld HLA-J 
To examine whether HLA is involved in the presentation of PO for T cell proliferation, 
PBMC cultures of 7 healthy donors were incubated with either anti-HLA class I and II 
antibodies, known to block antigen presentation for 30 minutes before addition of PO. 
Both antibodies were able to inhibit proliferation ofT cells, although anti-HLA-I antibod-
ies partly depressed the proliferation, and anti-HLA-class II antibodies completely blocked 
proliferation. This is consistent with the finding that more CD4+ T cells proliferate in 
response to CD8 + cells (figure 5). 
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Figure 5. Presentation ofPG is mediated by HLA-I and II. To assess whether presentation ofPG is 
required for proliferation ofT cells, anti-HLA-I and 3nti-HLA-II blocking antibodies were added to 
the PBMe cultures. Anti-HLA-II was able to inhibit T cell proliferation at a concentration of 1 j..tglmJ. 
Anti-HLA-I also markedly inhibited PG induced proliferation. Proliferation was expressed as mean 
cpm +/- SD of triplicate cultures. 
DISCUSSION 
The present study shows that PO isolated from sterile human spleen is able to induce prolif-
eration ofCD4+ and CD8+ o:~ TCR+ T cells. CDl4 is necessary for uptake of PO by anti-
gen presenting cells and proteolytic processing is required for presentation of PO, involving 
HLA-class II and I. 
It has been reported previously that PO isolated from cultured Staphylococcus aureus was 
able to induce proliferation of human T and B cells (28,29), but the current report, to our 
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knowledge, is the first to demonstrate that PG present in human tissues is able to induce T 
cell proliferation. In the present study we analyzed the kinetics of the proliferative response 
ofPBMC after stimulation with PG. It was shown that after 7-8 days of culture the highest 
proliferation could be measured. Together with the data that the proliferative response can 
be inhibited with anti-class I and II HLA antibodies, this suggests that PG induces an anti-
gen specific T cell response. Although PG from spleen contained protein, activation of T 
cells by protein contamination is highly unlikely in view of the following two facts; first, 
different fractions ofPG with different protein and PG concentrations were shown to induce 
cytokine production dependent on PG concentration and not protein concentration (24). 
Second, the inhibition assays with anti-CDl4 confirmed that the proliferation is CDI4-
dependent, and it is highly unlikely that contaminating proteins use CD 14 as a receptor. 
Furthennore, LPS contamination of the PG fraction has previously been excluded by coin-
cubation with polymyxin B, an efficient LPS antagonist (24). 
Flow cytometry using an antibody recognizing Ki-67, a nuclear antigen of proliferating 
cells (40), showed that both CD4+ and CD8+ a~ TCR + T cells proliferate after stimulation 
with PG. The observation that PG-induced proliferation could be blocked by anti-HLA-
class II and I was consistent with proliferation of both CD4+ and CD8+ T cells, respectively. 
Most proliferating cells were CD4+, and proliferation could be completely blocked by anti-
class II antibody. The observation that CD8+ cells could be activated by (exogenous) PG 
is consistent with recent studies (41,42), showing that exogenous antigens are able to reach 
intracellular compartments for loading onto class I molecules for stimulation ofCD8+ cells. 
In macrophages, two fundamentally different pathways for the presentation of exogenous 
antigens in HLA class I molecules have been described, one involving unconventional post-
Golgi loading ofHLA class I (43), and another involving unusual access of exogenous anti-
gens into the classical loading pathway (44). Proliferation induced by PG could be inhibited 
by leupeptin, an inhibitor of lysosomal proteinases, and by chloroquine, a weak base which 
elevates the pH in endocytic compartments and thereby inhibits the action of acid-optimal 
proteinases, and finally by brefeldin A, a selective inllibitor of Golgi transport. All three 
inhibitors blocked T cell proliferation in a concentration-dependent manner at equal as pre-
viously used for classic protein antigens (45-47). This suggests that PG induced prolifera-
tion is dependent upon proteolytic antigen processing. Our binding studies showed that PG 
associates with CD 14, which is present on both monocytes and granulocytes. After 5-10 
min, PG from feces had already bound to monocytes confimling results earlier published for 
soluble PG (12). The blocking ofT cell proliferation by anti-CDl4 indicates that monocytes 
are required for the activation of T cells, probably as antigen presenting cells. This is in 
accordance with a study in which monocytes were necessary to induce stimulation ofT cells 
by PG derived from cultured Staphylococcus aureus (29). 
The question remains which PG-epitopes are presented by HLA. HLA molecules mainly 
present peptides derived from proteins, but recently it has been shown that glycopeptides 
are also able to elicit CD4+ or CD8+ T cell responses after presentation restricted by HLA 
class I and II (48-50). Therefore, theoretically, PG provides at least three potential sources 
of epitopes; peptides, carbohydrates and peptide in combination with one or two carbohy-
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drate molecules. T cell proliferation induced by a carbohydrate structure seems unlikely 
because proliferation of yo TCR+ T cells which is the major cell population stimulated 
by carbohydrate molecules, was hardly found after PG stimulation (51,52). To examine 
whether single PG peptides are able to induce T cell proliferation is difficult because the 
configuration of the peptides present in PG is complex and cannot be generated syntheti-
cally. When carbohydrate together with the peptide structure induces proliferation, degrada-
tion of PG is probably necessary because it has been shown that only one or two sugar 
molecules connected to a peptide can be recognized by a~ TCR+ T cells (51,52). Complete 
degradation of PG on the other hand prohibits T cell responses as lysozyme digestion of 
PG resulted in an abolishment of the T cell activation (29). The present study also supports 
this notion as 10-1 OO-fold higher concentrations of the more degraded PG isolated from the 
human gut are needed to generate T-cell responses similar to those elicited by the structur-
ally more preserved PG isolated from human spleen. 
The present study shows that PG, which is present in various tissues of healthy persons, 
is able to elicit proliferation of CD4+ and CD8+ a~ TCR+ T cells. The fact that healthy 
subjects respond to this antigen implies that T cell tolerance is not induced despite the 
continuous presence of PG in mucosal sites, which are optimally suited for tolerance 
induction. This lack of tolerance induction may be due to the adjuving properties of PG 
which elicits cytokine production (24) (9). Recently it has been argued that continuous 
exposure to bacterial antigens is important in regulation ofThelper I (Thl) and Thelper 2 
(Th2) CD4 positive T-cells (53). Disturbances of the Thl/Th2 balance may contribute to 
autoimmune diseases. Reduced gut barrier function may result in increased access of PG 
to non-mucosal sites (54). Macrophages containing PG migrated to non-mucosal sites, for 
example synovial tissues, might be able to persist and induce local inflammatory responses 
(55). To further examine the role of PG in rheumatoid arthritis, TIS cell and cytokine 
responses induced by PG are under current investigation in a group of rheumatoid arthritis 
patients. 
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ABSTRACT 
The gut flora is believed to playa role in the pathogenesis of rheumatoid arthritis (RA). 
Peptidoglycan, a major cell wall component of gram positive bacteria, is a candidate anti-
gen because of its capability to trigger production of proinflammatory cytokines, to induce 
arthritis in rodents, and because of its presence in antigen presenting cells in RA joints. 
We investigated whether the systemic and local antibody levels against an peptidoglycan-
polysaccharide (PO-PS) fraction isolated from the human gut is related to presence and dis-
ease activity ofRA. Systemic antibody levels (IgM, IgO, IgA) against PO-PS were analyzed 
in sera of 125 healthy donors, 44 early and 63 longstanding RA patients. Local antibody 
levels against PO-PS were analyzed in synovial fluids of 15 RA patients. All healthy donors 
had antibodies (IgM, IgO, and IgA) against PO-PS in serum. Signiflcantly lower levels 
of IgO directed against PO-PS were found in healthy females compared to healthy males. 
Healthy females showed an age-related decrease in IgA levels specific for PO-PS, while Ig 
levels of all three isotypes against PO remained stable in males of different ages. Levels 
of IgO directed against PO were significantly reduced in early RA and longstanding RA 
patients compared to sex and age-matched healthy controls. 
In all synovial fluid samples, antibodies against PO-PS could be detected. Titers of IgA 
antibodies correlated positively with disease activity. These data showing reduced systemic 
IgO levels against PO associated with rheumatoid arthritis and the presence of antibodies 
against PO in synovial fluids, suggest that antibodies against PO are attracted to the syno-
vial sites or that IgO mediates protection against spreading of PO to non-mucosal sites. 
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INTRODUCTION 
The search for the trigger (auto)antigen in the etiology of rheumatoid arthritis (RA) has 
been the topic of many studies, and in some of those a microbial etiology has been sug-
gested. In reactive arthritis, the triggering antigens are thought to be microbes that cause 
infections of the gut or urogenital tract, such as Chlamydia trachomatis, Yersillia, or Sa/mo-
lIella species (1). Antigens of these bacteria have been detected in synovial cells (2-4) and 
T cells specific for these antigens have been found in the synovium (5-7). Because RA is 
a chronic disease, it can be suggested that the bacterial load in the intestine with which the 
human body is in lifelong close contact might be important for the induction and perpetua-
tion of RA. This is supported by the observation that some patients with Crohn's disease and 
ulcerative colitis, both intestinal autoinnnune diseases, suffer from joint inflammation (8,9). 
Furthermore, Crohn's-like inflammatory bowel disease and chronic inflammatory arthritis 
develop spontaneously in a knockout mice lacking a TNF AU-rich element, responsible for 
TNF mRNA destabilization and translational repression in hemopoietic and stromal cells 
(10). 
We and others have previously hypothesized that peptidoglycan (PG) plays a role in the 
pathogenesis of RA (11-14). Peptidoglycan (PG) is the major component of the cell wall 
of gram-positive bacteria and is composed of long sugar chains of altemating N-acetyl glu-
cos amine (GlcNAc) and N-acetyl muramic acid (MurNAc) residues, which are interlinked 
by peptide bridges, resulting in a large complex macromolecular stmcture (15). PG isolated 
from the anaerobic bacterium Eubacterium aero/aciells which is present in numbers> 10'/g 
human feces, induces a severe and chronic arthritis in rats (16-18). FurthemlOre, PG could 
be detected in APC in synovial tissues of RA patients using a specific antibody (19,20). 
PG could also be isolated from sterile normal human spleen using biochemical methods 
(21,22). III vitro analysis showed that this PG fraction is able to induce production of the 
proinflammatory cytokines TNF-o:, IL-I and IL-6 (22) which are crucially involved in RA 
pathogenesis (23). 
Peptidoglycan can also be isolated from feces in soluble form. This macromolecular pepti-
doglycan polysaccharide complex (PG-PS) was shown to originate from the normal endog-
enous gut flora (24). Since PG is present at 0.5 mg/g feces (wet weight) it could be calculated 
that the intestinal anaerobic flora produces up to 200 mg ofPG daily in healthy adults. 
As high antibody titers of the IgM, IgG and IgA subclasses against PG can be found in 
healthy persons, it is obvious that the immune apparatus of the body is in continuous 
close contact with PG possessing strong arthritogenic capacity (25,26). Several studies have 
shown that increased levels of antibodies against PG are present in patients with bacterial 
infections (27) and in patients with various rheumatic diseases like ankylosing spondylitis, 
Reiter's syndrome, juvenile rheumatoid arthritis and rheumatoid arthritis (28-30). However, 
a study of Rantakokken et al. (31) showed that patients with RA had decreased antibody 
levels against streptococcal PG compared to healthy controls. 
In the present study we analyzed systemic and local antibody levels against PG-PS isolated 
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from the human gut in a large panel of healthy donors versus early and longstanding RA 
patients to assess whether antibodies specific may for PG-PS be involved in the pathogen-
esis ofRA. 
PATIENTS AND METHODS 
Sera 
ContlVl sera 
Sera of 98 healthy blood bank donors were obtained as a kind gift of the Department of 
Neurology of the Erasmus University and University Hospital-Dijzigt Rotterdam and 27 
additional sera of healthy donors were a kind gift of the Department of Epidemiology from 
the Erasmus University and University Hospital-Dijzigt Rotterdam (table I). Additional 
sera of 6 healthy volunteers (2 females, age 32 and 37 and 4 males age 26, 27, 27, 31 ) 
used for determination of optimal serum dilutions were obtained from the Department of 
Immunology of the Erasmus University Rotterdam. 
Patient sera 
Sera of 63 RA patients diagnosed with RA fulfilling the American College of Rheumatol-
ogy criteria (32) were obtained from the Zuiderhospital, Rotterdam and the Leiden Univer-
sity Medical Center. The majority of the patients received no immunosuppressive medica-
tion, some patients received low doses of prednisone (up to 10 mgt day) or methotrexate 
(up to 30 mg Iweek). Sera of 44 patients with RA ofless than I year's duration as measured 
from the first clinical signs of arthritis were obtained from the Leiden University Medical 
Center (table I). The majority of the patients received no immunosuppressive medication. 
Stalldard serum 
A pooled standard serum (~500 bloodbank donors) selected for high PG-PS reactivity was 
used in each ELISA plate as a reference for calculating antibody levels against PG-PS. 
Synovial fluid 
Paired samples of serum and synovial fluid were obtained from 15 RA patients with long-
standing RA from the Zuiderhospital Rotterdam. 
Clinical scoring 
RA disease activity of39 patients at time of donation (including the synovial fluid patients) 
was determined by the DAS (disease activity score)-28 score (33): 
0.56 "TJC + 0.28 "SIC + 0.7 log ESR + 0.014 GH 
were TJC~ number of painful joints (out of28) 
SIC~ number of swollen joints (out of28) 
GH~ general health score on a visual analogue scale (0-100) (table I). 
Erythrocyte Sedimentation Rate (ESR) (mmlhour) was used as a measure of disease activity 
of all other RA patients (table I). 
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Table 1. General features of the donor groups 
Group Source Number Age Duration DAS score* ESR 
male! (years) (months) (mm/hour) 
female 
Healthy controls serum 67 52(30-83) n.d. n.d n.d. 
58 50(19-88) n.d. n.d. n.d. 
RA patients: 
Early serum 17 64(28-84) < 12 n.d. n.d 
27 50(23-82) < 12 n.d. n.d. 
Long-term semm 20 62(33-84) 89(8-240) 5.6(3.3 - 7.4) 71(23-113) 
43 63(31-82) 132(13-420) 5.1 (1.9-7.2) 68(15-140) 
Synovial fluid 3112 63(46-82) 66(8-180) 5.7(3.4-7.4) n.d. 
expressed as mean with the range shown in parentheses 
# erytrocyte sedimentation rate, n.d.= not done 
Isolation of PG jimn illlman feces 
PG-PS from feces of a healthy subject was prepared as described previously (24). Briefly, 
feces was diluted in distilled water (40 g in 100 m!) and homogenized in a Model 400 
Lab Blender (Stomacher, Colworth, UK). After cambric gauze filtration the suspension was 
centrifuged for 45 minutes at 5,000 g. Four volumes of 96% ethanol were added to I volume 
of supernatant. After 2 hours at 4'C, the precipitate was centrifuged for 15 min at 5,000 g. 
The pellet was dissolved in and dialyzed against milliQ water for 48 h. Next, the suspension 
was centrifuged for I hour at 100,000 g and the clear supernatant was collected. Size exclu-
sion chromatography was performed using dilutions of 15-60 mgi30 ml (depending on the 
viscosity of the solution), with a TSK HW75 column. After passage of 100 ml void volume, 
fractions (8 mll5 minutes) were collected and assayed for their protein and carbohydrate 
contents. High-molecular-weight fractions containing carbohydrates but no protein were 
pooled, dialyzed, and lyophilized. From 100 g offeces about 50 mg PG could be retrieved 
by this procedure. 
Enzyme-linked immllllosol'bent-assay (ELISA) 
To measure anti-PG-PS-anlibodies in serum and synovial fluid an ELISA was performed. 
50 J.d ofPG-PS (10 Jlg/ml) was coated overnight at 50'C in 96-well polystyrene microliter 
plates. The plates were washed three times with PBS-0.02% Tween 20. 100 JlI serum or 
synovial fluid diluted in PBS-0.2% Tween was added to the wells and after I hour at 37'C 
unbound antibody was removed by three wash steps. As detecting antibody, peroxidase con-
jugated rabbit anti-human IgM, IgG or IgA (Jackson Immunoresearch, Inc., Westgroove, 
PAl diluted in PBS-Tween 0.2% was used during I hour at 37'C. After washing tbree times 
the development of the colorimetric assay took place at 37'C for 30-45 minutes after the 
addition of 100 JlI of ortho-phenylenediaminelH,O,. The reaction was stopped by adding 
50 JlI 4M H,S04 and the optical density was measured at a wavelength of 492 nm with a 
Titertek Multiskan (Flow Laboratories, Irvine, Scotland). Results were expressed as optical 
density (OD) units. On each plate the standard serum was included and each sample was 
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tested in triplicate. Background absorption ofthe conjugate was also tested in triplicate. The 
average OD reading ofthe sera and standard serum minus the background staining was used 
to calculate concentrations of antibodies in a ratio versus the standard serum according to 
the following fonnula: 
This ELISA has been validated previously (19), we excluded crossreactivity with rheuma-
toid t:1ctor (RF), by preincubating sera with known amounts of RF with PG. This did not 
interfere with subsequent detection ofRF. 
Determination oj optimal dilutions Jar measuring antibody levels against PG-PS 
Standard serum, sera of six healthy volunteers, as well as synovial fluids of five RA patients 
were titrated from 1:2 to I :6400 and added to the wells coated with either 5, 10 or 20 ~g/ml 
of PG-PS to detennine the optimal concentration of serum and antigen. Optimal senun con-
centration was the concentration in the linear area in the dilution curve. Based on checker-
board titrations, anti-PG-PS antibodies were measured after coating plates with 10 ~g/ml 
PG-PS and serum dilutions of I :400, I: 1600 and I :200 for IgM, IgG, and IgA, respectively. 
To analyze PG-PS antibodies in synovial fluid, dilutions of I :20, I :200 and I :80 were used 
respectively for IgM, IgG, and IgA. 
Total immunoglobulin determinations 
Of II randomly chosen sera of RA patients total IgM, IgG and IgA concentrations were 
measured using immunonephelometry (34) to examine whether total immunoglobulin con-
centrations were in the normal range. 
Statistical analysis 
The ratio's ofIgM, IgG and IgA measured in the PG-PS ELISA ofRA patients versus stan-
dard serum and controls were compared with Student's T test to analyze significant differ-
ences between the two groups. Linear regression was used to detect any age-related influ-
ence on the levels of immunoglobulin specific for PG-PS in healthy controls and to evaluate 
correlation between disease activity and anti-PG-PS antibodies in synovial fluid. 
RESULTS 
Systemic antibody levels against PG in healthy Jemales compared to healthy males 
Antibody levels against PG-PS were analyzed in the healthy control group to examine 
whether levels against PG-PS differ between male and female donors. Figure I shows that 
females have a significantly lower mean ratio of anti-PG-PS IgG antibodies to standard 
serum, compared to males (p<O.OI). Levels ofIgAand IgM antibodies against PG-PS were 
not different in females compared to males (figure I). These results show that IgG antibody 
levels against PG-PS differ in healthy male and female donors and have to be analyzed 
separately. 
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Figure 1. Systemic antibody responses against PO in healthy females compared to males. Levels of 
IgM, IgG and IgA against PG·PS were measured in 67 healthy men and 58 healthy women (table I). 
Levels ofIgGwere significantly reduced in women compared to men (p<O.Ol). Results are indicated 
as mean values + standard deviation, 
Systemic alltibody levels agaillst PG ill heallhy dOllars ill relatioll to age 
To examine whether antibody levels against PG-PS are related to age, the same sera used 
for determination of the sex difference in systemic antibodies against PG-PS were analyzed. 
Figure 2 shows that in females a decline occurs in antibody levels of all three isotypes with 
advancing age. This correlation was only significant for IgA antibodies. In males, a minor 
decline could be observed in IgA titers with age but this difference was not significant. 
These results imply that age-matched controls have to be used for the examination ofPG-PS 
antibodies in female RA patients compared to healthy controls. 
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FJgul'e 2. Systemic antibody responses against PGMPS in relation to age of healthy females and males. 
Levels ofIgM, IgO and IgAagainst POopS measured in 67 heallhy males and 58 heallhy females were 
related with age. The decline of JgA antibodies in female was significantly related to increasing age 
(p<O.Ol) (r'~O.24). 
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Systemic alltibody levels agaillst PO ill RA patiellts 
To detennine whether the systemic antibody levels against PG-PS are different in RA 
patients compared to healthy controls, sera of III healthy controls and of 61 RA patients 
were compared. Males and females were compared separately and RA females were com-
pared with age matched controls. Analysis of 67 male donors (mean age 52, range 30-83) 
and 21 RA patients (mean age 62 range 33-82) showed that RA patients had lower IgG 
antibody levels against PG-PS compared to healthy controls (figure 3). 
Figure 3 also shows that IgG antibody levels against PG-PS were lower in 40 sera of RA 
females (mean age 63 range 30-84) compared to 34 sera of healthy controls (mean age 63, 
range 31-88). Using Student's T test, this difference was found to be significant for both 
males (p<0.0 I) and females (p< 0.01). No differences conld be observed in IgM and IgA 
antibody levels against PG-PS in male or female RA patients compared with healthy con-
trols. 
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Figure 3. Systemic antibody responses against PG-PS in early and long-tenn RA patients. Levels 
of IgM, IgG and IgA against PG-PS were compared in early and long-ternl RA for male and female 
patients. Levels ofIgG were reduced in RA patients compared to healthy controls. This difference was 
significant for long-tenn RA males and females (p<O.Ol) and for early RA male and female donors 
(p<O.Ollp<O.05). Results are indicated as mean values + standard deviation. 
As antibody levels shortly after the disease onset might be more infonnative than those in 
long tenn RA, we also compared patients with newly developed disease (less than one year) 
and healthy controls. 
Sera of27 females with early RA (mean age 50, range 23-84) were compared with 58 sera 
of healthy controls (mean age 50, range 19-88). 
The level of IgG specific for PG-PS was reduced compared to healthy controls. No dif-
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ferences were observed between levels of IgM and IgA of females with early RA and 
healthy controls. Sera of 17 male donors with early RA (mean age 64, range 28-84) and of 
67 healthy controls (mean age 52, range 30-83) were compared. Again IgG levels against 
PG-PS were reduced and no differences were observed in IgM and IgA antibodies. The 
reduction in levels of IgG antibodies against PG-PS was significant for both male and 
female donors (p<0.01, p<0.05 respectively). 
Antibody levels specific Jor PG ill synovial fluid oj RA patients 
To examine whether antibodies can also be detected locally in synovial fluids ofRA patients 
where they might affect inflammation, antibody levels against PG-PS were determined in 
synovial fluid of 15 RA patients. In all synovial fluids IgM, IgG and IgA antibodies against 
PG-PS could be measured. 
To assess whether anti-PG-PS antibody levels occurring in the joints correlated with disease 
activity, linear regression was performed. No correlation could be observed between disease 
activity and anti-PG-PS IgG. In contrast, synovial IgM and IgA titers against PG-PS were 
related positively with disease activity (figure 4), but only the correlation found for IgA 
against PG-PS and disease activity was significant. 
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Figure 4. Antibodies against PG-PS synovial fluid in relation to disease activity in RA. In 15 synovial 
fluid samples orRA patients IgM, IgO and IgAagainst PG-PS were measured and in relation to dis-
ease activity (DAS score). All 15 synovial fluid samples contained IgM, IgG and IgA against PG-PS. 
IgA levels against PG were significantly positively related wilh disease activity (p<O.05) (r'~O.3). 
DISCUSSION 
The present slndy showed that early and long term RA patients had significantly lower 
systemic IgG antibody levels against PG-PS than healthy controls, and that the amount of 
IgA antibodies against PG-PS in synovial fluid samples of RA patients is positively corre-
lated with disease activity. Furthermore, this study showed that IgG antibody levels against 
PG-PS were significantly lower in healthy females than in healthy males, and levels of IgA 
against PG-PS are negatively correlated with age in healthy female donors. 
This slndy was perfonned to analyze systemic and local antibody levels against PG-PS in 
an extended panel ofRA patients and healthy controls. As shown before (25,26), all healthy 
donors have serum antibodies against PG-PS indicating that no tolerance at the B cell level 
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occurs despite continuous exposure to PG-PS at the mucosal surface of the gut, which is 
thought to be optimally suited for tolerance induction. 
A lower antibody level was found in serum of females compared to males, which was sig-
nificant only for IgG (p<0.0 I). We also observed a negative relationship between age and 
PG-PS-specific IgA antibodies in females. Although there is no evidence of causal linkage, 
it is of interest to note that the lower antibody levels against PG-PS in females compared 
to males correlates with the 2-3 fold higher general incidence of RA in females. In addi-
tion, the decrease of antibody levels against PG with age in females parallels the rise ofRA 
incidence with advancing age (35,36). 
RA patients had significantly lower IgG antibodies against PG-PS compared to healthy 
controls. To exclude the possibility that the decrease in antibody levels to PG-PS in RA 
patients was due to generalized depression ofantibody levels, total IgG, IgM and IgA levels 
were measured in 15 randomly selected RA sera. These levels were either normal or slightly 
increased, indicating that no general decrease of innnunogiobulin titers had occurred (data 
not shown). To analyze whether the decrease of immunoglobulins against PG-PS in RA 
was also apparent during early stages of the disease we analyzed patients with early RA 
« I-year disease duration). Both male and female patients had significantly lower IgG 
levels specific for PG-PS, suggesting that this phenomenon is apparent already early in 
the disease. Of five early RA patients, we also obtained a blood sample one-year after the 
first sample. The antibody levels in the paired samples were comparable indicating that dis-
ease progression has no influence on antibody levels specific for PG-PS (data not shown). 
Decreased antibody levels against PG-PS possibly were not due to disease progression as 
can be concluded from the fact that in early RA male patients the level of IgG specific for 
PG-PS was even lower than in longstanding RA patients. 
The present study also showed the presence of IgM, IgG and IgA antibodies specific for 
PG-PS in synovial fluid ofRA patients and that the level ofIgA anti-PG-PS antibodies cor-
related positively with disease activity ofthe patients. At present it is unclear whether these 
antibodies aggravate local inflammation (e.g. due to immune complex formation or activa-
tion of cells through Fc-receptor binding), or that they locally capture PG with beneficial 
results. Neither is it known whether antibody is produced locally by plasma cells, or leaks 
into the synovium from the circulation. Inflammation can enhance permeability of the syno-
vial membrane (37). Paired analysis of serum and synovial fluid showed a positive relation-
ship between synovial fluid and serum IgM, IgG and IgA levels specific for PG-PS, sug-
gesting that at least part of the antibodies present in the synovial fluid could be derived 
from the circulation (data not shown). The local inflammatory response in the synovium 
may attract lymphocytes. It is known that especially mucosal lymphocytes are able to home 
to the synovium by expression of relevant adhesion molecules. (38-40). Trapping of PG in 
the synovium may result in the attraction of PG specific plasma cells, due to local antigen 
deposition as well as antigen-driven T cell activation which can provide impOllant 'second 
signals' for expansion and terminal differentiation of mucosal Ig-producing immunocyles 
at secretory effector sites (41). 
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Some earlier studies focussing on antibody levels against PO in RA reported elevated and 
not decreased antibody titers against PO (27-29). An explanation for this discrepancy might 
be that the innnunoglobulin levels were measured using PO isolated from cultured bacteria, 
which may be structurally distinct from PO physiologically present at the mucosa. We used 
PO-PS derived from the indigenous intestinal flora representing PO to which the body is 
continuously exposed at high quantities. Other studies support our findings. For instance, 
Rantakokko et al. (31) found lower IgO levels against PO from cultured StreptococclIs Pyo-
gelles in RA patients compared to controls. Another study showed that ill vitro responses of 
B cells to PO were markedly depressed in RA patients compared to healthy controls (42), 
which might provide a mechanistic explanation for reduced antibody levels in RA patients. 
The lower antibody levels against PO-PS in RA might be explained by the capture of IgO 
antibodies by inflammatory sites. With radiolabelled IgO scintigraphy, it has been demon-
strated that IgO accumulates at the site of inflammation (43). Increased exudation of the 
radiolabelled IgO through the leaky capillary walls at the site of inflammation into the 
locally expanded extravascular space (43), and the chemical nature ofthe radiolabel (44,45) 
are all factors important in IgO localization. In addition, it has been shown that radiolabelled 
IgO binds to gram-negative and in even higher extent to gram-positive bacteria ill vivo and 
ill vitro (46,47). Furthennore it has been shown that radiolabelled IgO is able to bind to 
extracellular matrix components (48). Although it is unclear to what extent accumulation of 
PO-PS specific antibodies in inflamed joints will be reflected in the lowered serum levels, 
it can be hypothesized that IgO antibodies specific for PO-PS accumulate in the synovium 
and bind to PO located in the synovium andlor to extracellular matrix components. 
Another explanation for the reduced amount of systemic IgO antibodies in RA patients is 
a lowered antibody response against PO, suggesting that antibodies against PO can have a 
protective effect against the development of RA. This hypothesis is supported by two find-
ings. First, lower antibody levels against PO in healthy persons are correlated with RA inci-
dence. Second, RA patients have lower antibody levels against PO than healthy controls. A 
possible mechanism is that more PO reaches tissues outside the mucosal sites, and is cap-
tured in the synovial tissue where it promotes proinflammatory responses (22). Increased 
access of PO to non-mucosal sites may be due to at least two mechanisms. First, reduced 
gut barrier function may result from inflammation, leading to increased bacterial transloca-
tion. Ultrastructural lesions ofthe gut wall have been reported in RA patients (49). Second, 
lower antibody levels against PO may not be sufficiently capable of eliminating the bacte-
rial products from mucosal sites andlor the bloodstream. Antibodies that reach the mucosal 
lumina perfonn 'inullune exclusion', a tenn coined for non-inflammatory mucosal surface 
protection against antigens. This function is perfonned by secretory IgA or IgM (S-IgA, 
S-IgM), but also by serum IgO antibodies (50,51). 
In conclusion, the lower antibody levels against PO in RA patients suggest a local accu-
mulation of IgO antibodies to inflammatory sites or a protective role of IgO antibodies. 
The protective properties of antibodies against PO can be further investigated by measur-
ing mucosal antibody levels in feces and intestinal fluids. The correlation between synovial 
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fluid IgA antibodies against PG and disease activity suggesting intra-articular production 
of IgA is currently being further investigated by ill situ detection of PG specific antibody 
forming cells in synovial tissues using labeled PG. The study implies that restricting the 
access of PG to non-mucosal sites may contribute to dampening RA-activity. Therapeutic 
agents designed to decrease mucosal permeability should therefore be investigated in in 
vitro and ill vivo models of bacterial translocation to assess whether they might have clinical 
relevance. 
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Bacterial peptidoglycan from hnman spleen induces 
T cell proliferation and inflammatory mediators 
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ABSTRACT 
Peptidoglycan (PO), a component of gram-positive bacteria may be involved in rheumatoid 
arthritis (RA) because of its capability to induce production of proinflammatory cytokines, 
to induce arthritis in rodents, and its presence in antigen presenting cells in RA joints. The 
present study shows that physiologically relevant PO fractionated from human spleen is 
able to induce T cell proliferation in peripheral blood and synovial fluid samples of RA 
patients but the magnitude of the response did not differ from that of cells from healthy 
subjects. In addition, production of cytokines associated with RA (IL-I p, IL-6, IL-8, IL-I 0, 
IL-12, TNF-o:) and of the matrix metalloproteinase, gelatinase B (MMP-9) was induced in 
blood and synovial fluid cultures of RA patients. The fhct that PO, which can be found in 
antigen presenting cells in synovial tissues of RA patients is able to induce production of 
inflammatory mediators supports the hypothesis that PO plays a role in the pathogenesis of 
RA by influencing the inflanmlatory microenvironment of the joint. 
INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the infiltra-
tion and proliferation of macrophages and T cells and to a lesser extent of B cells, fibro-
blasts and dendritic cells into the synovial membrane. Within this pannus tissue, inflamma-
tion, cellular proliferation and humoral and cellular illllllune responses lead to release of 
different mediators including antibodies, cytokines and matrix metalloproteases, contribut-
ing to degradation of cartilage, bone and other connective tissue. 
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For many years, the most attractive concept of the pathogenesis of RA has been the model 
of autoimmunity in which autoreactive CD4+ T cells play an important role. The association 
of susceptibility to RA and disease outcome with HLA-DR4/DRI antigens (1,2) has been 
regarded as the strongest argument for the T cell-dependent nature ofthe disease. Moreover, 
T cells present in the inflamed joints predominantly consist of the primed CD45RO subset, 
expressing early and late activation antigens (3-5). However, despite the expression ofacti-
vation markers, the T cell population at the site of inflammation is in a hyporesponsive 
state (6,7). Furthermore, the fact that T-cell derived cytokines like IL-2, IL-4 and IFN-y 
can hardly be detected in RA joints (8,9) and that T cell-directed therapies using depleting 
anti-CD4 mAbs, as well as IL-2-receptor immunotoxins have yielded disappointing results 
so far (10- I 2) argue against the T cell as the initiator of RA. Therefore alternative view-
points have been suggested to explain autoimmune diseases (13). The importance of inter-
actions between T cells and antigen presenting cells (APC) as shown by the expression of 
CD40L, CD28, CTLA4 by T cells and B7- I (CD80), B7-2 (CD86) and CD40 by APC in 
the synovium has focussed attention on the role of antigen presenting cells in RA (14-17). 
A cmcial role of antigen presenting cells in the pathogenesis of RA is suggested by the 
high expression and production of the proinflammatory cytokines IL-Ip, IL-6 and TNF-u 
produced by monocytes/macrophages, which affects fibroblasts, chondrocytes and lympho-
cytes in blood, synovial fluid and synovial tissue of RA patients (18). This is supported 
by the promising results with anti-TNF-u or anti-TNF receptor therapies in RA patients 
(19) and the development of spontaneous arthritis in TNF-u mice (20,21). Furthermore, the 
matrix metalloproteinase gelatinase B, the expression of which is regulated by cytokines 
and other inflammatory mediators, has been detected in synovial fluid ofRA patients (22). 
The (auto)antigen(s) leading to chronic stimulation ofT cells and/or macrophages are still 
unknown. In reactive arthritis, the triggering antigens are thought to be microbes that cause 
infections of the urogenital tract and the gut, such as Chlamydia trachomatis, Yel'sil/ia, and 
Salmol/ella species (23,24). Antigens of these bacteria have been detected in synovial cells 
(25-27), and T cells specific for these antigens have been found in the synovium (28,29). It 
can be suggested that the bacterial load in the intestine, with which we are in lifelong close 
contact, might be important for the induction and perpetuation ofRA. This is supported by 
the observation that some patients with Crohn's disease and ulcerative colitis, both intestinal 
autoinunune diseases, may suffer from arthritis (30,31). Furthennore Crohn's-like inflam-
matory bowel disease and chronic inflammatory arthritis develop spontaneously in a knock-
out mouse strain lacking a TNF AU-rich element, responsible for TNF mRNA destabiliza-
tion and translational repression in hemopoietic and stromal cells (32). 
We and others have previously hypothesized that peptidoglycan (PG) plays a role in the 
pathogenesis of RA (33-36). Peptidoglycan (PG) is the major component of the cell wall 
of gram-positive bacteria and is composed of long sugar chains of alternating N-acetyl glu-
cos amine (GIcNAc) and N-acetyl muramic acid (MurNAc) residues, which are interlinked 
by peptide bridges, resulting in a large complex macromolecular stmcture (37). PG isolated 
from the anaerobic bacterium Eubacterium aerojaciens, which is present in numbers over 
1O'/g human feces, induces a severe and chronic arthritis in rats (38). Furthermore, PG 
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could be detected in antigen presenting cells in synovial tissues of RA patients using a 
specific antibody (39,40). PG was also isolated from sterile normal human spleen using 
biochemical methods (PG,p'~,,) (41,42). III vitro analysis showed that the latter PG fraction 
is able to induce production of the proinflammatory cytokines TNF-a, IL-l and IL-6 (42), 
which are crucially involved in RA pathogenesis (I8). Furthermorl', it was shown that PG 
isolated from human spleen is able to bind its receptor (CDI4) and to elicit T cell prolifera-
tion ofCD4+ and CD8+ apTCR+ T cells after proteolytic processing (Schrijver et al. sub-
mitted). Previously, low T cell responses against peptidoglycan-polysaccharide complexes 
(PG-PS,,,,,) isolated from human feces were analyzed in peripheral blood and synovial fluid 
of RA patients (43). In the current study we used PG,p'''" because it reflects the properties of 
PG present in human tissues, it is structurally more intact than PG-PS,,,,, and it has a 10-100 
fold higher biological activity (42). 
To further delineate the role ofPG in the pathogenesis ofRA we determined the influence of 
PG fractionated from sterile human spleen on T cell proliferation and production of inflam-
matory mediators. Therefore we assessed the production of the proinflammatory cytokines 
IL-lp, IL-6, IFN-yand TNF-a, the iInmunoregulatory cytokine IL-IO, the chemokine [L-8 
and the matrix metalloproteinase gelatinase B using peripheral blood ofRA patients as well 
as control subjects and synovial fluid samples of RA patients upon PG stimulation. 
PATIENTS AND METHODS 
Blood samples 
Heparin blood samples of 29 RA patients fulfilling the American College of Rheumatol-
ogy criteria (44) were obtained from the Zuiderziekenhuis Hospital Rotterdam. Patients 
received no immunosuppressive medication except for some patients receiving low dose 
prednisone (up to 10 mgt day) or methotrexate (up to 30 mg Iweek). 
RA disease activity at time of donation was detennined score by an experienced rheuma-
tologist using the DAS-28 score (45): 
0.56 "TJC + 0.28 "SJC + 0.7 LOG ESR + 0.014 GH 
TJC= number of painful joints (out of 28) 
SJC= number of swollen joints (out of28) 
GH= general health score on a visual analogue scale (0-100) 
27 blood samples of healthy donors were a kind gift of the Depa11ment of Epidemiology 
from the Erasmus University and University Hospital Rotterdam-Dijkzigt.l 0 blood samples 
were obtained from healthy volunteers. Donor features are shown in Table 1. All blood 
samples were processed within 2-5 hours after collection. 
Synovial flllid samples 
Synovial fluid samples of an inflamed joint of [4 RA patients were obtained from the 
Zuiderziekenhuis in Rotterdam (table I). Synovial fluid was collected in heparin tubes. 
Paired blood and synovial fluid samples were collected from 10 of these patients. 
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Table 1. General features of the donor groups 
Group Source Sex Age Duration DAS scorc* 
(mil) (years)' (months)' 
Healthy controls blood 12/21 60 (25-84) n.a. n.a. 
RA patients blood 9121 58 (30-82) !OI (8-360) 5.0 (1.6-7.8) 
synovial fluid 3/1\ 63 (46-82) 66 (8-180) 5.7 (3.4-7.4) 
.. expressed as mean, with the range shown in parentheses 
n.a.= nol applicable 
Proliferation assays 
Peripheral blood mononuclear cells (PBMC) of all healthy donors and RA patients and 
synovial fluid mononuclear cells (SFMC) of 14 RA patients were isolated from heparin 
blood using Ficoll Hypaque (Pharmacia, Uppsala, Sweden). 2xlO' cells in 100 III were cul-
tured in 96 well plates in the presence of 100 III PO isolated from human spleen contain-
ing 0.70 Ilg muramic acid (42), POopS from human feces containing 70 Ilg/mlmuramic 
acid (46), 2 Ilg/ml lipopolysaccharide (LPS) (Sigma, St. Louis, MO) or 6 Lf/ml tetanus 
toxoid (TT) as a control recall protein antigen (RIVM, Bilthoven, the Netherlands). Cells 
and antigens were diluted in RPMI (Biowittaker, Verviers, Belgium) + 10% heat inactivated 
human serum. All antigens were analyzed in triplicates and concentrations mentioned in 
the result section are final concentrations. The cells were cultured during 7 days, the last 
8 hours in the presence of tritiated thymidine (Amersham, Pharmacia Biotech, Little Chalf-
ont, Buckinghamshire, UK). The cells were then harvested and the incorporated radioactiv-
ity counted in a liquid scintillation cOllnter. The proliferative response was expressed as 
counts per minute (cpm) or stimulation index (SI), the ratio of mean cOllnts per minute in 
the presence and absence of antigen. When SI > 3, it was concluded that proliferation had 
occurred. 
Induction of cytokine release in whole blood or PBMC after stimulation with PG 
Cytokine induction was performed in 20 blood and 9 synovial fluid samples of RA patients 
and in 6-10 healthy control blood samples. 12.5 III of RPMI 1640 (Biowittaker) containing 
90 ng/ml PO (muramic acid) or 25 ng/ml LPS (Sigma) were added to a polypropylene tube 
containing 112.5 III blood, synovial fluid, PBMC or SFMC. The mixtures were incubated 
for 4 or 17 hours at 37'C in a 5% CO, atmosphere. Then 375 III RPMI was added to each 
tube and the mixtures were centrifuged for 10 minutes at 400 g. The sllpematants were 
stored at -20'C until cytokine and gelatinase B analysis. 
Determination of cy/okines 
Cytokine prodllction was measured by commercial capture ELISA. In a pilot study of 10 
healthy donors, IL-I~, IL-4, IL-6, IL-8, IL-IO, IL-12p40, TNF-o:, INF-y and OM-CSF 
were measured in culture supematants of 4 hand 17 h sllpematants. IL-4 and OM-CSF 
could hardly be measured in the sllpematants. After LPS stimulation, IL-I~, IL-6, IL-IO, 
IL-12 and TNF-o: reached highest levels after 4 h of stimulation and IL-8 and IFN-yafter 
17 h. Therefore IL-I~, IL-6, IL-IO, IL-12p40 and TNF-o: prodllction was measured in the 4 
h supematants and IL-8 and IFN-y in the 17 h sllpematants. ELISA was performed accord-
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ing to the manufacturers' guidelines (Biosource, Fleurus, Belgium). Briefly, polystyrene 
micro titer wells (Irmnuno Maxisorp, Nunc, Roskilde, Demnark) were coated overnight at 
room temperature with monoclonal anti-cytokine antibodies followed by washing (0.9% 
NaCI) and 2 h of blocking (PBSIBSA 0.5%). Freshly thawed supernatants of the cell cul-
tures and recombinant human cytokine-standards were incubated in duplicates for two hours 
in the presence of a biotinylated second anti-cytokine antibody, followed by washing steps, 
poly-streptavidin-horseradish peroxidase (CLB, Amsterdam, The Netherlands) and enzyme 
substrate (TMB peroxidase, (KPL, Gaithersburg, MD). Optical density was measured at 
450 run. 
Determination of gelatillase B activity 
Gelatinase B (MMP-9) was measured by two methods in the supernatants obtained after 4 
h of stimulation. First, the quantitative gelatine zymography method was used, which is a 
densitrometric method that, by inclusion of appropriate standards, discriminates inducible 
gelatinase B (MMP-9) from constitutive gelatinase A (22,47). Quantitative detennination of 
gelatinase activity was achieved by computerised image analysis through two-dimensional 
scanning densitometry. Gelatinase activity was expressed in scanning units representing the 
scanning area under the curves, which is an integration ratio that takes into account both 
brightness and width of the substrate lysis zone. Second, the gelatinolytic activity which 
results from the balance between enzymes and enzyme inhibitors (the so-called protease 
load) was measured in the samples using fluorescence-activated gelatine conversion. Both 
methods were described in detail earlier (22,47,48). 
Statistical aI/a lysis 
Statistical analysis was performed using the Mann-Whitney method to analyze differences 
between PG-induced proliferation and production of effector molecules between RA patients 
and healthy subjects. Furthermore, the Wilcoxon signed rank test method was used to ana-
lyze whether PG was able to induce cytokine production. Linear regression was perfonned 
to detennine relationships between disease activity or disease duration with T cell prolifera-
tion and cytokine production. p values < 0.05 were considered significant. 
RESULTS 
Proliferatiol/ 0/ PBMe after stillllliatiol/with PG 
To examine whether proliferation ofT cells against PG was increased in RA patients versus 
healthy subjects, 29 RA patients and 33 age-matched controls were examined for the prolif-
erative response against PGsple~n and PG-PSf;:,;~s. LPS and TT were used as positive controls. 
The results show (figure I) that after 7 days of culture, T cell proliferation was elicited 
by PG,pl~o in 21 of the 29 RA patients. Twenty-five of 33 healthy donors reacted against 
PG'PI~O' The median of the SI values was 6.9 for RA patients and 6.7 for healthy subjects. 
The proliferative response against PG-PSf~" was lower compared to PG,pl~O despite the 
1 OO-fold higher concentration used. 
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Figure 1. PO isolated from sterile human spleen induces proliferation of peripheral blood mono-
nuclear cells (PBMC) in both RA patients and healthy SUbjects. PBMC isolated from 29 RA patients 
and 20 healthy controls were incubated during 7 days with PG$PI«nI PGf"'~" LPS or TT. Results are 
indicated as stimulation index (SI). No differences were observed between RA patients and healthy 
controls after stimulation with both PO sources, LPS and IT induced proliferation were decreased in 
RA patients, hut these effects did not reach significance. The horizontal line indicates the cut offpoint 
for proliferation (SI~3). 
The proliferative response against LPS and TT was lower in RA patients than in healthy 
donors, but this difference did not reach significance. 
Proliferatioll oj SFMC after stimulatioll with PG 
Synovial fluid was obtained from 14 RA patients. Mononuclear cells were isolated from 
both samples using Ficol!. In only two ofthe synovial fluid samples a proliferative response 
against PG;pr,," could be measured (figure 2). After stimulation with PG-PSf~'" LPS and TT 
none, 3 and 2 patients out of 14 did respond, respectively. 
When the proliferative responses of 10 samples of synovial fluid mononuclear cells of the 
four analyzed antigens were compared with paired peripheral blood cells, responses were 
significantly lower, despite the use of identical cell numbers and stimulation conditions 
(data not shown). 
Relationships between proll/eration and disease activity or disease duration 
Correlation analysis was performed to determine the possible relationships between prolif-
eration and RA disease activity or disease duration as scored at the time of sampling. No 
correlations were found for any of the four antigens examined. 
Cytokine production in peripheral blood after stimulatioll with PGspleen 
To investigate whether PG is able to stimulate production of cytokines involved in RA, 
production ofIL-I~, IL-6, IL-8, IL-IO, IL-12, INF-yand TNF-a was measured after whole 
blood cell stimulation of 20 RA samples and 10 healthy donor samples. The samples were 
stimulated with PG;pr,," and LPS served as a positive inducer. Results of RA and healthy 
donor samples stimulated with medium and PGsp!een are shown in figure 3. 
These results show that without stimulation, concentrations of all analyzed cytokines were 
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Figure 2. PG<pk~o induces proliferation of RA synovial fluid mononuclear cells (SFMC). SFMC iso-
lated from 14 RA patients were cultured during 7 days with PGsr1t>/'n, PGfe,:w LPS and TT. Results are 
indicated as stimulation index (SI). Proliferation of SFMC of 2 patients was observed after PGsplun 
stimulation. After stimulation with PGfe.:eSl LPS and TT none, 3 and 2 out of 14 patients responded 
respectively. The horizontailine indicates the cut otfpoint for proliferation (SI=3). 
higher for RA patients compared to healthy subjects. Because this higher concentration was 
mostly due to 5-7 high responding patients the difference between control subjects and RA 
patients was only significant for IL-IO. 
In healthy subjects, PG,pl",-induced production of IL-l~, IL-6, IL-8, IL-IO, IL-12 and 
TNF-o: was significantly increased compared to spontaneous production. In the RA patients 
a significant increase in the production of IL-l~, IL-6, IL-8, IL-IO, and TNF-o: was 
observed. 
Because cytokine levels in unstimulated samples of RA patients were very high, probably 
due to cytokines already present in the plasma, mononuclear cells were isolated to measure 
newly secreted cytokine. Table 2 shows that after control stimulation with medium alone 
all cytokine levels were low except IL-8. After PG stimulation a significant increase was 
observed for all cytokines except for IL-8, IL-12 and IFN-y. 
Table 2. PG5rl~n induces production of cytokines by peripheral blood mononuclear cells 
Cytokine Medium PGsp1«n 
[L-IP 3 (0-233) 217 (13-1763)' 
IL-6 30 (0-1418) 1602 (84-4118)' 
[L-8 2938 (372-3962) 3293 (567-3779) 
[L-IO 2 (0-42) 80 (0-280)' 
[L-12 0 (0-444) (0-2470) 
IFN-y 0 (0-0) 0 (0-0) 
TNF-o: 13 (0-7002) 2864 (0-13263)* 
results are shown as median cytokine production (pglml) with range in parentheses 
• p<O.OI 
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Figure 3. PG.pl",n induces cytokine production in healthy subjects and RA patients. Whole blood cell 
samples 0[20 RA patients and 10 healthy controls were stimulated with and without PGsp!un' Produc-
tion ofiL-IP, IL-6, IL-8, IL-IO, IL-12 TNF-a and IFN-ywas assessed by ELISA. Levels of all cyto-
kines analyzed were higher in unstimulated samples of RA patients compared to healthy controls, 
which was significant for IL-lO. PO,p!",!! was able to induce significantly production ofIL-lP, IL-6, 
IL-8, IL-J 0 and TNF-a. in both healthy subjects and RA patients. IL-12 was only significantly induced 
in healthy subjects. 
Cytokine production ill synovial fluid after stimulation with PG5pfcen 
Cytokine production was induced and measured in supernatants of whole synovial fluid 
mononuclear cells and of isolated mononuclear cells of 9 RA patients. The results show 
that all cytokines analyzed were present in the synovial fluid. After stimulation with PG the 
production ofiL-IP, IL-6, IL-S and TNF-o: was increased (table 3). 
When mononuclear cells were isolated, high concentrations ofIL-6, IL-S, and TNF-o: were 
measured without further stimulation, indicating that activated mononuclear cells spontane-
ously produced these cytokines. After PG stimulation, IL-IP, IL-S, IL-IO and TNF-o: were 
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produced at significantly higher levels, indicating that PG can enhance production of these 
cytokines in SFMC. 
Table 3. PO spleen induces production ofproinfianunatory mediators in synovial fluid (SF) samples 
Cytokine Medium PGsp!~n 
whole SF SF mononuclear cells whole SF SF mononuclear cells 
IL-IP 9 (0-59) 7 (0-14) 36 (0-556)· 121 (65-168)· 
IL-6 789 (0-9452) 133 (2736-3453) 1286 (0-9443)· 496 (444-2761) 
IL-8 498 (34-1295) 3003 (2736-3453) 1530 (960-3570)· 3438 3233-3866)* 
IL-I0 49 (0-733) 2 (0-16) 150 (0-678) 86 (32-133)· 
IL-12 320 (0-2543) 0 (0) 348 (0-2918) 0.5 (0-1.5) 
IFN-y 0 (0-8089) 0 (0) 0 (0-8132) 0 (0-12) 
TNF-a 279 (0-3638) 952 (0-4080) 2147 (0-9099)- 8668 (6182-15697)· 
gelatinase B 719 (612-2122) n.d. 607 (70-2003) n.d. 
data shown as median cytokine production (pglml) and median gclatinase B production (scanning units) with range 
in parentheses, n.d. ~ not done 
·p<O.05 
For 9 patients paired samples of peripheral blood and synovial fluid were analyzed. Concen-
trations of the different cytokines in unstimulated samples were comparable in peripheral 
blood compared to synovial fluid except for IL- I 0, IFN-y and IL- I 2 for which cytokine 
concentrations were higher in synovial fluid compared to peripheral blood but these differ-
ences were not significant (data not shown). 
Gelatillase B productioll ill whole blood alld sYllovial fluid after stimulatioll with PG,pl,," 
Quantitative analysis of gelatinase B production showed that in blood cells, gelatinase B 
concentration was higher, although not significant, in RA patients compared to healthy sub-
jects, suggesting a higher spontaneous release of gelatinase B in the peripheral blood ofRA 
patients (figure 3). Furthermore it was shown that PG induces production ofgelatinase B. In 
blood samples of healthy subjects this induction was significant (figure 3). In synovial fluid 
samples the induction of gelatinase B by PG did not reach significance (table 3). Analysis of 
the kinetics of the dose dependent induction of gelatinase B by PG showed that gelatinase 
B was induced after 4 h of incubation (data not shown). To evaluate whether this induction 
resulted in an increase of gelatinase B activity all samples were also analyzed by fluorescent 
activated substrate conversion. None of these samples showed net gelatinase B activity. 
Relationships between cytoidne production and disease activity or disease duration 
To examine the possible relationships between (PG-induced) cytokine and gelatinase pro-
duction and RA pathology, linear regression was perfonned for cytokine production sepa-
rately for both peripheral blood and synovial fluid and disease activity and disease duration. 
Although cytokine production by unstimulated cells showed a positive relationship with 
disease activity in both blood and synovial fluid samples with most cytokines, in particular 
with IL-6 and TNF-a, no significant correlation could be observed (data not shown). 
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DISCUSSION 
The present study shows that PO fractionated from sterile human spleen is able to induce 
T cell proliferation in peripheral blood and synovial fluid of RA patients, and that PO is 
able to induce production of the inflammatory mediators IL-l~, IL-6, IL-8, IL-IO, TNF-a. 
as well as gelatinase B in peripheral blood and synovial fluid cells. No differences were 
observed between RA patients and healthy subjects for T cell proliferation and cytokine 
production induced by PO. 
In about 75 % ofRA patients and control donors proliferation ofPBMC against PO could be 
observed. This indicates that no apparent disturbances of specific T-cell proliferation exists 
against PO in RA patients compared to healthy donors. The lower proliferative response 
against PO-PSf~" in both groups even with a 1 ~O-fold higher concentration does support the 
importance for intact PO stmcture in the induction of T cell proliferation because PO,pl~o 
contains intact peptide bridges which are almost absent in PO-PSf~'" In addition, there 
are also no indications that, at the site of inflammation, proliferation after stimulation with 
PO contributes to pathogenesis, because in only 2 of the 14 RA patients analyzed, pro-
liferation was observed. Because T cell proliferation in synovial fluid mononuclear cells 
is very low after stimulation with the positive control stimuli LPS and TT, it can be sug-
gested that the method used was not optimal. The mean ratio of antigen presenting cells (i.e 
monocytes/macrophages) over T cells was I : 1.4 in the synovial fluid as shown by morphol-
ogy analysis of cytospins of the synovial fluid cells (data not shown). In peripheral blood 
this ratio is approximately 1 to 5 implying that many more potentially responsive T cells are 
present in the wells. Another explanation for the lack of synovial fluid T cell proliferation 
is that most synovial fluid T cells, despite the expression of CD45RO, are hyporesponsive 
upon stimulation by anti-CD3 and anti-CD28 (7). A defect in T-cell-receptor mediated sig-
naling at the level of tyrosine phosphorylation has been suggested (6). 
Cytokine induction by PO was measured using two different cell popUlations, whole blood 
or synovial cells and isolated mononuclear cells. The whole blood cell culture technique 
has proved to be quite reproducible (49-51) and to closely reflect the ill vivo situation. How-
ever, because in some RA patients, cytokine concentrations present in unstimulated samples 
were considerably high, further enhancement by PO on cytokine production was difficult 
to examine. Therefore we also used Ficoll purified mononuclear cells to measure newly 
secreted cytokines and not cytokines already present in the plasma. 
A number of cytokines known to playa role in the pathogenesis of RA was analyzed. The 
proinflammatory cytokines IL-l~, IL-6, IL-12 and TNF-o: are able to activate T and B cells, 
and are major effectors of cartilage and bone destmction (18,52). The chemokine IL-8 is a 
potent attractor of leukocytes to the inflamed joint and may contribute to inflammation and 
the fomlation of the pannus (53,54). IL-8 has also been shown to activate neutrophils to 
secrete gelatinase B (47). Although IL-l 0 has proinflammatory properties like B cell activa-
tion, in RA, IL-IO has predominantly anti-inflalmnatory properties such as inhibition of 
TNF-a. and IL-l production (55). Therapy with IL-IO has resulted in clinical improvement 
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ofRA (56). Although the expression ofIFN-y is not high in RA synovia, cytokine profile 
analysis of T cells from synovial fluid has shown that these cells mainly produce IFN-y 
compared to IL-4. This indicates that a Thl-pattern ofT cell reactivity occurs, which may 
contribute to delayed hypersensitivity responses (57). 
Both in blood and synovial fluid of RA patients, higher levels ofIL-6, IL-8, IL-IO, IL-12, 
IFN-y and TNF-C( were present in unstimulated samples compared to healthy subjects. This 
is consistent with earlier reports (l8,58,59). Production of IL-lP, IL-6, IL-8, IL-IO and 
TNF-C( was enhanced after PG,pl~" stimulation in both healthy donors and RA patients by 
cells in peripheral blood and synovial fluid. An enhancement ofIL-12 after PG,pl,," induc-
tion was only found in whole blood cell stimulations of healthy subjects. No production of 
IFN-y induced by PO,pl,," could be demonstrated. This is not surprising as IFN-y is mainly 
produced by T cells and T cell stimulation by PG,pl~" reached highest levels after 7 days 
of culture instead of 17 hours. In accordance with this, cytokine production measured in 
PBMC stimulations of healthy donors at day 7 showed that high amounts ofIFN-y(137-399 
nglml) were produced and no IL-4 (data not shown). 
Gelatinase B is detected iri synovial fluid (22) and is expressed in the synovial tissues of 
RA patients (60,61), where it plays an important role in connective tissue destruction by 
degrading components ofthe extracellular matrix (62). This study shows that PG",~" is able 
to induce production of this enzyme. Whether this enzyme is induced directly or indirectly 
through e.g. IL-8 or TNF-C(, which is known to induce gelatinase B (22,63,64), has to be 
fi.lrther analyzed using specific antibodies. The kinetic analysis of gelatinase B expression 
is in favor, however, of a direct effect of PG. The lack of net gelatinase B activity in the 
samples can be explained by the presence of natural and possibly induced inhibitors of 
gelatinase B activity (65). 
To determine if the biological properties of PG are directly involved in the pathogenesis 
of RA, a relationship between cellular proliferation, cytokine/gelatinase B production and 
disease activity or disease duration was analyzed using correlation analysis. For most cyto-
kines a trend could be observed that higher cytokine production was positively related with 
disease activity and negatively related with disease duration. These trends did not reach 
significant levels. 
The question remains which role PO plays in the pathogenesis of RA. The main indication 
for a role of PG in RA is the presence of PG in antigen presenting cells in synovial tissues 
(40) suggesting that bacterial antigens, ubiquitously present at that mucosa, gain access to 
the joints, probably carried by phagocytic antigen presenting cells in the bloodstream (66). 
The distribution of PG might be increased by ultrastructural gut lesions (67) or a lowered 
mucosal surface protection provided by antibodies against PG (Schrijver et al submitted). 
Although this study did not identity disturbances in the T cell response against PG, the 
results do show that PG is able to induce production of effector molecules crucially involved 
in RA. Based on these results we hypothesize that PG is involved in the pathogenesis ofRA 
by inducing cytokines and gelatinase B. First, the production ofthese cytokines and gelatin-
ase B can lead to destmction of the joint tissue. Second, cytokines might allow autoreactive 
T cells to overcome self-tolerance to certain autoantigens. Recent studies have shown that 
various infectious and pro inflammatory antigens, such as LPS, a functional PG analogue, 
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are capable of reversing the tolerant state of CD4+ (68) and CD8+ (69) positive T-cells 
in the presence of specific (auto) antigens by production of cytokines stimulating T-cell 
proliferation and survival (70,71). Cytokines may also be involved indirectly in the break-
ing of tolerance to autoantigens. T cells might be exposed to autoantigens upon destruction 
of joint tissue by cytokines leading to activation of these T cells. Autoantigens involved in 
this process are cartilage antigens like collagen and cartilage protein HC-gp39 to which T 
cell reactivity has been found in the synovium (72,73). Thus, infimmnatory activity within 
the RA joint may be dependent on factors governing redistribution of PG to non-mucosal 
sites. Therapeutic intervention restricting the access of PG to non-mucosal sites may there-
fore be of clinical benefit to patients. This can be examined using ill vivo bacterial transloca-
tion models. 
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Chapter 4.1 
Pararosaniline fixation for detection of costimulatory molecules, 
cytokines and specific antibody 
Ingrid A. Schrijver, Marie-Jose Melief, Marjan van Meurs, Arjen R. Companjen and Jon 
D. Laman 
ABSTRACT 
Department of Immunology, Erasmus University ROllerdam and 
University Hospi/al-Dijkzigt Rotterdam, The Nether/ands 
Integral immunohistochemical analysis of immune responses in frozen sections requires 
that in addition to constitutively expressed membrane CD markers, less stable determi-
nants can be reliably visualized. Therefore, we compared the commonly used acetone fixa-
tion method with pararosaniline fixation for six determinant categories. These categories 
included selected constitutively expressed markers, inducible costimulatory molecules, pro-
and anti-inflammatory cytokines (including the novel cytokine IL-18, also known as IGIF 
and IL-I y), antigen-specific antibody in plasma cells, bacterial peptidoglycan and lysosomal 
acid phosphatase activity. 
Human spleen and mouse spleen activated by agonistic anti-CD40 antibody or TNP-Ficoll 
immunization were analyzed in parallel with brain tissue from multiple sclerosis (MS) 
patients and marmoset monkeys with experimental autoimmune encephalomyelitis (EAE), 
an animal model for MS. Fixation with pararosaniline resulted in better morphology of 
all tissues and inhibited endogenous alkaline phosphatase activity in brain tissue. Most 
determinants could be reliably detected. Staining sensitivity and intensity were markedly 
increased for selected determinant-tissue combinations, e.g. for IL-4 in human spleen and 
CD40 in human and mouse spleen. 
These data show that pararosaniline is a useful alternative to acetone, resulting in superior 
morphology and specific staining for selected detenninant-tissue combinations. This pro-
vides additional flexibility for in situ analysis of immune reactivity. 
INTRODUCTION 
Chronic inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis 
(MS) are generally believed to result from the activity of autoreactive CD4+ T cells. The 
fonnation and activity of lesions caused by infiltrating mononuclear cells are complex pro-
cesses that are incompletely understood, and this also holds true for the cellular effector 
mechanisms that might be responsible for the tissue damage that leads to temporary and 
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cumulative clinical symptoms. Such effector fimctions include local (auto)-antigen presen-
tation, (auto)-antibody production, secretion of pro- and anti-inflammatory cytokines and 
activity of enzymes involved in proteolysis and nitric oxide production (1,2). It is there-
fore crucial to analyze inflammatory lesions fimctionally ill situ by conventional and novel 
immunohistochemical methods to provide an integral view of ongoing cellular activities. 
Relevant parameters are the localization of antigen possibly involved in inflammation (e.g. 
bacterial peptidoglycan (PO) in RA). PO may be involved in the pathogenesis of chronic 
inflannnation, particularly in RA (3,4). With a monoclonal antibody against PO (Mab 2E9) 
antigen presenting cells (APC) containing PO can be detected in synovial tissues (5,6). 
Furthermore the integrity of antigen binding sites of antibodies present in the cytoplasm of 
plasma cells can be evaluated (7-9). This was studied by detection of antibody forming cells 
specific for 2,4,6-trinitrophenyl (TNP) in mice immunized with TNP-Ficoll (10). 
The identification of mononuclear cell subsets (e.g. T, Band APC, granulocytes) by mark-
ers such as IgM, IgO, CDI4 and HLA-DR or enzyme activity (lysosomal acid phosphatase 
in macrophages) can be used to examine the presence ofB cells and antigen presenting cells 
that can contribute to pathogenesis ofRA and MS by producing antibodies and cytokines or 
enzymes. Functional activation profiles can be identified by strongly regulated costimula-
tory molecules such as CD40, CD40L, CD80 (B7-1) and CDS6 (B7-2) (11,12) which have 
been claimed to play an important role in the inflammatory process of both MS (13,14) 
and RA (13-16). Other important activation markers in immunological responses are intra-
cytoplasmic soluble cytokines (17, IS) like the anti-inflammatory cytokines IL-4 and IL-I 0, 
the proinflammatory cytokines TNF-o:, IFN-y, and the novel cytokine IL-IS, also known as 
interferon gamma inducing factor (IOlF) and IL-Iy (19-21). 
To identifY all these relevant parameters involved in inflammation by immunohistochemis-
try, adequate fixation of frozen sections is an essential requirement. The main function of 
fixation is to preserve morphology of the tissue which is often best accomplished by strong 
fixation. The disadvantage of strong fixation is that the structure and integrity of the param-
eters are changed resulting in a poor quality of the staining pattern. The optimal fixation 
condition, therefore, consists of a compromise between these contradictory requirements, 
and may differ depending on the nature of the antigen (22). 
Pararosaniline has previously been shown to have good fixation properties for frozen tissue 
sections without affecting antigenicity. This was concluded from staining for constitutively 
expressed markers in mouse Iympho-hemopoietic organs in which acetone fixation was 
compared with pararosaniline fixation (22). 
The aim of this study was to determine whether pararosaniline has advantages over acetone 
fixation for detection of less stable determinants such as bacterial antigen, intracellular 
cytokines, co-stimulatory molecules and specific antibody located in plasma cells. Expres-
sion of the markers was examined in different types of organ tissues (spleen, brain) from 
three species (human, mouse and monkey). Tissues were activated either by chronic inflam-
mation or by ill vivo administration ofTNP-Ficoll (a thymus independent type 2 antigen) or 
agonistic anti-CD40 antibody. 
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MATERIALS AND METHODS 
Human and animal tissues 
All mouse markers (except CD40) were examined in spleens of BALB/c mice immunized 
intravenously with 20 J.lg TNP-Ficoll, a polysaccharide thymus independent type 2 antigen, 
which evokes IgM and IgG antibody fonning cells, expression of CD40L (CDI54), and 
several cytokines four days after injection (10). CD40 detection was performed on C57BI/6 
spleen in which CD40 expression was upregulated by i.v. injection of 100 fIg agonistic 
anti-CD40 antibody (FGK-45) (23,24). At 96 h after injection the mice were sacrificed and 
spleen tissue was removed. 
To study expression of costimulatory molecules and cytokines in tissue affected by chronic 
autoimmune inflammation, brain tissue from mannoset monkey EAE (CallilhrixjaccJll/s) 
was used. The monkeys were bred at the Biomedical Primate Research Center (BPRC) 
and used under conditions approved by Dutch laws on animal experimentation. EAE was 
induced essentially as described previously (25-27). Per animal 20 mg of human myelin 
(28) in PBS was emulsified with an equal volume of complete Freund's adjuvant, contain-
ing 3 mgiml of Mycobacterium luberculosis (H37 RA strain). Intracutaneous injections of 
150 J.lI were divided over four sites on the dorsal axillmy and inguinal regions. Animals 
were sacrificed during active disease periods and brain tissue was obtained. 
Expression of human markers was determined in human spleen without evidence of infec-
tion or inflammation. Two human spleens were removed after damage to the spleen occurred 
during surgery for a stomach carcinoma. 
To study expression of costimulatory molecules and cytokines in human tissue affected 
by chronic autoimmune inflammation, brain tissue of MS patients was used for detennina-
tion of all cytokines and costimulatory molecules expected to be expressed in lesions. Two 
human MS brain tissue specimens were obtained at autopsy with short post mortem inter-
vals from the Netherlands Brain Bank in Amsterdam, The Netherlands (coordinator Dr. R. 
Ravid). 
Tissue processing 
All tissues were snapfrozen in liquid nitrogen in aluminum containers, which were stored at 
-80'C. Six micron frozen sections were cut on a cryostat and thaw-mounted on slides pre-
coated with 0.1 % gelatin (Merck, Darmstadt, Gennany) and 0.01 % chromium potassium 
sulfate (Merck). The sections were kept overnight in a box with humidified atmosphere after 
which they were air dried at room temperature for I h and stored in a box with silica until 
use. 
Fixatives 
Acetone (purity < 99.5%) (Fluka, Chemie AG, Buchs, Switzerland) supplemented with 
0.5% H,O, (from a 30% stock solution) was used at RT. 
Pararosaniline was prepared as described by Burnstone (29) with minor modifications (22). 
Four percent (w/v) pararosaniline (Sigma Chemical Co., St. Louis, MO) was dissolved in 2 
M HCL by heating at 70'C. After the pararosaniline was dissolved the solution was filtered 
and I ml of this solution was mixed with I ml 4% (w/v) NaNO, in distilled water. After 
115 
Chapter 4.1 
precisely I min this reaction mixture was dissolved in 200 ml milliQ water (Millipore, Bed-
ford, MA PF+ system, resistance> 18 MQ). This solution can be used for at least up to I 
month when stored at 4'C. Pararosaniline and solutions containing this chemical should be 
handled with precaution in view of their potential carcinogenicity. 
Table 1. Fixation procedures 
Acetone 
Treatment Duration Temperature 
(min) 
a~etOl~e with 0.5% H2O/ 10 RT 
air dry RT 
wash in PBS-Tween 5 RT 
primary reagent ovemight 4'C 
* 0.5% H20 2 obtained from a 30% stock solution. 
(IlIllllllllO) h is toeh em is fly 
Pararosaniline 
Treatment Duration Temperature 
(min) 
pararosaniline 2 RT 
wash in PBS 5 RT 
0.5% H20 2 in PBS* 10 RT 
wash in PBS-Tween 5 RT 
primary reagent overnight 4'C 
Sections were fixed according to the different protocols (table I). The slides were next 
washed with PBS and then with PBSIO.05% (v/v) Tween 20 (Fluka) and incubated with 
the first reagent (antibody, antigen-enzyme conjugate (TNP-AP) or enzyme substrate solu-
tion) in PBSIl% BSNO.05%Tween (HPLC-grade, fraction V, Sigma) (table 2) overnight 
at 4'C (or 30 min at 37'C for the acid phosphatase substrate). After washing the slides 
twice with PBS/0.05% Tween, the sections were incubated with the appropriate secondary 
reagent (PBS/I %BSNO.05% Tweenll % normal human serum) for 30 minutes at RT (table 
2). For some stainings the slides were then washed twice with PBS/Tween and incubated 
for 30 min with the tertiary reagent (table 2). After the slides were rinsed twice in PBS, they 
were washed in 0.05 M NaAc buffer pH 5.0 for 5 minutes (except for the TNP-AP (alkaline 
phosphatase staining). Horseradish peroxidase activity (HRP) was revealed by incubating 
the slides for 15 min in substrate containing 1.5 ml of 3-amino-9-ethylcarbazole (AEC, 
Sigma) dissolved in N,N-dimethylformamide (DMF, Sigma) (17 mglml) and 30 ].II H,O, 
30% in 60 ml ofNaAc buffer pH 5.0, followed by a washing step in PBS. The use of AEC 
results in a bright red precipitate. The histochemical revelation of TNP-AP staining was 
performed with Fast Blue Base (FBB) substrate after rinsing the slides in 0.1 M TRIS-HCL 
pH 8.5. FBB substrate was prepared as follows. Sixteen mg FBB (Sigma) was added to 400 
].112M HCL and 400 ].II 4% NaNO, and was mixed for I min before adding to 65 ml of 
0.1 M Tris-HCL pH 8.5. Then 8 mg Naphtol-AS-MX-phosphate (Sigma) was dissolved in 
400 ].II of DMF and added to the solution. Finally 100 ].II of I M levamisole (Sigma) was 
added to the solution to inhibit endogenous alkaline activity. The slides were incubated in 
the substrate for 45 min. The slides were washed in NaAc buffer pH 5.0 or 0.1 M TRIS-HCI 
pH8.5. 
All slides were counterstained with hematoxylin (Mayer's) and washed for 10 minutes in 
tapwater after which they were embedded in Kaiser's glycerinlgelatin (Merck). 
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Table 2. Reagents used for the detection of different detenninants 
Primary reagent (supplier) 
PRIMATE 
Enzyme substrate 
Acid phos. substrate 
Antibody 
179-1.I-PO (TNO-PO) 
343-4.I-PO (TNO-PO) 
L234-bio (Coulter clone) 
MY-4 (Coulter Clone) 
5DI2 (Tanox Phanlla BV) 
24-31 (Dr. RJ Noelle) 
M24 (Tanox Phanlla BV) 
10- IO (Tanox Phanlla BV) 
MD-2 (Dr. P v/d Meide) 
B-S IO (Instrnchemie) 
Anti-IL-4 (Oenzyme) 
61E71-bio (Dr. P v/d Meide) 
IGlF-bio (R&D systems) 
2E9-bio (Dr. MP Hazenberg) 
MOUSE 
Enzyme substrate 
Acid phos. Substrate 
Antibody 
226aKappa + 210887 (Dr. HFJ Savelkoul) 
M5fll4 (ATCC) 
F4/80 (Dr. PJM Leenen) 
3/23 (lnstruchemie) 
MR-I (Dr. RJNoelle) 
019410 1020 (Phaoningen) 
OLI 1196 (ATCC) 
IIBII-bio (Dr. HFJ Savelkoul) 
SXC-I-bio (BPRC) 
DB-I-bio (BPRC) 
2E9-bio (Dr. MP Hazenberg) 
Antigen-enzyme 
TNP-AP 
Detects 
Acid pltos. activity 
IgM 
IgO 
HLA-ll 
CDI4 
CD40 
CDI54/CD40L 
CD801B7.1 
CD861B7.2 
IFN-y 
IL-IO 
IL-4 
TNF-a 
IL-18IIGlFIIL-ly 
Peptidoglycan (PO) 
Acid phos. activity 
IgM + IgO 
HLA-ll 
F4/80) 
CD40 
CD I 54/CD40L 
CD80/B7.1 
CD861B7.2 
IL-4 
IL-IO 
IFN-y 
PO 
aTNP-antibody 
Tissue fixation by pararosaniline 
Secondary Tertiary 
reagent reagent 
AV-PO (Sigma) 
HoaM-bio (Vector) AV-PO 
Hoo:M-bio AV-PO 
HoaM-bio AV-PO 
Hoo:M-bio AV-PO 
HoaM-bio AV-PO 
HoaM-bio AV-PO 
Hoo:M-bio AV-PO 
HoaM-bio AV-PO 
AV-PO 
SAY-PO (Jackson) 
SAY-PO 
RaRa-bio (Dako) AV-PO 
Ro:Ra-bio AV-PO 
RaRa-bio AV-PO 
Ro:Ra-bio AV-PO 
RaRa-bio AV-PO 
RaRa-bio AV-PO 
RaRa-bio AV-PO 
AV-PO 
AV-PO 
AV-PO 
SAY-PO (Jackson 
Abbreviations: acid phos. (acid phosphatase), AV-PO (avidin peroxidase), HoaM-bio (horse-anti-mouse-biotin), 
SAY-PO (streptavidin-peroxidase), RaRa-bio (Rabbit-anti-Rat-biotin) Suppliers: TNO-PO, Leiden, The Nether-
lands; Coulter Clone, Hialeah, FL; RJ. Noelle, DamlOulh College,Lebanon, NH; Tanox Pharma BV, Amsterdam, 
The Netherlands; Dr. P. van der Meide, BPRC, Rijswijk, the Netherlands; R&D systems, Abingdon, United King-
dom; Sigma Chemical Co., SI. Louis, MOjDr. P.J.M. LeenenIDr. H.F.J. SavelkoullDr. M.P. Hazenberg, EUR, Rot-
terdam, The Netherlands; Instmchemie, Hilversum, The Netherlands; Genzyme, Cambridge, MA; Phanuingen, 
San Diego, CA;ATIC, Rockville, MA; Dako, Glostrup, Denmark; Vector Lab., Peterborough, UK; Jackson lnnnu-
noresearch, Westgroove, PA 
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Evaluatioll alld qualltitatioll of (iIllIllUIlO)histochelllistIY 
Staining on two sections of each tissue was performed for each marker. All sections were 
evaluated for the following parameters; tissue morphology, sensitivity of the procedure as 
defined by number of positive cells, staining intensity per cell, and background endogenous 
enzyme activity (HRP and AP). The evaluation was performed by light microscopy by two 
independent observers blinded to the fixation procedure. 
RESULTS 
MOIphology 
To assess the preservation of tissue and cell morphology after the different fixation proce-
dures, the tissue sections were stained using the entire staining procedure but with omission 
of the primary reagent. As described previously (22), after acetone fixation the morphology 
was suboptimal for mouse and human spleen. The distinction between red and white pulp 
was not very clear, and the distinction between individual cells was not optimal, especially 
in the white pulp (figure l,a and b). The morphology of monkey EAE brain was reasonable 
after acetone fixation except for the mononuclear cell infiltrates in which the individual cells 
were not clearly discernible. Morphology of MS brain was good in unaffected parts but 
suboptimal in demyelinating parts of the tissue. 
In all tissues (except for MS brain) the morphology improved after fixation with pararos-
aniline. For MS brain tissue there was no difference between the two fixatives. 
After pararosaniline fixation, both densely populated areas such as the splenic white pulp 
and less densely populated areas (red pulp) of the spleen and infiltrates of EAE brain 
showed better morphology. At low power magnification, the distinction between spleen 
white and red pulp could be made much more easely after pararosaniline fixation compared 
to acetone. In addition, the distinction between individual cells and detennination of cell 
type based on the basis of morphology was much easier after pararosaniline fixation com-
pared to acetone fixation. After pararosaniline fixation the counterstaining ofthe nuclei with 
hematoxylin was morc intense compared to acetone fixation. 
Elldogellous ellzymatic activity 
To detennine whether endogenous peroxidase or AP activity could be inhibited by pararos-
aniline or acetone fixation, all tissues were stained with omission of the primary antibody 
and the histochemical revelation of HRP and AP-activity was performed with AEC sub-
strate and Fast Blue Base substrate respectively. Endogenous peroxidase activity was rou-
tinely inhibited by incubation with 0.05% H,O, and endogenous AP activity with levami-
sole added to the substrate. 
In none of the tissues endogenous peroxidase staining could be observed after acetone or 
pararosaniline fixation. In human and mouse spleen endogenous AP activity was completely 
blocked after both fixation procedures. In contrast, EAE and MS brain tissue showed a dif-
ference between the fixation procedures. After acetone fixation, endogenous AP activity 
was present in the endothelial cells ofthe blood vessels in MS brain and monkey EAE brain. 
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After pararosaniline fixation this endogenous AP activity was completely abolished (figure 
I, c and d). 
/" 
d H 
Figure 1. Morphology and endogenous alkaline phosphatase activity after acetone and pararosani~ 
line fixation. Morphology of human spleen tissue strongly improved after pararosaniline (b) fixation 
compared to acetone fixation (a). After pararosaniline fixation the distinction between red (RP) and 
white pulp (WP) is much clearer and hematoxylin counter staining is stronger. Endogenous alkaline 
phosphatase activity of endothelial cells of EAE brain could be observed after acetone (c). After 
pararosaniline fixation endogenous alkaline phosphatase activity was totally inhibited (d). Scale bar 
represents 20 ~m for all figures. 
Preservation of determinants 
To examine the effect of acetone and pararosaniline on antigen preservation, detection of a 
broad range of different determinants on various tissues was analyzed. The antigen preser-
vation after the fixation method was analyzed by two parameters. First the number of cells 
positive for the antigen was counted and second the staining intensity on a per cell basis 
was determined. The semi-quantitative results are shown in table 3. The staining properties 
were dependent on the combination of marker and tissue used. Many ofthe markers showed 
the same staining pattern after both fixation procedures. However, some markers showed 
considerably different staining patterns for the two fixation procedures. For example, para-
rosaniline is preferable for detection of CD40 in all tissues. For other markers the differ-
ence between the fixatives is restricted by the tissue used. For example, for IL-l 0 detec-
tion pararosaniline fixation is preferable for marmoset brain but not for human MS brain. 
In addition, in the six categories of markers described above there is no general rule as 
to which fixative is preferable. For example, higher numbers of IL-4 producing cells were 
detected with pararosaniline in human spleen, but no IL-18 could be detected. The general 
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impression is that for human and mouse spleen tissue, pararosaniline is the better fixative. 
The staining of the cells is more discrete compared to· acetone with which the staining is 
more diffuse, with some color precipitate outside the cell. Therefore it is sometimes dif-
ficult to determine which individual cell is positive for the determinant under investigation, 
which may lead to an overestimation of the number of positive cells after acetone fixation. 
Especially with markers present on a high number of cells, such as CD14 and HLA-DR, the 
staining intensity of the cells lVas higher after pararosaniline fixation. 
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Tissue fixation by pararosaniline 
A disadvantage of pararosaniline fixation is that no positive cells could be observed for 
IFN-yand IL-18 in human spleen and for CD86 in MS brain. 
Figure 2 shows some selected stainings representing the different categories of determi-
nants used in the study. Lysosomal acid phosphatase activity can be detected histochemi-
cally in all macrophages present in the EAE brain tissue. Pararosaniline fixation resulted in 
similar staining intensity compared to acetone fixation (figure 2, a and b). IL-4 is expressed 
in the red pulp of human spleen. The staining pattern is more discrete and stronger after 
pararosaniline compared to acetone fixation (figure 2, c and d). CD40 expression in mouse 
spleen injected with the agonistic anti-CD40 antibody is weak on B cells in the white pulp 
and strong on some macrophages in the red pulp. After pararosaniline the staining of the B 
cells is more intense compared to acetone fixation. (figure 2, e and I). Plasma cells contain-
ing intracellular antibody specific for TNP were detected in TNP-Ficoll inununized mice. 
Anti-TNP plasma cells were present in groups of 10-50 cells located in the outer pals and 
terminal arterioles of the spleen. Staining patterns did not differ between the two fixation 
procedures indicating that pararosaniline does not affect the integrity of antigen binding 
sites, but morphology of the tissue strongly improved after pararosaniline fixation (figure 2, 
g and h). 
DISCUSSION 
The present data clearly demonstrate that pararosaniline is a permissive and mild fixative 
for frozen sections, which can result in improved immunohistochemical staining compared 
to acetone, depending on the combination of the marker and the tissue under study. 
The purpose of this study was to identify improved fixation conditions for the study of 
immune responses ill situ. Integral immunohistochemical analysis of immune responses 
requires that in addition to constitutively expressed membrane CD markers, strongly regu-
lated determinants such as bacterial antigen, intracellular cytokines, costimulatory mole-
cules, enzyme activity and antigen specific plasma cells can be visualized reliably. Although 
some studies have reported that instable determinants such as cytokines are detected reliably 
in paraffin embedded tissue (30), most studies of strongly regulated determinants employ 
frozen sections because efficient detection of these markers remains difficult in paraffin 
embedded tissues. 
Figure 2. Antigen preservation of different markers after acetone and pararosaniline fixation. 
Acetone (left column) and pararosaniline (right column) fixed sections of non infiltrated part of EAE 
brain (a,b), human spleen (c,d) and mouse spleen (e,f)g,h). Macrophages containing lysosomal acid 
phosphatase were located throughout the section (a,b). No difference of staining pattern was found 
between the two fixatives. IL-4 producing cells (c,d) were mostly located in the red pulp ofthe spleen. 
After pararosaniline fixation, staining intensity per cell was improved compared to acetone in which 
the staining was more diffuse. CD40 was expressed on B cells and some macrophages (e,f). After 
pararosaniline fixation expression of CD40 on B cells was much stronger compared to acetone fixa-
tion. Plasma cells specific for TNP were analyzed in TNP-Ficoll injected mice (g,h). Groups of 10-50 
cells were detected in the outer pals and tenninal arterioles of the spleen. Pararosaniline fixation did 
not affect integrity of antigen binding sites of antibodies but morphology was strongly improved. 
Scale bars represent 20 J-lm for both left and right colomn figures. 
121 
Q 
Table 3. Staining intensity per cell (A) and number of positive cells (B) for six determinant categories analyzed in different tissues I~ Human spleen Human MS-brain Mannosct EAE-brain Mouse spleen ~ 
Acetone Pararosaniline Acetone Pararosaniline Acetone Pararosaniline Acetone Pararosaniline ~ 
Cell surface markers A B A B A B A B A B A B A B A B 
IgM + + ++ + + ± ++ ± + ± + ± ++ ++ + ++ 
IgG ± + ± ± ± ± ± ± + + + ++ ++ + ++ 
HLA-DR + +++ + +++ ± ++ + ++ + + ++ + n.a. n.a. 
F4/80 n.a. h.a. n.a. n.a. n.a. n.a. + ++ + ++ 
CDl4 ± ++ ++ ++ + + + + + + + + n.a. n.a. 
Costimulatory molecules 
CD40 ± + + + ± + + + ± + ± + ± + + + 
CD40L + + ± ± ± ± ± ± + ± ± ± ++ ++ ++ + 
CD801B7-l ± ± + ± ± + ± + ± ± ± ± ± ± + ± 
CD861B7-2 + + + ± ± + ± ± + ± ± + + + 
~ Cytokines tv 
tv IL-IO ++ + ++ ± + + ± ± ± ± + ± + ± + ± 
TNF-a + ++ ++ + + ++ ± ++ + ± + ± + ± + ± 
IFN-y + ± + + + ± + ± + ± + + ± + 
IL-4 ± + + + + ± ± ± ± ± + ± + + ± + 
IL-18 + + ± ± ± ± ± + + + n.a. n.a. 
Bacterial antigen 
Peptidoglycan ± ± ++ ± n.a. n.a. + ± + ± + + + + 
Enzyme substrate 
Acid phosphatase + +++ + +++ + + + + + ++ + ++ ++ +++ + ++ 
Antigen detection 
anti-TNP b.a. n.a. n.a. b.a. n.a. n.a. ++ + ++ + 
evaluation of number of positive cells: - no positive cells, +/- 0-5% of cells positive, + 5-10% of cells positive, ++ 10-50% of cells positive, +++ > 50% of cells 
positive BALB/c mice were immunized with TNP-FicoIl, CD40 expression was detected in C57BV6 mice injected with agonistic anti-CD40 antibody (FGK-45) 
n.a.: not applicable 
Tissue fixation by pararosaniline 
A major disadvantage of the use of frozen tissues is the frequently poonnorphology of 
cryosections. Morphology of the tissues is strongly dependent on the fixative used. Good 
morphology is achieved with paraformaldehyde, formaline and gultaraldehyde which are 
able to crosslink proteins. A major disadvantage ofthese fixatives is the alteration of tertiary 
structure by crosslinkage, resulting in alteration of antigenic structures of the tissues (31). 
In contrast, acetone, which precipitates proteins, is a reliable fixative for detection of differ-
ent markers but morphology is often poor (32). 
To improve morphology while maintaining staining intensity we compared the most com-
monly used mild acetone fixation with pararosaniline. Pararosaniline is a hexazonium salt, 
that contains three reactive diazonium groups and therefore, in theorie must be able to cross-
link proteins, which was shown previously to yield a better morphology of mouse tissue 
compared to acetone without affecting immunogenicity (22). In the present study detec-
tion of six categories of detenuinants was analyzed for different tissues. Human and mouse 
spleens were used because the spleen is an important secondary lymphoid organ in which a 
wide diversity of immune responses takes place. Therefore most of the markers examined 
are expressed in these organs. We also evaluated expression of these detenuinant catego-
ries in inflamed tissues of MS patients and EAE affected manuoset monkeys because it is 
expected to be chronically increased and because good morphology is very important in 
these activated tissues. 
Antigen preservation was analyzed by examination of staining intensity per cell and number 
of positive cells. In general the antigen preservation after pararosaniline fixation did not 
differ from that of acetone fixation. Staining of antigen specific antibodies and acid phos-
phatase could be detected reliably in all tissues implying that these determinants are well 
preserved. The preservation of strongly regulated molecules such as costimulatory mol-
ecules and cytokines differed between the two fixation procedures. The restriction of para-
rosaniline fixation is that for a few detemlinant-tissue combinations, the number of cells 
positive for the detenninant is lower compared to acetone fixation. In these cases, acetone 
fixation would be preferable. In all other cases fixation with pararosaniline is preferable 
over acetone fixation for four reasons. First, morphology is strongly improved after pararos-
aniline fixation, which results in a better judgment of the location of positive cells. Second, 
endogenous AP activity could be completely inhibited after pararosaniline fixation. This is 
especially important when double stainings are perfornled with revelation of both peroxi-
dase and AP enzymatic activity (8). Third, in some cases staining intensity after pararosani-
line fixation improved leading to a more discrete staining pattern compared to acetone fixa-
tion where sometimes color precipitate is seen outside the cell. Especially when high num-
bers of cells are positive for the detenuinant this will lead to a better distinction between 
positive cells. Fourth, hematoxylin counter staining of the tissue was much stronger com-
pared to acetone fixation leading to an improved distinction between adjacent cells. 
In conclusion, pararosaniline fixation gives a better morphology than acetone fixation and 
inhibits endogenous AP activity in brain tissue. Antigen preservation in general does not 
differ between the two fixatives for a wide range of detenuinants. When staining protocols 
are established for new and existing reagents pararosaniline is an easy and cost effective 
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alternative fixation for frozen sections. For studying a new marker-tissue combination it 
is recommended to analyze acetone and pararosaniline fixation routinely side by side to 
determine the optimal fixation procedure. 
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CHAPTER 4.2 
Antigen-presenting cells containing bacterial peptidoglycan in 
synovial tissues of rheumatoid arthritis patients coexpress 
costimulatory molecules and cytokines 
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and Jon D. Laman' 
JDepartment afImmullology, Erasmus University Rotterdam alld 
University Hospital Rotterdam-Dijkzigt, The Netherlands 
'Division of Clinical Immunology and Rheumatology, Department of Medicine, 
Academic Medical Centel; Amsterdam, The Netherlands 
ABSTRACT 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by intima lining 
hyperplasia and massive infiltration of the synovial sublining by antigen presenting cells 
(APC), lymphocytes and plasma cells. Peptidoglycan (PO), a major cell wall component 
of gram-positive bacteria, which is abundantly expressed in all mucosa, is believed to be 
involved in the pathogenesis ofRA, because of its capability to induce production of pro in-
flammatory cytokines and to induce arthritis in rodents. Furthermore, PO can be detected 
in APC in RA joints but little is known about the role of these cells in RA. In the current 
study the presence and immune competence of PO-containing cells in synovial tissues of 
14 RA and 14 osteoarthritis (OA) patients was analyzed in situ. Using immunohistochem-
istry, we examined the coexpression of phenotypic markers, costimulatory molecules and 
cytokines by PO-containing cells. PO was detected in both RA and OA synovial tissues, 
with a tendency towards higher numbers of PO-containing cells in RA. PO-containing cells 
were mainly macrophages but also some dendritic cells contained PO. A high percentage 
of PO-containing cells in both RA and OA synovial tissues coexpressed HLA-DR. CD40, 
CD80, and CD86 expression by PO-containing cells was higher in RA compared to OA, 
implying that the activation state of PO-containing cells is higher in RA compared to ~A. 
Furthermore, PO-containing cells coexpress cytokines which modulate inflammatory reac-
tions, especially TNF-a, IL-6, and IL-tO. The results suggest that PO-containing cells con-
tribute to inflammation in RA within the joint microenvironment. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease with primary manifestations 
in the synovial tissue. The synovium becomes thickened due to synovial cell proliferation, 
infiltration by inflammatory cells and impaired apoptosis. The infiltrating cells mainly com-
prise T lymphocytes, macrophages, and plasma cells but also other cell types such as den-
dritic cells infiltrate the synovial membrane (I). The etiopathogenesis of RA is still not 
understood. Several lines of evidence support an important role of T lymphocytes (2) and 
antigen presenting cells (APC) in the pathogenesis ofRA (3-5). 
The (auto)antigen(s) leading to chronic stimulation ofT cells and/or macrophages are still 
unknown. In reactive arthritis, the triggering antigens are thought to be microbes that cause 
infections of the urogenital tract or the intestine, such as Chlamydia trachoma tis, Yersinia 
or Salmonella species (6,7). Antigens of these bacteria have been detected in synovial cells 
(8-10), and T cells specific for these antigens are present in the synovium (8,11, 12). Because 
RA is a chronic disease, it can be suggested that the bacterial load in the intestine with 
which we are in lifelong close contact is important for the induction and perpetuation of 
RA. This is supported by the observation that some patients with Crohn's disease and ulcer-
ative colitis, both intestinal autoimmune diseases, suffer from attacks of joint inflammation 
(13,14). FurthemlOre, inflammatory bowel disease mimicking Crohn's disease and chronic 
inflammatory arthritis develop spontaneously in knockout mice lacking a TNF AU-rich ele-
ment, which is responsible for TNF mRNA destabilization and translational repression in 
hemopoietic and stromal cells (i5). 
We and others have previously hypothesized that peptidoglycan (PO) plays a role in the 
pathogenesis ofRA (16-18). Peptidoglycan (PO) is the major component of the cell wall 
of gram positive bacteria and is composed of long sugar chains of alternating N-acetyl glu-
cosamine (OlcNAc) and N-acetylmuramic acid (MurNAc) residues, which are interlinked 
by peptide bridges, resulting in a large complex macromolecular structure (19). PO isolated 
from the anaerobic bacterium Eubacterium aero/aciens which is present in numbers> 10'/g 
human feces induces a severe and chronic arthritis in rats (20). PO could also be isolated 
from sterile normal human spleen using biochemical methods (21,22). In vitro analysis 
showed that this PO fraction is able to induce production of the proinflammatory cytokines 
TNF-a, IL-l and IL-6 (21) which are crucially involved in the pathogenesis ofRA (23). 
When PO plays a role in RA, the presence and persistence of PO in the synovia of RA 
patients may be a prerequisite. With a monoclonal antibody (Mab) 2E9, PO could be 
detected in 8 out of IO RA synovia and in only 2 out of 20 non-rheumatoid synovial tissue 
samples (24). In addition, it was shown that the PO-containing cells were macrophages and 
dendritic cells as defined by coexpression with CD68 (macrophage marker), RFDI and L25 
(dendritic cell markers). Other studies using PCR techniques have detected bacterial DNA 
in RA synovia (25,26) suggesting bacterial involvement in RA. 
To investigate whether PO contributes to inflammation in the synovial tissues we analyzed 
whether the PO-containing cells produced cytokines and coexpressed costimulatory mol-
ecules in a panel of synovial tissues ofRA and osteoarthritis patients (OA). OA is a degener-
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ative disease of the joints characterized by a non-infectious chronic inflamnlatory condition. 
The OA patients in the present study were selected on the basis of clinically inflamed joints 
secondary to OA. Furthermore, we analyzed the cellular phenotype of the PG-containing 
cells with an extended panel of APC markers (CDI4, CD68, CD83, CDllb). Cytokines 
analyzed were !L-6, !L-IO, TNF-o: and IFN-y (23). CD80 (B7.1), CD86 (B7.2), CD40 and 
lILA-DR were analyzed to detenmne the involvement of PG-containing cells in antigen 
presentation and costimulation. 
PATffiNTS AND METHODS 
Patients and biopsies 
Synovial biopsies of 14 RA patients and 14 inflammatory OA patients were investigated. 
All RA patients had active arthritis and fulfilled the American College of Rheumatology 
criteria for RA (27). Patient features are shown in table I. 
Table 1. Patient features 
Patients MIF Age RF+IRF- CRP Disease duration 
(years) (months) 
Rheumatoid arthritis 4110 59 (41-80) 11/3 48 (7-118) 123 (8-300) 
Osteoarthritis 1/13 75 (69- 81) 3111 14 (5-60) 
age, CRP (C-reactiye protein level) and disease duration arc indicated as mean and range in parentheses 
Biopsies were taken from the knee joint of the patients with a Parker Pearson needle (26). 
The tissue samples were snap frozen together in Tissue-Tek OCT (Miles, Elkhart, IN) by 
immersion in methylbutane (-70'C) and stored in liquid nitrogen. Cryostat sections (5 !lm) 
were placed on adhesive glass sides (Starfrost, Knittelglaser, Germany), air-dried overnight, 
fixed in acetone for 10 minutes, and stored at -80°C until inununohistochemical analysis 
was perfonned. 
Immullohistochemisfly 
Procedures used here have been reviewed in detail previously (28,29). The sections were 
allowed to warm to room temperature and washed with PBS after which endogenous per-
oxidase activity was inhibited using 0.5 % H20 2 . The sections were washed between all 
steps with PBS/0.05% (v/v) Tween 20 (Fluka, Chemie AG, Buchs, Switzerland). The sec-
tions were incubated with the first antibody (table 2) diluted in PBSIT/I % BSA (HPLC-
grade, fraction V, Sigma) overnight at 4'C. The secondary and tertiary reagents diluted 
in PBS/I %BSAII % normal human sernm were incubated during 60 minutes at room tem-
perature (table 2). Biotinylated anti-PG (Mab 2E9) diluted in PBSITIl % BSA was incu-
bated overnight at 4'C followed by an incubation with streptavidin-peroxidase (Jackson 
Immunoresearch, Westgroove, PA) during 60 minutes. Histochemical detection of alkaline 
phosphatase activity was performed with Fast Blue Base (FBB) substrate after rinsing the 
sections in 0.1 M Tris-HCL pH 8.5. FBB substrate was prepared as follows. 16 mg FBB 
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(Sigma) was added to 400 III 2M HCL and 400 III 4% NaND, and mixed during I min 
before adding to 65 ml of 0.1 M Tris-HCL pH 8.5. Then 8 mg Naphtol-AS-MX-phosphate 
(Sigma) was dissolved in 400 III ofDMF and added to the solution. Finally, 100 III of 1M 
levamisole (Sigma) was added to the solution to inhibit endogenous alkaline activity. The 
sections were incubated in the substrate during 45 min. After alkaline phosphatase activity 
relevation, horseradish peroxidase activity (HRP) was revealed by incubating the sections 
during 15 min in substrate containing 1.5 tnl of 3-amino-9-ethylcarbazole (AEC, Sigma) 
dissolved in N,N-dimethylformamide (DMF, Sigma) (17 mg/ml) and 30 III H,O, 30% in 60 
ml ofNaAc buffer pH 5.0, followed by a washing step in PBS. The use of AEC results in a 
bright red precipitate. All sections were washed in tap water during 10 minutes after which 
they were embedded in Kaiser's glycerin/gelatin (Merck, Darmstadt, Germany). Sections 
from reactive human tonsils were included to provide internal positive control tissue. In 
control sections, the primary antibody was omitted or irrelevant antibodies were applied. An 
anti-sheep-red blood cells Mab (IgG3) was used as a negative control for the Mab against 
PG. 
Table 2. Reagents used for the detection of various detenninants 
Reagent 
Marker Clone Expressed by secondary tertiary 
C03 A452 pan T cells GaR-AP RaG-AP 
CDllb aMacMI monocytes, macrophages, RaRa-AP GaR-AP 
granulocytes, NK cells 
CDI4 MY-4 monocytes, granulocytes RaRa-AP GaR-AP 
CDI5 VimD5 granulocytes RaRa-AP GaR-AP 
C068 KP-I mOl1ocytes, macrophages RaRa-AP GaR-AP 
CD40 5012 macrophages, B cells RaRa-AP GaR-AP 
CD80/B7.1 M24 macrophagcs, dendritic cells, 8 cetts RaRa-AP GaR-AP 
C086/B7.2 lOlO mOl1ocytes, macrophages, RaRa-AP GaR-AP 
dendritic cells, B cells 
CDS3 HBI5a dendritic cells RaRa-AP GaR-AP 
HLA-DR L234 macrophages, dendritic cells RaRa-AP GaR-AP 
IL-4 anti-IL-4 T cells, mast cells RaRa-AP GaR-AP 
IL-6 anti-IL-6 TIB cells, macrophages, RaRa-AP GaR-AP 
endothelium, fibroblasts 
IL-lO B-SlO T cells, tnonocytes, macrophages RuRa-AP GaR-AP 
IFN-y MO-2 T cells, NK cells RaRa-AP GaR-AP 
TNF-a MCI6 monocytes, macrophages, T cells RaRa-AP GaR-AP 
Abbreviations: AP (alkaline phosphatase), GaR (Goat-anti-Rabbit), RaG (Rabbit-aoti-Goat) RaRa (Rabbit anti-
Rat), RaM (Rabbit-anli-Mouse). Suppliers: CD3, CD68 (Dako, Glostmp, Denmark) CDI4, CDlS, HLA-DR 
(Coulter Clone, llialeah, FL) CD40 (Tanox Phamla BC, Amstcrdam,:The Netherlands) CD83 (Immunotech, West-
brook, ME), CD80, CD86 (Innogenetics N.V., Gent, Belgium) anti-IL-4, anti-fL-6 (Genzymc, Cambridge MA) 
allti-IL-IO (lnslruchemie, Hilversum, The Netherlands). GaR-AP (DAKO), RaRa-AP, RaG-AP (Jackson Immu-
noresearch, Inc., Wcslgroovc, PAl. 
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Evaluation alld quantificatioll of (immullo)histochemislly 
Labeling for the relevant markers was scored by two independent observers using light 
microscopy. 2-3 tissue sections were analyzed per synovium to determine the number of 
PG-containing cells per mm'. Single labeling of the other markers was analyzed on a five-
point scale: 0 represented no or minimal staining, whereas a score of 4 was assigned to 
patients with the most abundant staining. All areas of each biopsy were taken into account 
when examining sections. The scoring system which has been described before, is cali-
brated for each marker and has been developed previously by examining an extended series 
of rheumatoid synovial tissues (1,30). Because some cell types or cytokines are present 
more abundantly than others, the evaluation of each requires a different sensitivity level. 
The scoring system of 0-4 therefore refers to different numbers of cells stained positive 
for each marker, e.g. for CD68 a score of 4 represents massive infiltration by macrophages 
compared to CD15 for which a score of 4 might be assigned for only a limited number of 
cells. Double labeling of these markers with PG-containing cells was analyzed by counting 
the PG positive cells and the number of cells expressing both PG and the secondary marker. 
Results are shown as the percentage of all PO-containing cells coexpressing the analyzed 
marker. 
Statistical allalysis 
The MaIm-Whitney or Student t-test method was used, dependent on the distribution of the 
data, to determine whether the number ofPG-containing cells differed between RA and OA 
synovial tissues and whether the percentage of double labeling for a particular marker dif-
fered between RA and OA synovial tissues. 
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Figure 1. PO containing cells in synovial tissues ofRA and OA patients. Immunohistochemistry was 
performed on synovial tissues of 14 RA and 14 OA patients using an antibody raised against PG 
isolated from human feces. Results are shown as the number of positive cells/uun2 for each patient. 
Samples are ordered according to increasing numbers ofPG containing cells. 
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RESULTS 
Number of PG-contallling cells In synovial biopsies 
The number of PG-containing cells was analyzed in 14 RA and 14 OA synovial tissues. 
Total numbers of PG-containing cells were counted and expressed as number of PG-con-
taining cells per mm2 , as shown in figure 1. 
All RA and OA synovia expressed PG-containing cells except for one OA synovium which 
was completely negative for the presence of PG. The mean number ± standard deviation 
of PG positive cells was 7.0± 6.8 for the RA synovia and 3.6±2.7 for the OA synovia but 
tlus difference did not reach statistical significance. The intensity of cytoplasnllc staining 
of cells containing PG was lugh (figure 2a) in both RA and ~A. The PG-containing cells 
were usually located throughout the whole section but could also be found in clusters in 
infiltrated areas (figure 2b). 
Different cell types and expression of costimulatOlY molecules and cytokines 
The expression of the different markers used to functionally characterize PG-containing 
cells were semiquantitatively analyzed using a four-point scale. As shown in table 3, the 
expression of all costimulatory molecules and cytokines tended to be lugher in RA com-
pared to OA, which was significant for CD3, CD80, CD86, IL-6, IL-lO and TNF-a as 
defined by the student-t test. 
Table 3. Phenotypic markers, costimulatory molecules and cytokines expressed in RA and OA 
synovium 
Category Marker 
Phenotypic marker cm 
CDllb 
CDI4 
CDl5 
CD68 
CD83 
Costimulatory molecule HLA-DR 
CD80 
CD86 
CD40 
Cytokine IL-6 
IL-IO 
TNF-a 
IFN-y 
RA 
2.0 ±1.0 
1.2 ±1.0 
2.0 ± 0.6 
2.3 ±1.2 
2.4 ±0.9 
1.6 ± 1.1 
2.6 ±0.7 
2.1 ±0.8 
2.4 ±0.7 
1.9 ± 0.8 
2.7 ±0.8 
2.6 ±1.0 
2.1 ±I.O 
1.8 ± 1.0 
OA 
0.9 ±0.7* 
0.7 ±0.6 
1.0 ± 0.8 
1.2 ±0.7 
1.3 ±I.O 
0.6 ± 0.8 
1.8 ± 0.8 
0.9 ±0.9** 
1.3 ±1.0* 
1.3 ±0.9 
1.4 ±0.9* 
1.3 ±0.8* 
0.6 ±0.7** 
1.5 ± 0.9 
Values arc expressed as the mean +1- SO of a semi-quantitative four point scale, 0« p < 0,05, ** P < 0.01 
Identity of PG-contailling cells 
To detennine the phenotype ofPG-containing cells, coexpression ofPG with CD3, CDI4, 
CD 11 b, CD 15, CD68 and CD83 was determined. The results are shown as the percentage 
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Figure 2. PO is localized in antigen presenting cells expressing costimulatory molecules and cyto-
kines, PO (red cells) can be detected in synovial tissues of RA patients in the cytoplasm of cells dis-
tributed throughout the tissue (a) or clustered (b), Double labeling with different markers (blue cells) 
showed that PO-containing cells are often found within CD3+ T cell infiltrates (c). Furthermore, PO 
is often found in cells expressing CD68 (d) and HLA-DR (e). Coexpression was also found for CD86 
(f) and C040 (g), both costimulatory molecules, In addition, it was shown that PO containing cells 
can coexpress the proinfiammatory cytokines TNF-a; (h) and IL-6 (i). Arrows point to cells expressing 
both PO and the analyzed marker. 
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of coexpression by all PO-containing cells (figure 3a). The results show that T lymphocytes 
and granulocytes (CD3+, CDI5+ respectively) do not contain PO, and that PO is present in 
both immature CDI4+ and mature CD68+ (figure 2d) macrophages and only in low num-
bers of CD 11 b+ macrophages and CD83+ dendritic cells. PO-containing cells were often 
found within T cell infiltrates as shown with double labeling with CD3 (figure 2c). Only 
minor differences could be observed between the phenotype of PO-containing cells in RA 
and OA synovia. 
Expressioll of costimulatOlY molecules by PG-colltaillillg cells 
To examine whether the PO-containing cells coexpress molecules involved in antigen pre-
sentation, the presence of PO was analyzed simultaneously with HLA-DR, CD80, CD86 
and CD40 expression. The percentages of all PO-containing cells coexpressing the different 
markers are shown in figure 3B. The majority of PO-containing cells do express HLA-DR 
(figure 2e) and a high number of cells also express CD80, CD86 (figure 2g), and to a lesser 
extent CD40 (figure 21). The expression of CD80, CD68, and CD40 on PO-containing cells 
is less frequent in OA synovia compared to RA synovia, which is significant for CD80 (p < 
0.05), suggesting that these cells have lower costimulatory activity in vivo. 
Cytokille pmductioll by PG-colliaillillg cells 
To asses whether PO-containing cells produce cytokines involved in the pathogenesis of 
RA, coexpression of PO with the cytokines IL-6, !L-lO, TNF-o: and IFN-ywas analyzed. In 
figure 3C the percentage of PO-containing cells expressing the different cytokines is shown. 
Especially TNF-o: (figure 2h) and !L-6 (figure 2i) are coexpressed by a high number of PO-
containing cells. Although coexpression of PO was found with JL-I 0, !L-I 0 containing cells 
were also often detected directly juxtaposed with Po- containing cells. Such colocalization 
was also found for IFN-y. The coexpression ofTNF-o:, IL-6 and !L-lO by PO-containing 
cells was significantly (respectively p < 0.05, P < 0.05, P < 0.01) higher in RA synovial tis-
sues compared to OA synovial tissues. 
DISCUSSION 
TIllS study shows that PO-containing cells are present in both RA and OA synovial tissues 
and that they have a more activated phenotype in synovial tissues of RA patients than OA 
patients. The number of PO-containing cells tended to be higher ill RA compared to OA, 
but this difference did not reach significance. In all RA synovia PO-containing cells could 
be detected. These results are in accordance with earlier findings (31) where PO could be 
found in 8 out of lO RA synovia. In that particular study a completely different reference 
group, synovia obtained by arthroscopy after sport injuries, was used in which only limited 
numbers of PO-containing cells could be observed. To detect PO in synovial tissues, Mab 
2E9 was used which is raised against a pure fraction of peptidoglycan-polysaccharides iso-
lated from normal human feces (31). The specificity of this Mab has been extensively inves-
tigated and confinned. First, inhibition studies using ELISA show that 2E9 recognizes cell 
wall fragments, muramyl dipeptide and lysozyme-solubilized cell walls of different gram-
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positive bacteria (31), These experiments suggest that the Mab binds to the glycan backbone 
of PG since muramic acid forms part of the stnlCtnre recognized. Second, spleen sections 
of germ-free rats and of neonatal rats in which the gut flora has not been established yet 
display no PG-containing phagocytes, whereas spleens of adult rats do, In addition, intra-
venous il\iection of PG into neonatal rats results in binding of 2E9 to phagocytes in spleen 
sections (31), Third, immuno-electron microscopy shows that Mab 2E9 binds to cell walls 
of Staphylococcus epidermidis surviving intracellularly in macrophages around infected 
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Figure 3. Antigen presenting cells containing PO are more activated in RA synovial tissues com-
pared to OA synovial tissues. Using immunohistochemistry, double labeling was performed with 
the anti-PO antibody and various subset markers and functional markers of antigen presenting cells. 
Results are indicated as mean percentage of PO containing cells expressing the analyzed marker + 
standard deviation (SD), PO is present in both macrophages (CD 14/CD 11b/CD68) and dendritic cells 
(CD83) (A)_ These antigen presenting cells are capable of antigen presentation by the expression of 
HLA-DR. PO containing cells in RA synovia have a more activated phenotype as shown by the higher 
percentage of PO containing cells expressing CD40, CD80 and CD86 (B). Expression of cytokines 
by PO containing cells was also higher in PG containing cells of RA and OA patients (C). * Indicates 
significantly higher percentage of double labeled cells in RA synovial tissues compared to OA syno-
vial tissues as defined by the Mann-Withney method. 
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biomaterial. Fourth, 2E9 displays no detectable reactivity against more than ten thousand 
random dodecapeptides and eight thousand tripeptides in Pepscan approaches (32), continn-
ing tlus Mab has very low crossreactivity with non-PG epitopes (Slootstra l.W. , Meloen 
R.H. unpublished). The present study shows that the PG-containing cells are mainly pres-
ent in macrophages and only in a small fraction of dendritic cells. PG could not be detected 
in T cells, as expected. The absence of PG in granulocytes, despite their expression of the 
PG-receptor CDI4, can be explained by the fact that N-acetylmuramyl-L-al31une anUdase 
(NAMLAA) is present in granulocytes which is able to degrade PG in joint action with 
lysozyme (33,34). NAMLAA is not present in monocytes which nught result in increased 
persistence of PG in these cells (33). The more frequent coexpression of CDl4 by PG-
containing cells in RA synovial tissues compared to OA synovial tissues suggests that 
these cells are relatively immature and have probably infiltrated more recently compared 
to the cells in OA synovial tissues. The lugh percentage of PG-containing cells expressing 
HLA-DR shows that these macrophages are able to present antigenic peptides to T cells. 
This is consistent with the expression of costimulatory molecules as CDSO, CDS6 and 
CD40 wluch are required for optimal T cell activation (35). CDS6 has been thought of as an 
important costimulatory molecule in RA. It has been shown that CDS6 is more abundantly 
expressed in RA than CDSO in RA (36,37), and anti-CDS6 was a potent inhibitor of a nuxed 
lymphocyte reaction by RA dendritic cells (3S,39). In contrast to these earlier studies in the 
present study both CDSO and CDS6, although in lower numbers compared to RA, are also 
expressed in OA synovial tissues, which can be explained by differences in patients selec-
tion. The OA patients in the present study were selected on the basis of clirucally inflamed 
joints secondary to OA. CD40 and its ligand CD40L (CDI54) have also been described 
as important molecules in the pathogenesis of RA (40,41). In the synovial tissues of RA 
patients of the current study, CD40 was mostly expressed in infiltrates. The percentage of 
PG-containing cells expressing CDSO, CDS6 and CD40 is higher in RA compared to OA 
suggesting a more activated phenotype. Cytokines are believed to play an important role 
in the pathogenesis ofRA (1,23). Especially the proinfiammatory cytokines like IL-I, IL-6 
and TNF-o: are abundantly expressed in RA (1,42,43) and are able to activate T and B cells 
but can also induce cartilage and bone destruction (44). Immunoregulatory cytokines like 
IL- IO produced mainly by macrophages, are also expressed inlugh concentrations in RA 
synovial tissues (45,46). The role ofiL-IO in RA is mainly anti-infiarrnnatory as shown 
by ill vitro experiments and by the possible clinical improvement upon IL-J 0 treatment in 
RA patients (47). The detection of the T cell derived immunoregulatory cytokine ILA has 
been difficult up to now in contrary to the detection of the proinfimrnnatory T cell derived 
cytokine IFN-y (4S). Therefore it is hypothesized that RA results mainly from a T helper 
-1 response. In the present study we analyzed whether PG-containing cells coexpress these 
cytokines. It was shown that the expression of IL- IO and TNF-o: was higher in the RA 
synovia compared to OA. Simultaneous labeling of PG and IFN-y resulted in only a few 
double labeled cells. Instead, IFN-y positive cells could often be found directly adjacent 
to PG-containing cells. This suggests that interactions rnight occur between PG-containing 
cells and IFN-y positive cells, probably T cells. This was confirmed by the presence of PG-
containing cells witlun infiltrates of CD3+ cells. 
Coexpression with PG was found mainly with IL-6, IL-IO and TNF-o:. The percentage of 
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coexpression of IL-6, IL-IO and TNF-a by PG-containing cells was significantly higher in 
RA synovia compared to OA synovia. As PG isolated from sterile human spleen is able to 
induce these cytokines ill vitro it can be hypothesized that PG contributes to the cytokine 
production in the synovial tissues (21). 
The presence ofPG, an antigen ubiquitously expressed at the musosal sites, in synovial tis-
sues suggests that PG derived from the mucosal sites is able to circulate through the blood-
stream in monocytes (49,50) and can enter the synovial tissue. The distribution ofPG may 
be dependent on two factors. First, reduced gut barrier function may result from inflamma-
tion, leading to increased bacterial translocation. Ultrastructural lesions ofthe gut wall have 
been reported in RA patients (51). Second, antibodies against PG may not be sufficiently 
capable of eliminating the bacterial products from mucosal sites and/or the bloodstream. 
Antibodies that reach the mucosal lumina perform immune exclusion and immune elimina-
tion to protect the mucosal surface against (bacterial) antigens. This is performed by secre-
tory IgA or IgM (S-IgA, S-IgM), but also by semm IgG antibodies (52,53). It has been 
shown that RA patients have significantly reduced systemic IgG antibody levels against 
PG (Schrijver et al. submitted) implying that lowered antibody responses against PG occur, 
may lead to increased translocation ofPG in the circulation. 
An increased circulation of PG-containing cells in combination with the preference of 
mucosal macrophages to home to the synovial sites (54) may lead to infiltration of PG-
containing cells into the synovium. Once infiltrated into the synovium. PG-containing cells 
may contribute to inflammation. It has been shown that monocytes recruited from the blood 
are more relevant for synovial inflammation and destruction than local proliferation of mac-
rophages (55). The presence ofPG-containing cells in both RA and OA synovia raises the 
question whether the migration of PG is a primary or secondary event in RA and ~A. OA 
is a degenerative disease of the articular cartilage believed to be primary non-inflammatory, 
but a secondary synovitis is often observed. (56,57). The OA synovia analyzed in the pres-
ent study display also signs of inflammation as shown by the infiltration of T cells and 
expression of CD40, CD80, CD86 and cytokines. It can be hypothesized that infiltration 
of PG-containing cells due to primary events promotes secondary infianunatory events in 
OA. Because PG-containing cells possess a more activated phenotype in RA compared to 
OA it can be suggested that PG plays a more prominent role in RA. Whether PG is involved 
in the initiation of RA is difficult to determine because the clinical debut of RA already 
represents a chronic phase of the disease (1,58). However, the ability ofPG to induce arthri-
tis in rodents clearly supports this hypothesis. PG lnight contribute to inflammation by the 
production of cytokines and the activation ofT cells. Recently, it has been shown that T cell 
tolerance to autoantigens can be broken by additional stimuli such as LPS (59-61). It can 
be hypothesized that PG, which is a functional analog ofLPS, activates autoreactive T cells 
specific for different cartilage antigens such as collagen (62) or HC-gp39 (63,64). 
In conclusion, PG is observed in synovial tissue from especially RA patients. The activation 
state of the PG-containing cells is higher in RA patients compared to OA patients, suggest-
ing a contribution ofPG in the inflammatory process. To investigate whether PG is involved 
in the pathogenesis ofRA, the effect of restriction ofPG access to extra-intestinal sites can 
be investigated in animal models. 
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Bacterial peptidoglycan promotes immune reactivity in the central 
nervous system in multiple sclerosis 
Ingrid A. Schrijverl , Marjan van Meurs l , Marie-Jose Melief, C. Wim Ang', 
Dragan Buljevac', Rivka Ravid', Maarten P. Hazenberg l and Jon D. Laman l 
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3Netherlands Brain Bank, Amsterdam, The Netherlallds 
ABSTRACT 
Microbial antigens such as lipopolysaccharide can breach peripheral T-cell tolerance in 
experimental animal models, contributing to development and perpehmtion of autoimmune 
disease. Peptidoglycan, a major component of the gram-positive bacterial cell wall, is a 
functionallipopolysaccharicle analogue with potent proinflall1l1latory properties and is con-
ceivably a mediator of sterile inflannnation. We here demonstrate that peptidoglycan is 
present within antigen presenting cells in the brain of multiple sclerosis patients. These 
cells have macrophage and dendritic cell characteristics, and are immunocompetent as evi-
denced by coexpression of inilannnatory cytokines and costimulatory molecules. In addi-
tion) intrathecal) plasma cells specific for peptidoglycan are present in multiple sclerosis 
brain) and antibodies binding peptidoglycan are present in cerebrospinal fluid during active 
disease. Peptidoglycan can thus contribute to T- and B-cell activity during brain inflamma-
tion without a requirement for local bacterial replication. 
INTRODUCTION 
According to prevailing dogma, multiple sclerosis (MS) is caused by autoreactive CD4+ 
T cells specific for myelin components with a proinflammatory T helper phenotype (I). As 
healthy donors have similar numbers of myelin-reactive T cells as patients) additional fac-
tors are clearly needed to promote (auto)-reactivity of T cells within the central nervous 
system (CNS) (2). Recent studies in several experimental models including the experimen-
tal autoilfnnune encephalomyelitis (EAE) model for MS have shown that various infec-
tious and proinflalfnnatory agents such as lipopolysaccharide (LPS) are capable of revers-
ing the tolerant state ofCD4+ and CD8+ T cells (3-6). Activation of these cells is crucially 
dependent on the presence of both the stimulatory agent and the specific (auto)-antigen 
(5). Research on inflammatory properties of bacterial antigens in brain tissue has shown 
that bacteria iqjected into the brain parenchyma are able to induce inflammatory responses 
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Figul'e 1. Peptidoglycan promotes immune reactivity in brain tissue of multiple sclerosis patients. 
Peptidoglycan is present in the white matter of multiple sclerosis patients 011 the edge of infiltrates or 
active lesions (a), or distributed in nannal appearing white matter (b). Co-expression was found with 
C080 (c) and colocalization with other cells expressing IL-l 0 (d), Both coexpression and colocaliza-
tion was found with TNF-a (e), Using biotin-labeled PO, antibody forming cells specific for PO could 
be detected in MS brain tissue (f + inlay), (Original magnification 630x, f: 400x, inlay 630x) 
only after peripheral sensitization ofT cells (7). However, there is no clear evidence to date 
that bacterial agents or components derived thereof, such as LPS, are functionally involved 
in initiation or perpetuation of MS disease activity. In addition, studies attempting to link 
infectious agents to (autoimmune) inflammation are often based on the premise that replica-
tion occurs within the affected organ (8), but this is not necessarily the case. 
Peptidoglycan (PG) is a major constituent of the cell wall of gram-positive bacteria, which 
are abundantly present at all mucosa, and most prominently in the gut as part of the normal 
microbial flora (see (9) for review). PG is composed of long sugar chains of alternating 
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N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) residues, which are 
interlinked by peptide bridges, resulting in a large complex macromolecular stmcture (10). 
PG is only a very minor constituent of the cell wall of gram-negative bacteria. PG can be 
regarded as a functional analog ofLPS and both molecules activate iImate immune defence 
mechanisms (11). First, both molecules use CDI4 on monocytes Imacrophages and granu-
locytes as their cellular receptor. Second, the intracellular signaling pathways employed 
by both molecules are highly similar ifnot identical (9,12,13), engaging the recently iden-
tified Toll-like receptor (14-16). Third, both LPS and PG induce strong proinfiammatory 
responses ill vitro, including production of cytokines such as IL-l and TNF-a (12,17,18). 
LPS and PG are complex macromolecules which are difficult to digest by phagocytes (19). 
Macrophages lack amidase (N-acetyl muramyl L-alanine amidase (NAMLAA» expression 
(20,21) which is required for fiIll degradation ofPG injoint action with lysozyme (22). Tllis 
resistance to degradation explains at least in part the persistence of microbial cell walls, 
which may be a pivotal factor in chronic (autoimmune) inflammation (8). 
Antigen presenting cells containing PO are present in the joints of patients with rheumatoid 
arthritis, possibly contributing to the local inflammatory environment (23,24). Interestingly, 
PG retaining proillfianunatory capacity such as the induction of TNF-a and IL-l, can be 
fractionated from sterile human spleen (17,25,26), suggesting that continuous redistribution 
of PG occurs from the mucosa to the secondary lymphoid organs as well as to other ana-
tomical sites in the absence of sepsis and without requirement for local bacterial replication. 
Tllis is fillly consistent with the presence of circulating leukocytes carrying PG in human 
healthy subjects (27) and distinct patient categories (28). 
In view of the strong influx of macrophages into the CNS of MS patients facilitated by 
severely impaired blood-brain barrier function (29), we hypothesized that phagocytic anti-
gen presenting cells carrying PG gain access to the eNS and can locally promote iuullunc 
reactivity of T and B cells. We here show that PG-containing antigen presenting cells are 
present in human MS brain tissue and that they express costimulatory molecules and immu-
nomodulatory cytokines. In addition, antibody forming cells specific for PG are present in 
human MS brain tissue and patients with active disease have antibodies against PG in the 
cerebrospinal fluid. These findings imply that PG promotes immune reactivity in the brain. 
METHODS 
Patient samples 
Human brain tissue taken at autopsy was provided by the Netherlands Brain Bank in 
Amsterdam (Coordinator Dr. R. Ravid). Average post-mortem delay was 6 hours (range 
4-9) for MS patients and 8 hours (range 6-10) for control patients. No abnormalities could 
be detected at autopsy in the brain tissues of these subjects passed away by different causes 
like cardiac arrest, cancer and pneumonia. 
Cerebrospinal fluid samples of 10 MS patients and 10 control patients were obtained from 
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the Department of Neurology of the Erasmus University and University Hospital Rotter-
dam-Dijkzigt. Cerebrospinal fluid samples of relapsing-remitting MS patients were taken 
prior to innnuno-modulating therapy during a relapse of MS. Control subjects were patients 
presented with severe headache for which no cause could be detennined. 
ImlJ1ullohislochemistlY 
Immunohistochemical procedures used for detection of cellular subsets) antigens) antigen 
specific plasma cells) costimulatory molecules and cytokines in frozen sections have all 
been described in detail previously (30). Antibodies used were: CDI4 (MY-4, Coulter 
Clone, Hialeah, FL), CD68 (KP-I, DAKO, Glostrup, Demnark), CD83 (M43, Inununo-
tech, Westbrook, ME), CDla (DAKO), CD3 (DAKO), HLA-DR (L234, Coulter Clone), 
CD80 (M24, Irmogenetics N. v., Gent, Belgium), CD86 (1 GJ 0, Irmogenetics), CD40 (SD 12, 
Tanox Pharma BV, Amsterdam, The Netherlands), IL-Ia (Vmp 18), IL-IP (Vhp20), IL-4 
(Genzyme, Cambridge, MA), IL-6 (Genzyme), IL-IO (B-SIO, Instruchemie, Hilversum, 
The Netherlands), IL-12 (PharMingen, San Diego, CAl, IFN-y (MD-2, a kind gift of Dr. 
P. van der Meide, BPRC, Rijswijk, The Netherlands), TNF-a (MCI6, BPRC). To detect 
specific antibody forming cells, peptidoglycan-polysaccharide isolated from human feces 
(31) was labeled with biotin (32,33). Sections from reactive human tonsils were included on 
each individual object slide to provide intemal positive control tissue. Sections were evalu-
ated by two independent observers blinded to the staining procedure. 
Monoc/onal antibody against peptidoglycan (2£9) 
2E9 is a murine monoclonal antibody Mab (IgG3) raised against a pure fraction of peptido-
glycan-polysaccharides isolated from nom,.1 human feces (34). The specificity of this Mab 
has been extensively investigated and confirmed. First, inhibition studies using ELISA show 
that 2E9 recognizes cell wall fragments, muramyl dipeptide and lysozyme-solubilized cell 
walls of different gram-positive bacteria (34). These experiments suggest that it binds to the 
glycan backbone ofPG since muramic acid forms part of the stmcture recognized. Second, 
spleen sections of gemlfree rats and of neonatal rats in which the gut flora has not been 
established yet display no PG-containing phagocytes, whereas spleens of adult rats do. In 
addition, intravenous injection of PG into neonatal rats results in binding of 2E9 to phago-
cytes in spleen sections (34). Third, irnmuno-electron microscopy shows that Mab 2E9 
binds to cell walls of Staphylococcus epidermidis surviving intracellularly in macrophages 
around infected biomaterial. Fourth, 2E9 displays no detectable reactivity against more than 
ten thousand random dodecapeptides and eight thousand tripeptides in Pepscan approaches 
(3S), confirming tlus Mab has very low crossreactivity with non-PG epitopes. 
An isotype-matched control antibody (NS?, IgG3) of irrelevant specificity (sheep red blood 
cells) was used throughout the studies and displayed no binding activity in brain tissue of 
MS patients or control subjects. 
Statistical analysis 
The number ofPG-containing cells and plasma cells binding PG present in MS brain tissue 
and control brain tissue were compared using the Mann-Whitney rank-sum test. 
A p value < O.OS was considered to be significant. 
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PGELISA 
To measure anti-PG antibodies in cerebrospinal fluid, an ELISA, extensively validated and 
used before, was performed as described (36). Briefly, 50 III ofpeptidoglycan-polysaccha-
rides (10 Ilglml) was coated ovemight at 50'C onto 96-well polystyrene microtiter plates. 
100 III of 1:2, 1:4 and 1:8 dilutions of cerebrospinal fluid were incubated during I hour 
at 37'C. As detecting antibody, peroxidase conjugated rabbit anti-human IgM, IgG or IgA 
(Jackson Immunoresearch, Inc., Westgroove, PAl was used during I hour at 37'C. The 
development of the colorimetric assay took place at 37'C for 30-45 min after the addition 
of 100 m1 of ortho-phenylenediaminelH,O. The reaction was stopped by 4 M H,S04 and 
the optical density was measured at a wavelength of 492 nm with a Titertek Multiskan 
(Flow Laboratories, Irvine, Scotland). Between all incubation steps the plates were washed 
three times with PBS-0.02% Tween and cerebrospinal fluid and conjugates were diluted in 
PBS-0.2% Tween. 
RESULTS 
PG-colllainillg cells are present ill MS brain tissue 
The presence of PO was analyzed in cryo-sectiollS of brain white matter of MS patients 
and control subjects using a monoclonal antibody against PG (34). The numbers of PG-
containing cells were significantly higher in MS brains compared to control patients (figure 2) 
(p~0.00 I). In MS patients, PG-containing cells were mainly present on the edge of active 
lesions (37)(figure la), as defined by Oil-red 0 staining for myelin breakdown products 
ingested by macrophages. Furthermore, PG-containing cells were present around blood 
vessels, or scattered in the normal appearing white matter (figure I b). Only rarely could 
PG-containing cells be found within the fully demyelinated foci forming the center of 
lesions. To further analyze the role of PG-containing cells in inflammation of the brain, 
double labeling was perfonned on brain tissue of MS patients selected for high numbers of 
PO-containing cells, to determine the phenotype and activation state of the PO-containing 
cells. 
PG is present in JJlaclVphages and dendritic cells 
To determine the phenotype ofPG-containing cells, coexpression ofPG with CD68, CD83, 
CDI4, 27EIO, CDla and CD3 was analyzed. Figure 3 shows that PG is mostly present 
in macrophages expressing CD68 and dendritic cells expressing CD83. CDI4, which is 
the cellular receptor for both PG and LPS present on relatively immature phagocytes, was 
expressed by 17% (range 0-27%) of the PG-containing cells (38). The majority of the 
PG-containing cells (mean 62%), and in 2 out of 9 patients even all of these cells (range 
33-100%) expressed 27E10, an acute stage inflammatory macrophage marker characteristic 
for active MS lesions (39). Coexpression of CD 1a was analyzed since it is concievable 
that PG being composed of carbohydrates is presented by the CD I a antigen presenting 
molecule. However, only very few PG-containing cells coexpressed CDla. PG could not be 
detected in T cells (CD3). 
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Figul'e 2. Peptidoglycan is present in the white matter of brain tissue of multiple sclerosis patients. 
Immunohistochemistry was performed on brain tissue of 17 multiple sclerosis patients and 10 control 
subjects using Mab 2E9 raised against PO isolated from human feces. The median (horizontal bar) of 
the number of positive cells was 82/100 nun2 in multiple sclerosis patients compared to 12/100 mm2 
in the control subjects. * p=O.OOI lIsing the Mann-Whitney rank-sum test. 
PG-colltainillg cells coexpress costimulatOlY molecules 
The capability of PG-containing cells to present antigen was examined by double staining 
for HLA-DR, CDSO/B7-1, CDS61B7-2 and CD40, which are centrally involved in (co)-
stimulation of CD4+ T cells, Coexpression with PG occurred for all four molecules to 
varying extents, in particular for CDSO (figure Ie), suggesting that PG-containing cells are 
mainly f\mctionally competent, active antigen presenting cells (figure. 3). 
Peptidoglycal/ containing cells coexpress different cytokines 
To asses whether PG-containing cells can contribute to CNS inflammation in MS by pro-
ducing cytokines, double labeling was performed for proinflammatory cytokines (IL-I a; and 
f), IL-6, IL-12, TNF-a;, IFN-y) and immunoregulatory cytokines (IL-4, IL-IO). Except for 
IL-Ia;, all cytokines analyzed were expressed by PG-containing cells, to varying extents. Of 
the proinflammatory cytokines, coexpressioll was most frequently found for TNF-ct (mean 
44% of PG-containing cells, range 9-100%). In one patient, all PG-containing cells pro-
duced the strongly proinflammatory and myelotoxic cytokine TNF-o:. In addition, TNF-a; 
was also often strongly expressed by cells directly adjacent to PG-containing cells (figure Ie). 
Coexpression ofPG was also found for IL-f) (mean 30%, range 14-52%), IL-6 (mean II %, 
range 0-22%), IL-12 (mean IS%, range 0-65%) and IFN-y (mean II %, range 10-73%), 
although the latter cytokine was mostly expressed by cells directly adjacent to PG-contain-
ing cells. Inununoregulatory cytokines were prominently produced by PG-containing cells. 
IL-4 was detected in 5S% (range 13-93%) of PG-containing cells. IL-IO was mainly pro-
14S 
PG inMS 
duced by cells directly juxtaposed with PG-containing cells (figure Id), but coexpression 
was found in40% (range 0-83%) of all PG-containing cells . 
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Figure 3. Peptidoglycan is present in macrophages and dendritic cells capable of antigen presenta-
tion. Using immunohistochemistry, double labeling was perfonned with the Mab 2E9 raised against 
peptidoglycan (PG) isolated from human feces and various subset markers and functional markers 
of antigen presenting cells. PO is present in both macrophagcs (CD68/27ElO) and dendritic cells 
(CDS3), which are capable of antigen presentation and costimulation as reflected by the expression 
ofHLA-DR, CD80 and CD86. Horizontal bars represent mean numbers of PO-containing cells coex-
pressing the analyzed marker, 
Antibody [orllling cells speciJic[orpeptidog/ycal/ are present in MS brain tisslle 
Healthy human subjects have systemic IgM, IgG and IgA levels against PG (36), reflect-
ing continuous exposure to gram-positive bacteria at the mucosa, To determine whether 
intrathecal antibodies against PG were produced in MS brain tissue, plasma cells specific 
for PG were visualized in situ using biotin-labeled PG (32,33). Plasma cells specific for 
PG could be detected in 7 out of 13 MS patients and in 2 out of7 controls (figure 4). The 
numbers of plasma cells specific for PG were limited in control patient tissues and 3 of the 
MS patients, however 4 MS patients had high numbers of PG-specific antibody fonning 
cells. In MS patients, the number of antibody fomung cells against PG was directly COf-
related with the number ofPG-containing cells (p < 0.01). Antibody fonning cells specific 
for PG were scattered throughout the tissue (figure If) and could often be found nearby 
blood vessels, Pre-incubation of tissue sections with unlabeled PO resulted in a dose depen-
dent reduction of the number of PG-binding cells, confirming the specificity of staining. 
Double labeling for IgM plus IgG and PG-biotin confirmed that PG-binding cells were 
indeed plasma cells containing lugh levels of cytoplaslnic immunoglobulin. 
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Figure 4. Peptidoglycan-specific plasma cells are present in brain tissue ofmllltiple sclerosis patients. 
Using biotin-labeled PO, antibody fanning cells could be detected in 7 of 13 multiple sclerosis (MS) 
patients and only in 2 of 7 control subjects. In four of the MS patients relatively high numbers of 
antibody forming cells could be detected. Horizontal bars represent the median of the number of PO 
specific plasma cells in both groups. 
Antibodies specific for peptidoglycan are present in cerebro;pinal fluid of patients with 
active MS 
To confirm our finding of intrathecal production of antibodies against PO ill situ in MS 
autopsy brain tissue, ELISA was used to detennine IgM, IgG and IgA antibody levels 
against PO in cerebrospinal fluid samples. 
Samples taken during relapse from relapsing-remitting MS patients not treated with immu-
nosuppressive drugs were compared to samples from patients with severe headache for 
which no cause could be detemUned. In none of the control patients anti-PG antibodies 
could be detected. Using conservative cut off values, 6 out of 10 MS patients displayed 
considerable levels of anti-PG antibodies of the IgG and/or IgA isotypes (figure 5). 
DISCUSSION 
The present study shows that the gram-positive cell wall antigen peptidoglycan, abundantly 
present at all mucosal surfaces, is present in antigen presenting cells in the central nervous 
system of multiple sclerosis patients. Here, it contributes to inflammation by secretion of 
cytokines modulating T-cell function and stimulating antibody fonnation in the centralner-
vous system of multiple sclerosis patients. 
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Figure 5. IgA and IgG antibodies against PG are present in cerebrospinal fluid samples of multiple 
sclerosis patients. Using ELISA IgM, IgG and IgA levels against peptidoglycan (PG) were measured 
in cerebrospinal fluid samples (CSF) of 10 relapsing-remitting multiple sclerosis (MS) patients taken 
during a relapse and of 10 control patients with severe headache for which no cause could be deter-
mined. Using a CSF dilution of 1:2 anti-PG IgG and/or IgA antibodies could be detected in 7 of 10 
MS patients. In none of the control patients antibodies against PG could be detected. The broken line 
at 0.19 shows the mean 00 + 3SD of the control patients. IgM was not detected in any of the fluids 
analyzed. 
The presence of bacterial peptidoglycan in CNS tissue sheds a different light on the search 
for infectious agents involved in MS, where the emphasis has been on identification of 
viruses (e.g. HIN-6) and not on bacteria (40,41). Recently, Chlamydia pneumoniae and 
specific antibodies have been detected in the cerebrospinal fluid ofMS patients (42). In that 
particular study and others the implicit assumption often is that local replication of viruses 
or bacteria needs to occur. In sharp contrast, we show that peptidoglycan stimulates CNS-
infianunation in the apparent local absence of viable bacteria and replication, implying that 
this antigen is a microbial mediator in sterile inflammation. Thus, our data support novel 
emerging insights that persistence of bacterial cell wall antigens can contribute to autoim-
mune diseases (8). 
Shldies of autopsy brain material, including MS and Alzheimer patients, routinely and con-
sistently reveal a partial overlap of pathological characteristics between patient and control 
subjects tissues (43,44). For example, activated macrophages can be found in control sub-
ject tissues (45). Since quantitative differences and the less outspoken expression of these 
pathological characteristics in control tissues are widely recognized differential parameters, 
this overlap does not in any way prevent clear interpretation of autopsy material studies 
(discussed by (43». Furthermore, in the current report, cerebrospinal fluid from MS patients 
with disease relapse was also evaluated, confinning the ill situ presence of PG-specific 
plasma cells. 
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Elltly a/peptidoglycan cOlltaining cells into the braill 
Recent studies have shown that leukocytes can enter the blood-brain barrier and brain 
parenchyma under nomlal circumstances) most likely as a part of routine itmnune surveil-
lance (reviewed in (46)). This may explain why low numbers of PO-containing cells can 
occasionally be found in brain tissue of control patients. A few days after brain trauma such 
as contusion, massive infiltration of mononuclear cells into the brain occurs, including lym-
phocytes and antigen presenting cells (macrophages and dendritic cells) (47). This indicates 
that in the absence of known infectious Or autoimmune insults, inflammatory infiltrates can 
develop. The high number of PO-containing cells we find in MS brain tissue is likely due 
to the severely impaired blood-brain barrier function, leading to recruitment of high num-
bers of macrophages. It is highly unlikely that PO gains access to the brain in the post-
mortem phase due to bacterial translocation over mucosal barriers, because PG is present 
in the cytoplasm of antigen presenting cells, necessitating active ingestion of PO. In addi-
tion, antibody forming cells specific for PO could be found in the brain tissue. Furthermore, 
ongoing experiments in EAE models in the marmoset monkey (48,49) and the SJL/J mouse 
(50) show that PO-containing cells and specific plasma cells can be detected in perivascular 
infiltrates in tissues processed immediately after sacrifice. We currently favor the interpreta-
tion that access of PO-containing cells to the eNS is a stochastic process, influenced by 
the activation state of the cells affecting the expression profile of adhesion molecules. We 
therefore predict that PO-containing cells will occur in inflammatory diseases of the CNS 
other than MS. In that sense, there are currently no grounds to assume a single antigenM 
disease link, which is consistent with novel views on polymicrobial involvement in chronic 
inflammatory disease (8). 
Intrathecal antibody sYllthesis agaillst peptidoglycan 
Plasma cells producing antibody specific for PO were also present in situ in MS brain. This 
demonstrates that intrathecal antibody production against PO occurs. To confirm this find-
ing, cerebrospinal fluid ofMS patients and control patients was analyzed, showing that none 
of the control patients had specific antibody titers, whereas the majority ofMS patients had 
detectable specific IgO and IgA levels. The specificity and pathological relevance of plasma 
cells in the brain and oligoclonal innnunogiobulins in MS has beell highly obscure thus 
far (see (51)). Our finding that PO evokes specific intrathecal antibody production in situ 
identifies a hitherto unknown specificity oflocal plasma cells. 
Peptidoglycan is present in fimctiolJal/y competent antigen presenting cells 
Characterization of PO-containing cells sllOwed that macrophages containing PO were 
mostly mature, while only a minority had all innnature phenotype. The persistence of PO 
in macrophages can be explained by the fact that amidase can not be detected in macro-
phages (21). High expression of amidase and its lytic action in granulocytes may explain 
why PO calillot be detected in these cells. The high percentage of27ElO expression by PO-
containing cells indicated that PO is present in active lesions (39), of which 27ElO is a reli-
able marker. This is consistent with the concept that antigen presenting cells mature upon 
uptake of antigen and migration (52), where migration through vascular endothelium is a 
cmcial step promoting functional maturate and loss of surface markers such as CD 14 (53). 
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CD14+ monocytes can also maturate into dendritic cells, a transition enhanced by bacterial 
stimuli (54), which may explain the presence of PO in a limited number of dendritic cells. 
The expression of HLA-DR, CD40, CD80 and CD86 by PO-containing cells indicates 
that these cells are potent stimulators of antigen-specific T-cell activation. In addition, PO-
containing cells synthesized cytokines involved in regulation of inflammatory activity (e.g. 
IL-IJ3, IL-6, IL-12, TNF-o:, IFN-y, IL-4 and IL-l 0), demonstrating that they produce soluble 
mediators directly affecting T-cell proliferation, activation and survival (4,55). PO isolated 
from sterile human spleen is capable of inducing IL-I, IL-6, TNF-o: (26) by macrophages 
in vitro, and ongoing experiments show that also IL-IO, IFN-y and IL-12 and gelatinase B 
are induced upon PO stimulation in vitro. This confirms that PO can indeed be responsible 
for the cytokine production by the PO-containing cells in the CNS. 
Peptidoglycan and 'f.cell tolerance 
We hypothesize that PO in the CNS contributes to breaching T-cell tolerance and promotes 
T-cell activity by antigen presentation and induction of cytokine production (3-6). This is 
supported by the expression of HLA-DR, costimulatory molecules and cytokines by PO-
containing cells in MS brain. It has been shown in animal models that inflannnatory pro-
cesses created by bacterial infections or LPS lead to activation of autoreactive CD4+ cells 
(3) or CD8+ cells (5) which otherwise die by apoptosis. The major mechanism leading to 
breaking of tolerance is cytokine induction by infectious agents leading to T-cell survival 
(4,56). This view is supported by the finding that LPS induces EAE in mice injected with 
myelin basic protein (MBP)-specific T cells through induction ofIL-12 (6). Therefore, the 
presence and persistence of PG in brain tissue may promote loss of tolerance breakdown 
against autoantigens present in the brain like MBP, proteolipid protein (PLP) and others. 
Perspective 
In conclusion, this study shows that immunocompetent PO-containing cells are able to 
reach the brain in MS and promote immune reactivity, by expression of costimulatory mol-
ecules and cytokines and by stimulating intrathecal antibody formation. Redistribution of 
PO from mucosal sites to the brain depends on the intricate interplay between several fac-
tors such as the permeability of the intestine, activity of enzymes specifically involved in 
PO degradation (21), and mucosal and systemic antibody responses against PO (Schrijver 
et aI., submitted). Restricting the access of PG to non-mucosal sites may therefore be of 
clinical benefit to patients, as this may lead to lower levels of inflammation. 
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CHAPTERS 
General discussion 
Peptidoglycan (PG) is a bacterial cell wall antigen present in large amounts in gram-positive 
bacteria and only in small amounts in gram-negative bacteria. PO is composed of alter-
nating N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) long sugar 
chains, which are interlinked by peptide bridges resulting in a large complex macromolecu-
lar structure (I). PG and lipopolysaccharide (LPS) of gram-negative bacteria bind both to 
CD 14 on human cells and have similar biological properties such as induction of cytokines 
and Band T cell activation (2). 
Rheumatoid arthritis (RA) and multiple sclerosis (MS) are both chronic inflammatory dis-
eases, characterized by infiltration of T cells, antigen presenting cells (APC) and plasma 
cells. The inflammatory process in both diseases is the result of interactions between 
(auto)antigens, cells of the immune system and resident cells of the diseased tissue (3). 
Cmcial mediators in the inflammatory process are cytokines, chemokines and matrix metal-
loproteinases (4-6). In both RA and MS, the antigen(s) involved in tItis process have not 
been identified. Particularly in RA there are indications that PG may playa role in the 
pathogenesis of the disease, such as the ability of PG to induce arthritis in rats and the 
presence ofPG-containing cells in synovial tissues ofRA patients 0-9). In tltis thesis the 
role of PG in RA and MS is investigated. In this chapter the results from the previous sec-
tions are discussed in the context of the possible role ofPG derived from the mucosa in the 
inflammatory events occurring in RA and MS. 
Peptidoglycan present ill human tissues 
A prerequisite for the hypothesis that PO is involved in inflammatory diseases is the pres-
ence and persistence of bacterial cell wall products in relevant human tissues. Although 
detection of PG is teclutically difficult, different studies have described the detection of 
PG in fluids like urine (10) and synovial fluid (II), and also in leukocytes (12,13). Using 
a monoclonal antibody which recognizes peptidoglycan-polysaccharides (PG-PS), these 
antigens could also be detected in APC in tissues such as spleen and RA synovia (14-16). 
In order to obtain more illfonnation on the molecular stmcture of PG in human tissues and 
to analyze its biological activities ill vitro, we purified PG from sterile human spleen (14). 
A macromolecular carbohydrate-rich fraction was obtained after several purification steps. 
The presence of PG in this fraction was confimled by the detection of MurNAc, a unique 
component of PG using an aminosugariamino acid analysis method. To further investigate 
the stmcture and biological properties of the purified PG, the isolation procedure was opti-
nllzed (chapter 2.1). The presence ofPG in the highly purified fraction obtained was con-
firmed using three different independent methods: ELISA using the monoclonal antibody 
against PG-PS (17), the colorimetric muramic acid method (18) and detection of MurNAc 
by aminosugarlamino acid analysis (14). Colorimetric muramic acid detection showed that 
PG present in human spleen was mainly intact i.e. the stem peptides were still linked to the 
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aminosugar. This suggests that the PG fraction isolated from sterile human spleen had not 
been degraded by N-acetylmuramyl-L-alanine amidase (NAMLAA) which hydrolyses the 
lactamide bond linking the MurNAc of the aminosugar chains to the L-alanine end of the 
peptide chain (19). 
Biological activities ojpeptidoglyccl1l ill human tissues 
The effect of PG on T cells, B cells and monocytes/macrophages has previously been stud-
ied using PG isolated from cultured bacteria. These studies have shown that PG is able to 
induce the production of the proinfiammatory cytokines IL-lp, IL-6 and TNF-a by mono-
cytes. This activity was dependent on CD 14 binding (20-23), the cellular receptor for PG 
and LPS. These studies also showed that PG is able to induce polyclonal antibodies (17,24) 
and to induce T cell proliferation dependent on monocytes (25). T cell clones specific for 
a PG subunit disaccharide tetrapeptide were able to induce a delayed type hypersensitivity 
response (DTH) (26,27). In the present thesis we showed that PG present in human spleen 
is still biologically active. Using bioassays and ELISA it was shown that PG isolated from 
sterile human spleen tissue is able to induce TNF-a, IL-l and IL-6 dependent on CD 14 
during cell culture (chapter 2.1). In addition to cytokine production, PG isolated from 
human spleen is able to induce proliferation ofT cells from healthy subjects (chapter 2.2). 
This is consistent with earlier findings showing activation ofT cells by PG stimulation (25). 
In those studies it was hypothesized that PG induces polyclonal T cell proliferation, but the 
identity of the T cells and the nature of the activation mechanism remained unknown. In 
chapter 2.2 we show that the T cell proliferation is dependent on binding of PG to CD 14. 
Recently it has been shown that signaling after PG or LPS binding to CD 14 is mediated by 
Toll-like receptors fonning a complex with CDl4 since CD14 is a GPI-anchored molecule 
that does not traverse the cell membrane (28). PG, processed and presented by APC, is 
able to induce proliferation of mainly aPCD4+ and also some apCD8+ T cells (chapter 
2.2). TIns suggests that PG act as a polyclonal T cell activator. The inhibition ofprolifera-
tion by anti-HLA-I and anti-HLA-II antibodies together with the proliferation peak at day 
7 -8, however, suggests an antigen-specific T-cell response. This is consistent with earlier 
findings that T cell activation by PG is dependent on monocytes (25). The proliferation of 
CD8+ T cells in response to PG has to be further analyzed because this is not common for 
exogenous antigens. However, recent shldies have shown that CD8+ T cells can be activated 
by exogenous antigens which are able to reach intracellular compartments for loading onto 
class I molecules (29-31). Furthennore, the nature of the antigen presentation and what 
role HLA molecules play in tIns process have to be detennined in detail. This is of interest 
because PG is not a classical T cell dependent protein antigen for which antigen processing 
and presentation has been studied extensively (32). Recent reports have shown that both 
CD4+ and CD8+ T cells can be stimulated by glycopeptides (33-35), as PG may yield after 
processing. Electron microscopy using the monoclonal antibody (Mab) 2E9 specific for 
PG-PS can be used to investigate the intracellular trafficking, processing and presentation 
of PG in APC and the epitopes involved in T cell activation (36). To further investigate 
epitopes involved in the activation of T cells by PG, T cell clones against PG need to be 
raised and their specificity and T cell receptor usage analyzed. 
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Importallce of structure of peptidoglycall 
From chapters 2.1 and 2.2 it is clear that the stmcture of PG is important for its ability to 
stimulate cytokines and T cell proliferation. PG from human spleen was 10-100 times more 
active than PO isolated from human feces in which most stem peptides were not bound 
to MurNAc. This suggests that the biological activity of PG is dependent on the peptides 
linked to the MurNAc molecule. This is consistent with an earlier study from our depart-
ment in which it was shown that both lysozyme and most cmcially NAMLAA degradation 
of PG in cell wall fragments of Eubacterium aerofadells resulted in total inhibition of its 
capacity to induce arthritis (37). The persistence ofPG with peptides still linked to MurNAc 
in human spleen tissue suggests that PG in spleen is able to escape NAMLAA degradation. 
This may be due to the fact that NAMLAA is not expressed in macrophage type APC in 
which intact PG can be found (16, 19). In addition, processing ofPG by the macrophage-like 
cell line RAW264 resulted in the detection of glycopeptides containing alanine suggesting 
that no cleavage of the stem peptide from muramic acid by NAMLAA had OCCUlTed (38). 
Biological relevance of the presence of peptidoglycall ill healthy tissues 
As described above, our studies show that PO is present in human tissues and is still biologi-
cally active in healthy subjects (chapter 2). The question remains whether the presence of 
PG in human tissues have a biological role. Recent papers have advanced the hypothesis 
that continuous exposure to microbes is necessary to educate the itmnune system (39). 
This is supported by studies using gennfree laboratory animals which have smaller lym-
phoid organs and reduced serum Ig levels (40). Furthermore, in these germfree animals, 
macrophage functions are impaired as the result of decreased chemotaxis and phagocytosis 
(41,42). Therefore, it has been hypothesized that the continuous encounters of an individual 
with the indigenous bacterial flora, including its PO, keep the immune system at a sufficient 
level of activation. The presence of bioactive PO in human spleen tissue may result in a 
continuous immune response keeping the immune system alert to react to other antigens. In 
addition, PG may have effects on the maturation of APC. It has been argued that continu-
ous exposure to bacterial antigens is important in the regulation ofT-helper I (Thl) versus 
T-helper 2 (Th2) CD4+ T cells (39). Therefore it has been hypothesized that modem vac-
cines and hygiene may disturb the balance between the activation of Th I and Th2 cells, 
which may lead to allergy or autoimmune diseases (43,44), but more evidence for tins 
hypothesis is needed. Studies in Fisher rats show that these animals are not susceptible 
to arthritis induction with cell wall fragments under conventional circumstances but do 
develop a severe arthritis after injection of bacterial cell wall fragments under germfree 
conditions (45,46). These studies suggest that T cell tolerance is at least partly generated 
and maintained by cross-talk of the immune system with the bacterial flora. 
Peptidoglycall ilt rheumatoid arthritis 
To itlVestigate whether immune responses induced by PG are disturbed in RA patients, anti-
body levels specific for PG, and the PG-induced cytokine production and the T cell prolif-
eration were compared between RA patients and healthy subjects (chapter 3). 
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Systemic antibody levels against PG 
Several studies have reported that PG is able to induce a polyclonal antibody formation 
(24,47). Circulating IgM, IgG and IgA against PG-PS isolated from human feces could be 
detected in all healthy humans (17,48). In earlier studies focusing on antibodies against 
PG or PG-PS, increased levels were found in RA patients as compared to healthy controls 
(49). In contrast, two studies showed that decreased levels of PG-specific antibodies were 
present in RA patients and activation of B cells and plasma cells by PG was decreased in 
RA patients compared to healthy controls (50,51). In these studies PG was isolated from 
bacterial cultures. Because we hypothesize that PG derived from the normal bacterial flora 
is involved in RA, we considered it of more relevance to study antibody levels against PG 
derived from the mucosal sites. PG-PS isolated from human feces was mainly used in our 
studies because the amount of PG isolated from human spleen was limited (chapter 3.1). 
In tlus PG-PS fraction also some polysaccharide chains like rhamnose are present. Healthy 
females had significantly lower antibody levels compared to healthy males, and in females 
the amount of anti-PG-PS antibodies was inversely related with age. Although there is no 
evidence of causal linkage, it is of interest that the lower antibody levels against PG in 
females as compared to males correlate with the 2-3 fold higher general incidence of RA 
in females and that the lower antibody levels at higher age parallel the increasing incidence 
of RA with age (52,53). Furthermore, both females and males with RA had significantly 
lower levels ofIgG allti-PG-PS compared to age and sex-matched controls. The same phe-
nomenon was also observed in patients with early RA, i.e. with a diagnosed disease period 
ofless than 12 months. Based on these results we hypothesize that anti-PG-PS antibodies 
regulate the translocation of bacterial products from the mucosa to non-mucosal sites. 
TrallslocatioJl of PG into lIoll-mucosal sites 
Translocation of bacterial products can occur via transport by M cells in the intestine or 
after intestinal injury. M cells, which are present in follicle-associated epithelium, are spe-
cialized epithelial cells that have few microvilli and abundant vesicles with few lysosomal 
enzymes (54-56). After transport by M-cells, the antigens are thought to be processed and 
presented by macrophages in the Peyer's patches resulting in stimulation ofT and B cells. 
IgA produced during this process becomes dimerized and is transported into the gut lumen 
preventing further translocation of the bacteria or bacterial antigens (57,58). IgG produced 
locally in the mucosa but also systentically aids significantly in the protection against infec-
tions by contributing to immune exclusion or immune elimination (59). Therefore the lower 
levels ofIgG antibodies specific for PG in the sennn rnight also lead to increased transloca-
tion ofPG to extraintestinal sites. 
Another mechanism which ntight lead to increased distribution of PG into extraintestinal 
sites is intestinal injury. There are some indications that the intestinal permeability is 
increased in RA patients (60,61), but it cannot be excluded that tlus effect is due to the use 
of non-steroidal anti-ittflarmnatory dmgs (NSAID) (62,63). In addition, fasting periods fol-
lowed by a vegetarian diet have been shown to have beneficial effects on the course of RA 
(64-66). Such diet results in changes in the fecal flora suggesting an involvement of the 
intestinal flora in RA. 
The hypothesis that bacterial translocation ntight be involved in the pathogenesis of RA is 
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supported by the fact that bacterial overgrowth of the small bowel causes joint inflamma-
tion in humans (67-69) and in animal models (70). In these animal models inflammation 
could be inhibited by mutanolysin, which is a peptidoglycan degrading enzyme similar to 
lysozyme, suggesting that PG is involved in the inflammation (71,72). Using these bacterial 
overgrowth models, the importance of absorption ofPG from the mucosal sites and the role 
of antibodies specific for PG herein can be further investigated. For example, the animals 
can be treated with other PG-degrading enzymes like lysozyme and NAMLAA and with 
monoclonal antibodies specific for PG like 2E9 or serum antibodies. Another approach is to 
increase the penneability of the intestine in animals susceptible to arthritis like Lewis rats 
and to determine whether these animals spontaneously develop a11hritis or are protected by 
higher levels of semm antibodies specific for PG (73,74). 
Antibodies against PG ill synovialfluid 
Because it has been shown that PG is located in the synovial tissues ofRA patients, possibly 
due to decreased immune exclusion of PG, it is important to know whether PG present in 
human tissues is able to induce or contribute to inflammation. We showed that antibodies 
specific for PG were present in the synovial fluid of RA patients (chapter 3.1). Therefore 
antibodies against PG in synovial fluid may contribute to tissue damage in RA by fonning 
immune complexes (75). The presence of these antibodies in synovial fluid can be explained 
by at least three mechanisms. First, the antibodies may be derived from the bloodstream by 
passive diffusion. Second, these antibodies may be captured in the joint as a result of local 
inflammation. With radiolabeled IgG scintigraphy, it has been demonstrated that IgG accu-
mulates at the site of inflammation. This may be due to increased exudation of the radio-
labeled IgG through the leaky capillary walls at the site of inflammation into the locally 
expanded extravascular space (76). Third, intra-articular production of the antibodies may 
occur. Because the level of IgA antibodies present in the synovial fluids correlates signifi-
cantly with disease activity. we hypothesized that one or both of the latter two mechanisms 
occur. Up till now there is no indication that intraarticular production of antibodies against 
PG occurs because we were unable to detect plasma cells specific for PO in synovial tis-
sues using labeled PG in immunohistochemistry, but this has to be fhrther evaluated (LA. 
Schrijver, unpublished data). 
11ljlammatOlY capacities o/peptidoglycan ill RA patients 
In chapter 2.2 we show that T cell proliferation can be induced by PG, but PG-induced T 
cell responses of peripheral blood mononuclear cells (PBMC) did not differ between RA 
patients and healthy humans (chapter 3.2). Locally, in the inflamed joints, only limited pro-
liferation of synovial fluid mononuclear cells was observed. This suggests that disturbances 
in specific T cell proliferation induced by PG do not playa prominent role in the pathogen-
esis of RA. However, T cell activation by PG can still contribute to the inflanunatory pro-
cess as PG-containing APe, which are abundantly present in synovial tissues ofRA patients 
and not in healthy subjects, may stimulate proliferation ofT cells locally in the synovial tis-
sues. Other important mediators in the inflanunatory events in RA are cytokines and matrix 
metalloproteinases (4-6). In chapter 3.2 we show that PG is able to induce IL-IJ3, IL-6, IL-8, 
IL-IO, IL-12, TNF-e< and the metalloproteinase gelatinase B in blood cells and synovial 
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fluid cells. These cytokines are most likely produced by monocytes or macrophages because 
a purified monocyte fraction also produced IL-I~, IL-6 and TNF-o: (unpublished results). 
In addition, the cytokines were induced during a short incubation period (4 -17 hours) and 
production of cytokines by T cells requires more time for activation of the T cells by APe. 
Therefore, production of cytokines by T cells would require a longer culture period. IL-4 
could not be detected in the PG stimulated samples, but IFN-y was detected after 3 days of 
culture (unpublished results). 
We hypothesize that the cytokines present in peripheral blood and synovial fluid of RA 
patients are at least in part induced by PG. The induction of these cytokines by PG might 
result in activation of other cells leading to destruction of joint and cartilage tissues. In vivo, 
the production of cytokines may be different between RA patients and healthy subjects, 
dependent on the localization ofPG and on the nature and amounts of cytokines induced by 
PG. 
There are several examples of polymorphisms occurring within cytokine genes, some of 
which are associated with disease susceptibility or clinical course (77-80). Polymorphisms 
within cytokine genes have also been described for arthritic disorders (79,81,82). Whether 
the induction of cytokine production by PG is dependent on particular cytokine polymor-
phisms has to be evaluated. These studies I,ave to be performed under strict conditions 
because cytokine production is highly dependent on the culture conditions and circum-
stances and time point the blood sample is taken (83). 
PG present ill RA synovial tissues promotes hif/ammatioll 
To investigate whether PG is also able to activate the inmmne system ill vivo, ill situ analysis 
of PG-containing cells was performed on human tissues. For tlus purpose PG-containing 
cells were characterized using immunological markers. Because detection ofthese markers, 
e.g. cytokines and costimulatory molecules, is difficult in paraffin-embedded tissues, cryo-
sections had to be used. The disadvantage of the use of cryosections is their relatively poor 
morphology. In chapter 4.1 we show that the mild fixative pararosaniline is an alternative 
for acetone fixation because it preserves antigenicity of the tissues and strongly improves 
the morphology. 
To study PG localization and function ill situ we used an antibody raised against PG isolated 
from human feces. The specificity of this Mab (2E9) has been extensively investigated and 
confirmed. First, inhibition studies using ELISA showed that 2E9 recognizes cell wall frag-
ments, muramyl dipeptide and lysozyme and NAMLAA-solubilized cell walls of different 
gram-positive bacteria. These experiments suggest that 2E9 binds to the glycan backbone 
of PG since the presence of muramic acid is necessary for recognition by 2E9. Secondly, 
spleen sections from gennfree rats and from neonatal rats in which the gut flora has not been 
established yet display no PG-containing phagocytes, whereas spleens of adult rats do. In 
addition, intravenous injection of PG into neonatal rats results in binding of 2E9 to phago-
cytes in spleen sections (15). Thirdly, immunoelectron microscopy shows that Mab 2E9 
binds to cell walls of Staphylococcus epidermidis surviving intracellularly in macrophages 
after an experimental ill vivo infection (36). Fourthly, 2E9 displays no detectable reactivity 
against more than ten thousand random dodecapeptides and eight thousand tripeptides in 
Pepscan approaches (R.J. Slootstra R.B., Meloen R.H, unpublished data), confirming that 
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this Mab has very low cross-reactivity with non-PG epitopes (84). 
PG-containing cells are present in synovial tissues of RA and osteoarthritis (OA) patients 
(chapter 4.2) (16). In both RA and OA synovia the PG-containing cells were mainly mac-
rophages (CD68+, CDI4+) and only a minority of the cells were dendritic cells (CD83+). 
PG could not be detected in granulocytes, which in principle are able to bind PG by the 
CD 14 receptor. Tltis may be explained by the fact that granulocytes contain NAMLAA and 
are therefore able to degrade PG, while monocytes do not, leading to persistence of PG in 
these cells (19). Although PG is present in both RA and OA synovia, the cells containing 
PG have a higher expression of more activated phenotype in RA as compared to ~A. Tltis 
was shown by the expression of CD80, CD86 and CD40, costimulatory molecules critical 
to the activation of T cells (85-87), and the expression of different cytokines, in particular 
TNF-o: and IL-6, wltich are both involved in RA (4). These data suggest that PG-containillg 
cells are able to interact with T cells and to induce cytokines not only ill vitro but also in 
the synovial tissues of RA patients. The presence of PG-containing cells in both RA and 
OA synovial tissues shows that the presence of PO is not restricted to the synovial tissues 
of RA patients. Because PO-containing cells circulate in the bloodstream they can reach 
all tissues (11,12). As mucosal leukocytes can preferentially home to synovia (88,89), tltis 
may enhance the distribution of PG-containing cells to synovia. T cells activated in the 
mucosal sites may also home to these tissues, which might explain why some people suffer-
ing from Crohn's disease and ulcerative colitis may also experience attacks of joint inflam-
mation (90). In these diseases it is assumed that the intestinal flora plays an important role 
as specific T cell responses towards bacterial antigens of the resident flora occur and disease 
flare-ups are enhanced by increased gut permeability (91-93). 
Peptidoglycan in IIlllltiple sclerosis 
Because it has been shown that PO is present in different tissues, even in healthy subjects, 
it can be hypothesized that PO may be involved in other chronic inflammatory diseases 
besides RA. Therefore we shtdied whether PG also occurs in the inflanullatory lesions in 
the brains of MS patients. The brain tissue is a special site for the inmmne system because 
it is protected by the blood-brain barrier. Therefore the presence of PG in brain tissue with 
intact blood-brain barrier seems unlikely. Up till now there is little evidence that bacterial 
antigens are involved in the pathogenesis of MS, but a few studies report the capability. 
of PG to induce inflammation in brain tissues of animal models (94-96). There are also 
some indications that patients with Crohn's disease can have brain lesions similar to MS 
(97,98). Chapter 4.3 shows that PG-contairting cells can be detected in MS brain tissue in 
significantly higher numbers than in control brain tissue. Interestingly, low numbers of PO-
containing cells were also observed in brain from patients who died from non-neurological 
diseases. This illustrates that the protection of the brain tissue from non-brain cells is not as 
strict as has been thought previously. Recent papers have shown that after brain conhtsion 
massive cellular infiltrates including macrophages and dendritic cells can be found in the 
brain tissue (99). Therefore it can be hypothesized that ntinor brain damage can also cause 
infiltration of leukocytes, among which PO-containing ceHs. 
The PG-containing cells present in the brain tissue ofMS patients possess an activated phe-
notype as shown by the expression of CD 40, CD80 and CD86 and the expression ofTNF-o:, 
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IL- I, IL-6, JL-12 and IL-I O. The expression ofHLA-DR molecules by PG-containing cells 
was low. This may be due to the fact that, in general, HLA-DR expression in brain tissue is 
low, presumably to prevent T cell responses and inflanunation. 
In MS brains, PG may contribute to the inflammation by the induction of intrathecal spe-
cific antibody production. In 60% of the patients, antibodies and plasma cells specific for 
PG could be detected in both the cerebrospinal fluid and the brain tissue. The presence of 
antibodies in the cerebrospinal fluid may be partly due to leakage from the blood but the 
presence of plasma cells specific for PG within the brain tissue shows that antibodies spe-
cific for PG are also produced intrathecally. The presence of plasma cells specific for PG in 
MS confirms that PG induces specific innnunological activity and suggests that antibodies 
against PG may be involved in the local pathology. The existence of antibodies against PG 
in the cerebrospinal fluid identifies a novel specificity of the immunoglobulins at this site 
and may partly be responsible for the occurrence of oligoclonal immunoglobulin bands in 
the cerebrospinal fluids ofMS patients (100). To coufirm tills, additional experiments have 
to be performed using blotting teclmiques. 
Induction of experimental autoilmnune encephalomyelitis (EAE) by PG will provide further 
evidence for the involvement of PG in MS. In ongoing experiments, PG has been detected 
in the central nervous system of mouse and mannoset EAE. Oral administration of PG may 
exacerbate EAE in these models (101,102) as has also been shown with LPS in collagen 
induced arthritis (103). 
A role of PG ill Halltoimmlmity"? 
The studies described in this thesis show that PG is present in different tissues undergoing 
chronic inflammation of presumably autoimmune origin, and that PG is able to contribute 
to inunune reactivity. The question that remains is how PG contributes to the development 
and pathogenesis of RA and MS. In other words, is PG able to promote autoimmunity in 
susceptible individuals? Both RA and MS are considered to be CD4+ T cell mediated dis-
eases of the Thl type (104,105). This means that T cells playa cmcial role in the initiation 
and perpetuation of the disease. It is believed that these T cells react against autoantigens as 
a result of the lack of self-tolerance. However, in recent years it has become apparent that 
self-tolerance is not complete, not even in healthy humans (106). Many healthy individuals 
have both T-cell mediated and antibody-mediated reactivity to a number of self-proteins like 
major basic protein (MBP) or cartilage antigens (107,108). In most individuals regulatory T 
cells and possibly regulatory APC keep this self-reactivity under control (109). These regu-
latory T cells are able to inhibit responses in a non-antigen specific way which is mediated 
by the production ofIL-IO and TGF-p (110). These cells probably induce an equilibrium of 
proinflammatory and inhibitory activities. When tills balance becomes disturbed, develop-
ment of (auto)immUtllty may be the result. 
We propose that PG may promote (auto)innmllllty by one of the following mechOlllsms. 
PG specific T cell respoJ/ses 
First, T cell responses against PG present in human tissues may result in tissue damage. The 
studies in this thesis show that PG is able to induce activation ofT cells but the specificity of 
these T cells has to be further evaluated. The proliferation ofT cells against PG in the joints 
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of RA patients was very low. TIns suggests that at least iu an advanced stage of RA tlns 
mechanism of PG induced autoimmunity in the affected organ itself is unlikely. Whether 
PG can stimulate T cells in the brain in MS or EAE has to be investigated. 
Molecular minlic/), 
The second mechanism by which PO may induce autoimmunity is molecular mimicry. It 
has been hypothesized that infectious agents are able to elicit T cell or antibody responses 
against epitopes which are more or less similar to epitopes present in normal tissues 
(111,112). These T cells or antibodies can subsequently cause damage to the individual's 
tissues. Because PO is able to induce both T cell and antibody responses, this phenomenon 
can occur at both levels. Thus far, there is no evidence supporting this hypothesis. For 
example, the antibody 2E9 which recoginzes PG does not cross-react with cartilage and a 
panel of 18,000 different peptides (84) (J.w. Slootstra, R.H. Meloen, personal connnunica-
tion), suggesting that for the 2E9 epitope ofPG, molecular nUnnery with peptides does not 
readily occur. Also other ill vivo studies do not support the hypothesis that cross-reactivity 
between bacterial epitopes and cartilage is the underlying mechanism in RA (113,114). 
Danger model 
Third, PG may fit in the 'Danger model' postulated by Matzinger (115,116). The described 
mechanisms for autoimmune diseases are all based on the self-noll-self-model of the 
immune system. The 'Danger model' suggests that immune responses are initiated by a 
'danger' signal. Danger signals induce T cell activation irrespective of whether the antigen 
is self or non-self. Danger signals are induced upon injury of cells and may activate neigh-
boring APC by induction of costimulatory molecule expression by these cells. PG therefore 
may act as a danger signal by inducing cytokines, wInch lead to tissue destruction and APC 
activation. According to Matzinger (auto)innnunity might be due to an ongoing infection in 
the target organ. The effector cells clear the pathogen but they also damage the target organ 
in the process. Because PG is always abundantly present at the mucosal sites and circulates 
through the bloodstream in leukocytes (12,13), tlus may reflect a continuous exposure to an 
infectious antigen. Although PG fits into this model it is difficult to explain why PG present 
in normal spleen and liver does not cause T cell activation and tissue damage. 
Breaking of tolerance for autoantigells 
A fourth mechatusm by which PG might induce (auto)inmlUluty is a variant of the danger 
model. Infectious agents like viruses or bacteria, but also bacterial cell wall fragments like 
LPS, have been shown to break tolerance to certain autoantigens (117,118). This means that 
autoreactive T cells need an additional stimulus such as LPS or PO to become activated. 
The breaking of tolerance to certain autoantigens can occur by different mechanisms. First, 
when the infectious agents cause damage of the tissue, exposure of usually 'cryptic' anti-
gens may be increased. T cells might recognize these antigens as non-self and proliferate 
and react to these antigens. Secondly, an additional stimulus such as LPS is able to activate 
autoreactive T cells leading to pathology. This mechmusm probably depends on the LPS-
induced production of particular cytokines. These cytokines activate T cells but are also 
able to promote the survival of the autoreactive T cells by inlnbiting apoptosis (119,120). 
167 
Chapter 5 
In animal models it has been shown that inflammatory reactions caused by bacterial infec-
tions or LPS lead to the activation of autoreactive CD4+ cells (117) or CD8+ cells (118) 
which otherwise go into apoptosis. This mechanism is supported by the finding that LPS 
induces EAE in mice injected with MBP-specific T cells through induction of JL-12 (121). 
Therefore, the presence and persistence of PO in brain tissue may promote loss of tolerance 
against autoantigens present in the brain like MBP, proteolipid protein (PLP) and others. 
Similarly, in RA autoreactive T cells against collagen (122,123), HC-gp39 (124) and other 
joint antigens may be activated by PG. 
Whether PG is involved in the development ofRA and MS by breaking tolerance to certain 
autoantigens has to be further evaluated. TillS can be performed in T-cell receptor (TCR) 
transgenic nllce with autoreactive T cells (125,126). TCR-transgenic lnice expressing a 
TCR specific for MBP spontaneously develop EAE dependent on the environment (127). 
The role of PG in tins process can be analyzed by injecting PG into these nllce. Further-
more, it can be hypothesized that in germfree animals EAE will not spontaneously develop 
due to lack of additional stimuli. When adnlllnstration ofPG to such animals leads to EAE 
induction this would provide further evidence for the role of PG in EAE. 
Contribution of PG to RA and MS is dependent on different factors 
The studies of tins thesis show that PG at least in part contributes to the inflammation in RA 
and MS. To what extent PG damages the host depends on different predisposing factors. 
First, PG has to gain access to the synovium or central nervous system. As shown in tItis 
thesis, synovia ofRA and brains ofMS patients contain more PG-containing cells than the 
same tissues of controls. The number of these cells will depend on the accessibility of the 
synovium and the penneability of the bloodwbrain barrier. Furthermore, recurrent infections, 
intestinal permeability, enzymatic activity ofPG degrading enzymes and the composition of 
the intestinal flora will influence the amount of circulating PG. Specific antibodies against 
PG may help retain the PG inside the mucosal tissues (chapter 3.1). Once present in the 
synovium and central nervous system, immune reactivity of PO will depend on genetic fac-
tors like certain cytokine polymorphisms and the ability of a person to react to self-antigens. 
The latter will mainly depend on HLA-restriction. In RA it has been shown that HLA-DR4 
molecules are potent binders of cartilage peptides (128). Therefore HLA-DR4 positive indi-
viduals probably have higher frequencies of potentially autoreactive T cells or autoreactive 
T cells with lngher avidity to the relevant antigenic peptides. These suggestions imply that 
the presence of PO in tissues is not sufficient to promote chronic inflanunation but that tIus 
is also dependent on other environmental factors and on genetic fhctors. 
Peptidoglycan promotes itif/ammation in RA and MS: a hypothesis 
The studies in this thesis show that PG might be one of the extemal thctors in the develop-
ment and perpetuation ofRA and MS. In what way PG can be involved in the pathogenesis 
ofRA and MS is summarized by the following hypothesis (figure). 
PO, which is abundantly present in the bacterial flora at all mucosal sites, is able to pass 
the mucosal epithelium either via M cells or by intestinal injury (figure A)(70). Whether 
released PG can pass the mucosal epithelium or translocates with the whole bacterium is not 
known. Macrophages or dendritic cells lying adjacent to the M cells may ingest the whole 
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Peptidoglycan promotes inflammation in RA and MS: A hypothesis (explained in text) 
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bacteria, or PG using the CD I 4 receptor (B). Transport ofPG to the extraintestinal sites can 
occur by two mechanisms: by monocytes in the bloodstream or by free circulating PG (C). 
The presence of PG in leukocytes has been confinned by the detection of muramic acid in 
these cells (12, I 3) but up till now no evidence has been postulated that free PG is circulat-
ing in the blood. The leukocytes travel through the body and pass the lymph nodes and the 
spleen. In these secondary lymphoid organs innnune responses against PG may take place 
(D). It has been shown that PG is able to induce proliferation of mainly aPCD4+ T cells. 
Tllis is dependent on interaction with CD14 and processing and presentation of the antigen 
by HLA. FurthemlOre, B cells may be activated as IgM, IgG and IgA antibodies specific for 
PO can be found in the semm of healthy donors. These inunune responses can also occur in 
the Peyer's patches (E). When the level of semm IgG specific for PG decreases, extraintes-
tinal sites may be increasingly exposed to PG. When PG-containing cells (macrophages or 
dendritic cells) lacking NAMLAA that renders PG less inftannnatory are trapped in tissues 
like synovial tissue and braio, PG can ioduce the production of cytokines and gelatinase B (F). 
In tlus thesis we show that macrophages exposed to PG ill vitro are able to produce IL- I p, 
IL-6, IL-8, IL- 10, IL-12, TNF-a and gelatinase B. Whether PG is also able to induce cyto-
kine production by dendritic cells has to be further evaluated. The production of these 
inflammatory mediators can have two different effects: first, direct tissue damage can occur, 
also resulting in an increased expression of cryptic antigens that activate T cells. Second, 
the production of cytokines activates and influences the survival of autoreactive T cells 
(119,120). In RA these autoreactive T cells are specific for autoantigens like heat shock 
proteins (129), collagen (122,123) and HC-gp39 (124,128), explahung the existence ofT 
cell reactivity against these antigens in RA joints (G). In MS, the T cell tolerance for auto-
antigens such as MBP, MOG and PLP (107,108) can be broken. In addition, B cells may 
be activated 10caHy inside the brain or synovial tissue. In the latter, germinal center-like 
structures have been found indicatiog the local fonnation of memory B cells (130,131) 
(H). In addition, plasma cells specific for PG can be redistributed to these tissues (1). The 
production of cytokines, matrix metalloproteinases, and antibodies by the various types of 
activated cells will lead to damage of cartilage and bone in RA and myelin of the central 
nervous system in MS as shown in figures 3 and 4 of chapter I, the general introduction. 
In this hypothesis, PO contributes to inflanunation by first activating macrophages, wllich 
subsequently leads to the activation ofT cells and lor B cells. Whether the development of 
RA in animal models by PG is dependent on all these cell types can be analyzed in differ-
ent knockout nuce. Recently it has been shown that arthritis can be induced by collagen in 
DBAII mice lacking mature T and B cells, suggesting an important role of macrophages 
and dendritic cells or resident cells of the synovium (132). Whether initiating events like 
joint injury, synovial inflanunation or breakdown of the bloodMbrain barrier have to occur 
before PG can reach the synovial tissues or brain tissue has yet to be established. Tlus can 
be investigated by monitoring the presence of PG-containing cells and the biologic activity 
of PG during the initiation and perpetuation of the inflammation. Because clinical signs of 
RA and MS usually become evident only long after the initiation of the disease process, 
this calmot be studied io humans. Therefore, animal models have to be used. The most 
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appropriate arthritis model for this purpose is arthritis induced in rodents by bacterial cell 
wall fragments. The presence ofPG in the brain tissues can be monitored in both mouse and 
marmoset monkey EAE. Other models like collagen induced arthritis (133) or spontaneous 
models for arthritis like TNF-a transgenic mice (134,135) are suitable models for the deter-
mination of the role of PG derived from the mucosal sites. To analyze the trafficking and 
immune reactivity ofPG the use of germfree animals is recommended because PG injected 
into these animals can be monitored as these animals do not have PG from the mucosal 
flora. 
Concluding remarks 
This thesis shows that PG present in healthy and chronically inflamed tissues is able to 
promote immune reactivity. We show that PG present in sterile spleen tissue has potent 
effects on T cells, B cells and macrophages, including the induction of proliferation, synthe-
sizing antibodies and producing cytokines and matrix metaUoproteinases. Furthennore, we 
show that PG is present in higher numbers of APC and with a more activated phenotype in 
inflamed tissues compared to non-inflamed tissues. A unique finding reported in this thesis 
is the presence ofPG in the brain tissues, which is usually considered to be protected by the 
blood-brain-barrier. These bacterial antigens may promote immune reactivity to MBP and 
other relevant antigens in the brains ofMS patients. 
These results, together with previous studies from our group showing that PG isolated from 
bacteria from the intestinal flora or ileostoma feces induces arthritis in a rat model, sup-
port the hypothesis that PG plays a central role in the pathogenesis of chronic inilatmnatory 
diseases. Cnlcial questions in this hypothesis are whether PG is the initiating agent in the 
development of the disease or only enhances the disease, whether PG is able to induce MS 
like disease in animal models and whether PG is able to break tolerance to certain 3utoan-
tigens. If additional research provides further evidence that PG plays an important role in 
the pathogenesis of (auto)immune diseases, intervention studies should be envisaged. Inter-
vention in PG-induced autoimmunity may be performed by restricting PG to the musocal 
sites by an appropriate diet, by administration ofNAMLAA, antibodies specific for PG, or 
antibiotics which inhibit PG synthesis. 
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Rheumatoid arthritis (RA) and multiple sclerosis (MS) are both chronic inflammatory 
diseases of unknown origin. CD4+ T cells are believed to play an important role, but anti-
gen presenting cells (APC) also contribute significantly to the pathogenesis of both dis-
eases. This is mainly due to the production of cytokines and matrix metalloproteinases. 
(Auto )antigens responsible for the activation of CD4+ T cells and/or macrophages are still 
not unequivocally identified. 
Peptidoglycan (PG), a m'\ior cell wall component of gram-positive bacteria, which is abun-
dantly present in all mucosa, is a candidate antigen. PG is composed of long sugar chains 
of alternating N-acetyl glucosalnine (GlcNAc) and N-acetyl muramic acid (MurNAc) resi-
dues, which are interlinked by peptide bridges, resulting in a large complex macromolecular 
structure. Because of its capability to induce production of proinflammatory cytokines, to 
induce arthritis in rodents and its presence in APe in RA joints it is believed to playa role 
in the pathogenesis of RA. 
In the present thesis we investigated whether PG is involved in the pathogenesis of RA 
and MS. III vitro, PG isolated from conventional bacterial cultures can induce secretion of 
pro-inflanunatory cytokines by human mOllocytes, indicating that PG may be involved in 
immune responses against infections by gram-positive bacteria. To investigate the biologi-
cal activity of PG present in human tissues, we developed an improved method to isolate 
PO present in APC from sterile human spleen tissue. Biochemical analysis demonstrated 
that PG isolated from human spleen was largely intact. Human whole blood cells were 
able to produce the proinflammatory cytokines TNF-a, IL-1 and IL-6 after stimulation with 
PG isolated from human spleen (chapter 2.1). We also investigated whether PG isolated 
from human. Furthennore, PG isolated from human spleen is able to elicit a proliferative 
response of CD4+ and CD8+ T cells after binding to CD 14 on monocytes, followed by 
intracellular processing and presentation mediated by HLA-class II and I (chapter 2.2). 
Disturbances in the immune response against PG may be related to the pathogenesis ofRA. 
Therefore we analyzed antibody levels against PG and induction of cytokine production 
and T cell proliferation by PG in RA patients and healthy controls. A reduced systemic 
IgG response against PG derived from the gut flora was associated with RA, suggesting an 
antibody-mediated protection against the spreading ofPG over non-mucosal sites (chapter 
3.1). T cell proliferation and cytokine production induced by PG did not differ between RA 
patients and healthy controls, but PG was able to induce cytokines (IL-I p, IL-6, IL-8, IL-I 0, 
IL-12, IFN-y, TNF-a and the matrix metalloproteinase, gelatinase B (MMP-9), all associ-
ated with RA (chapter 3.2). 
To determine whether these in vitro activities of PG are also operational ill vivo, immuno-
histochemical studies were performed. To detect unstable immunological markers, fIxation 
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agents have to be used which often result in sUboptimal morphology. Fixation with para-
rosaniline resulted in better morphology of all tissues and inhibited endogenous alkaline 
phosphatase activity in brain tissue wltile maintaining antigenicity (chapter 4.1). PG could 
be detected in APC in RA joints but little is known about the nlllction of these cells. In 
chapter 4.2 it is shown that PG is present in both macrophages and dendritic cells and that 
these cells co express HLA-DR, CD40, CD80 and CD86, suggesting that these cells are 
immunocompetent APC. Furthermore PG containing cells coexpressed cytokines such as 
IL-6, JL-IO and TNF-o:. 
Because it can be hypothesized that PG also plays a role in other chronic inflammatory 
diseases than RA, we detennined the presence ofPG in MS (chapter 4.3). We showed that 
PO-containing cells are present in APC in MS brain tissues. Similar to RA, these cells coex-
pressed costimulatory molecules and cytokines. In addition, the presence of plasma cells 
specific for PG in MS brain and anti-PG antibodies in cerebrospinal fluid from MS patients 
suggests that PG is able to induce antibody production intrathecally in MS. 
These data suggest that PO may translocate from the mucosa to the bloodstream. This may 
be dependent to little enzymatic degradation of PG, increased intestinal permeability or 
relatively low antibody levels against PG. After translocation, PG is distributed to non-
mucosal tissues carried by leukocytes in the bloodstream. When PG is captured in synovial 
or brain tissues, production of cytokines and metalloproteinases may lead to damage of the 
tissues but also to the breakdown of tolerance to certain autoantigens. Therefore PO may 
promote inflammation in RA and MS. 
Our studies identified PO as a bacterial modulator of infialmnation (cytokines, matrix metal-
loproteinases), but also of specific adaptive immmtity (T cell proliferation, anti-PG antibod-
ies). The presence of PO in APC coexpressing different activation markers in inflamed tis-
sues ofRA and MS patients suggests that PG may playa role in these diseases. The precise 
mechanisms of action and whether PG is involved in the initiation or perpetuation of the 
disease should be further elucidated. When the role of PG is further established, interfer-
ing with access ofPG to non-mucosal sites may be a novel approach to anti-inflammatory 
therapy. 
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Het immuunsysteem beschennt het lichaam tegen vreemde illdringers zoals bacterH~n en 
virussen. Cmciaal hierin is het samenspel van drie verschillcllde soorten celleuJ de antigeen-
presenterende cellen, de T cellen en de B cell en. Antigeen presenterende cellen zijn in staat 
om vreemde indringers (antigenen) 'op te eten' en deeltjes hiervan op hun oppervlak te 
brengen. De T cellen knnnen deze deeItjes herkennen waardoor ze geactiveerd worden. 
Deze geactiveerde T cellen kunnen dan de geillfecteerde eel vernietigen of activeren zodat 
het schadelijke antigeen opgeruimd wordt. Daamaast kunnen T cellen ook B cellen acti-
veren om uit te rijpen tot plasmacellen die antistoffen (eiwitten) maken die de vreemde 
antigenen kunnen binden en onschadelijk maken. hI SOlllluige gevallcll raakt deze immuun-
respons uit balans en richt het immuunsysteem zich ruet aIleen tegen bactcrien en vims-
sen, maar tegen stmcturen van het Iichaam zelf. De ziekten die hierdoor ontstaan worden 
auto-iUulluunziekten genoemd. Voorbeelden zijn reumatoYde artritis (RA), beter bekend als 
reuma, en multiple sclerose (MS). RA en MS worden gekelllnerkt door chronische ontste-
kingen in respectievelijk de gewrichten en het centrale zenuwstelsel (mggenmerg en de 
hersenen). Echter, de precieze oorzaak van beide ziekten is nog steeds onbekend. Acute 
vonnen van artritis, zoals reactieve artritis , worden veroorzaakt door bacteriele infecties van 
onder andere de darmen en urinewegen. Omdat RA een chronische ziekte is, wordt veron-
dersteld dat bacterien die zich pennanent op de slijmvliezen van de darm en luchtwegen 
bevinden, een rol kunnen spelen in het in stand houden van de ontstekingen. 
Een belangrijk bestanddeel van bacterien is peptidoglycaan (pG). PG bevindt zich in de 
eel wand van bacterien en is in staat om een ontstekingsreactie op gang te brengen. Dit wordt 
onder andere veroorzaakt door het aanzetten van de productie van cytokinen door antigeen 
presenterende cellen. Cytokillen zijn oplosbare signaaleiwitten die belangrijk zijn in ontste-
kingen. Omdat PG aangetoond kan worden in gewrichten van RA patienten en artritis kan 
veroorzaken in ratten wordt dit antigeen in verband gebracht met RA. 
Het doel van het onderzoek dat beschreven is in dit proefschrift, is om te onderzoeken ofPG 
een rol zou kunnen spelen in chronische ontstekingen, zoals RA. Daarvoor is het belangrijk 
om vast te stellen of het PG zoals het zich bevindt in weefsels in het lichaam, nog steeds 
biologisch actief is en niet onschadelijk is gemaokt door enzymen. In hoofdstuk 2.1 is een 
methode beschreven om PG te isoleren uit menselijk weefsel. Dat het PG nit menselijk 
weefsel nog steeds actief is blijkt uit het feit dat het in staat is om de productie van ontste-
kingsbevorderende cytokinen TNF-a, IL-I en IL-6 te stimuleren (hoofdstuk 2.1) en T cellen 
kan activeren. (hoofdstuk 2.2). 
De bijdrage van PO aan RA zou veroorzaakt iallllen worden door cen gestoorde immune 
reaktie tegenPG. Dit is onderzocht in hoofdstuk 3. Uit hoofdstuk 3.1 blijkt dat RA patienten 
een verlaagde hoeveelheid antistoffen gericht tegen PG in hun bloed hebben. Dit zou erop 
kUImen duiden dat RA patienten een verlaagde beschenning hebben tegen de verspreiding 
van PG vanuit de slijmvliezen. De stimulatie van cytokine productie en T eel activatie door 
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PG is niet verschillend tussen RA patienten en gezonde controles (hoofdstuk 3.2) maar 
uit dit hoofdstuk kwam weI naar voren dat PO in staat is om de productie van belangrijke 
cytokinen in het ontstaan van RA te stimuleren. 
De experimenten in deze studies zijn allemaal 'in vitro' experimenten. Dit wil zeggen dat 
we het effect van PO bestudeerd hebben buiten de situatie in het lichaam am. Om de rol van 
PO in het ontstaan van chronische ontstekingen ook 'ill vivo' te bestuderen, zijn immunohis-
tochemische technieken uitgevoerd op menselijk weefsel (hoofdstuk 4). Met itmnunohisto-
chemie worden in plakjes weefsel, in dit geval synovia uit de gewrichten van RA patienten, 
cellen aangetoond met behulp van specifieke antistoffen. Belangrijk bij deze methode is dat 
de cellen goed gefixeerd blijven en dat de vonn en structuur van deze cellen niet verandert. 
In hoofdstuk 4.1 wordt een fixatie methode beschreven waarbij dit het geval is. In hoofdstuk 
4.2 is onderzocht in wat voor cellen PO zich bevindt in synovia van RA patienten. Hieruit 
blijkt dat PG zich voomamelijk bevindt in antigeen presenterende cellen. Dat deze cellen 
geactiveerd zijn, blijkt uit de aanwezigheid van moleculen op het oppervlak van deze cellen 
die betrokken zijn bij de interactie tussen T en B cellen, en de expressie van cytokinen door 
de PG-bevattende cell en. Dit betekent dat deze cellen wellicht aktief betrokken zijn bij de 
antstekingsreactie in de gewrichten. 
Omdat PG in verschillende weefsels gedetecteerd kan worden, is het mogelijk dat PG ook 
in andere chronische ontstekingen dan RA een rol speelt. Daarom is een shIdie uitgevoerd 
waarbij in hersenweefsel is onderzocht of daar PG aanwezig is (hoofdstuk 4.3). De herse-
nen nemen voor het immuunsysteem een bijzondere plaats in ollldat de immuunreakties 
daar zoveel mogelijk onderdrukt worden om weefselschade te voorkomen. Daarom is er een 
zogenaamde bloed-hersen-barriere die de toegang van vreemde antigenen en cellen in de 
hersenen zoveel mogelijk voorkomt. In dit proefschrift is voor het eerst aangetoond dat in 
hersenweefsel van MS patH~nten antigeen presenterende cellen aanwezig zijn die PO bevat-
ten. Net als in RA zijn deze cellen geactiveerd. Verder zijn PO-specifieke plasmacellen en 
antistoffen tegen PG aangetoond in de hersenen van MS patienten. Dit betekent dat bij MS 
PO immunologisch aetief is in de hersenen. 
Gehypothetiseerd kan worden dat verspreiding van PG vanuit de slijlllvliezen kanleiden tot 
de aanwezigheid van PG in andere weefsels. In deze weefsels, zoals synovia en hersenen, 
zon dit kunnen lei den tot ontstekingsreacties als gevolg van de productie van cytokinen. Dit 
kan er onder meer toe leiden dat T cellen het lichaam zelf aanvallen, wat in RA leidt tot 
schade in de gewrichten en in MS tot schade aan het centraal zenuwstelsel. De aanwezig-
heid van PG zou dus een rol kuJlllefl spelen in chronische ontstekingen zoals RA en MS. 
Kart salllcngevat, PO is aanwezig in organcn van waar chrollische ontstekingen plaats 
vinden, en heeft de eigenschappen om zulke ontstekingen te induceren en/of in stand te 
houden. Of de rol van PO crueiaal is in de ontwikkeling van chronische ontstekingen zoals 
RA en MS, of dat het alleen een bijdrage levert aan zulke processen, dient onderzocht te 
worden met behulp van patientenmateriaal en in proefdiennodellen die de ziekte naboot-
sen. 
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ABBREVIATIONS 
AEC 
APC 
AP 
AV-PO 
BCG 
BPRC 
CNS 
CSF 
CII 
DAS 
DMF 
DTH 
EAE 
ELISA 
ENA 
ESR 
FBB 
FPLC 
GlcNAc 
GM-CSF 
GPI 
GRO 
HC-gp39 
HHV-6 
HPLC 
HoaM-bio 
HRP 
HSP 
IGIF 
IL 
IFN 
LIF 
LPS 
MAbs 
MAG 
MBP 
M-CSF 
MCP 
3-amino-9-ethylcarbazole 
Antigen presenting cells 
Alkaline phosphatase 
Avidin peroxidase 
Bacillus Calmette-Guerin 
Biomedical Primate Research Center 
Central nervous system 
Cerebrospinal fluid 
Type II collagen 
Disease activity score 
N,N-dimethylfonnamide 
Delayed type hypersensitivity response 
Experimental autoimmune encephalomyelitis 
Enzyme-linked inmlUnosorbent-assay 
Epithelial cell derived neutrophil activating factor 
Erythrocyte Sedimentation Rate 
Fast Blue Base 
Fast performance liquid chromatography 
N-acetyl glucosamine 
Granulocyte-colony-stimulating factor 
Glycosylphosphatidylinositol 
Growth regulated oncogen 
Human cartilage glycoprotein 39. 
Human herpes virus 6 
High performance liquid chromatography 
Horse-anti-mouse-biotin 
Horseradish peroxidase activity 
Heat shock proteins. 
Interferon gamma inducing factor 
lnterleukin 
Interferon 
Leukemia inhibitory factor 
Lipopolysaccharide 
Monoclonal antibodies 
Myelin-associated glycoprotein 
Myelin basic protein 
Macrophage colony stimulating factor 
Monocyte chemotactic protein 
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Abbreviations 
MDP 
MHC 
MIP 
MMP 
MOG 
MS 
MurNAc 
NO 
NAMLAA 
NSAID 
OA 
00 
PBMC 
POGF 
PG 
PG-PS 
PLP 
RA 
RaRH-bio 
RANTES 
RF 
ROS 
RP 
SA V-PO 
SO 
SI 
S-IgA, S-IgM 
SF 
SFMC 
TAL 
TCR 
TGF-
Thl 
Th2 
TT 
TLR 
TNF 
TNP 
WP 
Muramyl dipeptide 
Major histocompatibility complex 
Macrophage inflammatory protein 
Matrix metalloproteinase 
Myelin oligodendrocyte glycoprotein 
Multiple sclerosis 
N-acetyl muramic acid 
Nitric oxide 
N-acetylmuramyl-L-alanine amidase 
Non-steroidal anti-inflammatory dmgs 
Osteoarthritis 
Optical density 
Peripheral blood mononuclear cells 
Platelet-derived growth factor 
Peptidoglycan 
Peptidoglycan-polysaccharide 
Proteolipid protein 
Rheumatoid arthritis 
Rabbit-anti-Rat-biotin 
Regulated upon Activation, Normal T cell Expressed, and presumably 
Secreted 
Rheumatoid factor 
Reactive oxygen species 
Red pulp 
Streptavidin-perOlddase 
Standard deviation 
Stimulation index 
Secretory IgA, Secretory IgM, 
Synovial fluid 
Synovial fluid mononuclear cells 
Transaldolase 
T-cell receptor 
Transforming growth factor 
T helper I 
T helper 2 
Tetanus toxoid 
Toll-like receptors 
Tumor necrosis factor 
2,4,6-trinitrophenyl 
White pulp 
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